0001628280-24-019411 | 20-F | XBRL Viewer

Print Document

Consolidated statements of profit or loss and other comprehensive income - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Continuing operations
Revenue	$ 21,742,675	$ 13,163,841	$ 12,532,744
Direct costs	(12,912,788)	(9,545,546)	(8,930,147)
Gross profit	8,829,887	3,618,295	3,602,597
Other income and other net gains/(losses)	4,507,103	429,857	(202,176)
Selling and distribution expenses	(8,243,379)	(4,738,099)	(5,738,682)
Research and development expenses	(11,661,760)	(5,988,905)	(6,391,491)
Impairment loss of goodwill	(3,900,268)	0	0
Administrative and other operating expenses	(41,438,301)	(59,341,636)	(47,932,095)
Operating loss from continuing operations	(51,906,718)	(66,020,488)	(56,661,847)
Fair value loss on financial assets at fair value through profit or loss	(7,134,786)	(9,363,495)	(94,000)
Share-based payment on listing	0	(89,546,601)	0
Changes in fair value recognized in profit or loss	0	0	(29,054,669)
Fair value loss on preference shares liabilities	0	(60,091,353)	(125,398,798)
Fair value gain on warrant liabilities	3,351,035	3,196,538	0
Share of loss of equity-accounted investees, net of tax	(858,900)	0	0
Loss on disposal of a subsidiary	0	0	(292,132)
Other finance costs	(119,662)	(3,994,755)	(5,052,076)
Loss before taxation	(56,669,031)	(225,820,154)	(216,553,522)
Income tax credit/(expense)	269,359	244,816	(2,568,522)
Loss from continuing operations	(56,399,672)	(225,575,338)	(219,122,044)
Discontinued operation
(Loss)/profit from discontinued operation, net of tax	(8,377,660)	35,121,951	45,105,202
Loss for the year	(64,777,332)	(190,453,387)	(174,016,842)
Item that may be reclassified subsequently to profit or loss:
Exchange differences on translation of foreign operations	1,795,623	(4,842,932)	260,112
Total comprehensive income for the year	(62,981,709)	(195,296,319)	(173,756,730)
Loss attributable to:
Equity shareholders of the Company	(62,723,871)	(190,453,333)	(174,009,273)
Non-controlling interests	(2,053,461)	(54)	(7,569)
Loss for the year	(64,777,332)	(190,453,387)	(174,016,842)
Total comprehensive income attributable to:
Equity shareholders of the Company	(61,112,335)	(195,296,265)	(173,749,161)
Non-controlling interests	(1,869,374)	(54)	(7,569)
Total comprehensive income for the year	$ (62,981,709)	$ (195,296,319)	$ (173,756,730)
Loss per share
Basic ($ per share)	$ (5.58)	$ (37.57)	$ (178.81)
Diluted ($ per share)	(5.58)	(37.57)	(178.81)
Loss per share - Continuing operations
Basic loss per share from continuing operations ($ per share)	(4.83)	(44.50)	(225.17)
Diluted loss per share from continuing operations ($ per share)	$ (4.83)	$ (44.50)	$ (225.17)

Revenue	12 Months Ended
Revenue	Dec. 31, 2023
Revenue [abstract]
Revenue	Revenue See accounting policy in note 38(C). The principal activities of the Group are provision of preventive and diagnostic health testing and services. Revenue related to services are recognized at a point of time when control over a service is transferred to the customer. Revenue represents the sales value of services rendered for customers in accordance with IFRS 15 Revenue from contracts with customers. Revenue expected to be recognized in the future arising from contracts with customers in existence at the report date At December 31, 2023, 2022 and 2021, the amount of service fee income allocated to the remaining performance obligations under the Group’s existing contracts that are non-refundable is $6,111,017, $5,674,290 and $9,587,245, respectively. The Group will recognize the expected revenue in the future when the performance obligations are fulfilled, which may be after one year from the end of the reporting period. Such amount does not include any variable consideration.

Capital and reserves - Other reserve (Details)	1 Months Ended	12 Months Ended
Capital and reserves - Other reserve (Details)	Jan. 31, 2023 USD ($)	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2023 GBP (£) shares	Nov. 01, 2023 shares	Oct. 31, 2023 shares
Increase (decrease) through acquisition of subsidiary, equity \| $		$ 0	$ 39,783,820
Number of shares outstanding (in shares) \| shares					12,200,000	181,800,000
Other reserve
Increase (decrease) through acquisition of subsidiary, equity \| $		(5,061,304)	5,061,304
Other reserve \| ACT Genomics Holdings Company Limited
Increase (decrease) through acquisition of subsidiary, equity \| $	$ 5,061,304
Other reserve \| Oxsed Limited
Loan notes with a principal amount, first portion		$ 7,549,258		£ 5,865,450
Other reserve \| Oxsed Limited \| Ordinary shares
Number of shares issued (in shares) \| shares		110,150		110,150
Treasury stock
Number of shares outstanding (in shares) \| shares		14,134		14,134
Purchase of treasury shares \| $		$ 63,294	$ 661,519
Treasury stock \| Treasury stock
Number of shares outstanding (in shares) \| shares			20,722

Other non-current assets (Tables)

12 Months Ended

Dec. 31, 2023

Miscellaneous non-current assets [abstract]

Schedule of other non-current assets


	2023		2022
Deposits and prepayments	$	743,173	$	1,292,462

Property, plant and equipment - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]
Additions to right-of-use assets	$ 196,626	$ 833,538	$ 5,370,122
Office equipment, carried at depreciated cost
Disclosure of detailed information about property, plant and equipment [line items]
Lease term	5 years
Bottom \| Properties leased for own use, carried at depreciated cost
Disclosure of detailed information about property, plant and equipment [line items]
Lease term	2 years
Top of range \| Properties leased for own use, carried at depreciated cost
Disclosure of detailed information about property, plant and equipment [line items]
Lease term	10 years

Capital and reserves - Movement in ordinary shares of PHCL (Details)		12 Months Ended
	May 18, 2022 shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) Vote $ / shares shares	Dec. 31, 2021 USD ($) shares	May 06, 2022 USD ($) $ / shares shares
Disclosure of classes of share capital [line items]
Par value per share ($ per share) \| $ / shares		$ 1
Balance at the beginning		$ 13,698
Shares issued upon conversion of exchange loan notes		0	$ 0	$ 0
Balance at the end		$ 18,308	$ 13,698
Number of votes per ordinary share \| Vote			1
Number of shares issue in hold as result of pending statutory procedures \| shares	1
Amount of reclassification to share premium due to restructuring			$ 17,126,369
Class A ordinary shares
Disclosure of classes of share capital [line items]
Par value per share ($ per share) \| $ / shares		$ 0.0015
Class B ordinary shares
Disclosure of classes of share capital [line items]
Par value per share ($ per share) \| $ / shares		$ 0.0015
PHCL
Disclosure of classes of share capital [line items]
Number of shares authorised (in shares) \| shares		50,000	50,000
Authorized share capital		$ 50,000	$ 50,000
Balance at the beginning		$ 1
Exchange for Prenetics Ordinary Shares as part of Reverse Recapitalization (Shares) \| shares		0	(14,932,033)
Exchange for Prenetics Ordinary Shares as part of Reverse Recapitalization		$ 0	$ (1,493)
Balance at the end		$ 1	$ 1
Conversion ratio	2.03
Shares issued upon closing of the merger
Disclosure of classes of share capital [line items]
Increase in the number of shares outstanding during the period \| shares	1
Ordinary shares
Disclosure of classes of share capital [line items]
Par value per share ($ per share) \| $ / shares			$ 0.0001
Number of shares authorised (in shares) \| shares		33,333,334	33,333,334
Authorized share capital		$ 50,000	$ 50,000
Ordinary shares \| Class A ordinary shares
Disclosure of classes of share capital [line items]
Par value per share ($ per share) \| $ / shares			$ 0.0001
Number of shares authorised (in shares) \| shares		30,000,001	30,000,001
Authorized share capital		$ 45,000	$ 45,000
Balance at the beginning (in shares) \| shares		8,484,616	0
Balance at the beginning		$ 12,727	$ 0
Shares issued upon conversion of exchange loan notes		$ 79	$ 79
Balance at the end (in shares) \| shares		10,624,208	8,484,616	0
Balance at the end		$ 15,937	$ 12,727	$ 0
Ordinary shares \| Class B ordinary shares
Disclosure of classes of share capital [line items]
Par value per share ($ per share) \| $ / shares			$ 0.0001
Number of shares authorised (in shares) \| shares		3,333,333	3,333,333
Authorized share capital		$ 5,000	$ 5,000
Balance at the beginning (in shares) \| shares		647,591	0
Balance at the beginning		$ 971	$ 0
Balance at the end (in shares) \| shares		1,580,972	647,591	0
Balance at the end		$ 2,371	$ 971	$ 0
Ordinary shares \| PHCL
Disclosure of classes of share capital [line items]
Balance at the beginning (in shares) \| shares		1	14,932,033
Balance at the beginning		$ 1	$ 1,493
Shares issued upon conversion of exchange loan notes (in shares) \| shares		0	1
Shares issued upon conversion of exchange loan notes		$ 0	$ 1
Balance at the end (in shares) \| shares		1	1	14,932,033
Balance at the end		$ 1	$ 1	$ 1,493
Ordinary shares \| Redesignation of authorized share capital \| PHCL
Disclosure of classes of share capital [line items]
Par value per share ($ per share) \| $ / shares					$ 1
Number of shares authorised (in shares) \| shares					50,000
Authorized share capital					$ 50,000

Property, plant and equipment

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about property, plant and equipment [abstract]

Property, plant and equipment

See accounting policies in notes 38(H), (L)(ii) and (M).


	Right-of-use assets (note (a))		Leasehold improvements		Fixtures and furniture		Office and lab equipment		Computer equipment		Motor vehicles		Manufacturing equipment		Total
Cost:
At January 1, 2022	$	8,833,201	$	3,898,422	$	39,974	$	5,582,338	$	439,543	$	453,182	$	1,162,681	$	20,409,341
Additions	833,538		598,672		569		4,160,369		188,541		—		—		5,781,689
Additions from acquisition (note 34(C))	4,623,601		3,102,189		—		6,898,517		—		8,261		—		14,632,568
Disposals	—		(30,492)		—		(357,127)		(65,993)		(55,847)		—		(509,459)
Written off	(40,080)		—		—		(438,530)		(6,320)		—		(1,158,041)		(1,642,971)
Exchange differences	(180,180)		(92,424)		(3,669)		(158,913)		(37,044)		(40,483)		(4,640)		(517,353)
At December 31, 2022 and January 1, 2023	14,070,080		7,476,367		36,874		15,686,654		518,727		365,113		—		38,153,815
Additions	196,626		53,521		5,809		285,615		345		—		—		541,916
Disposals	(2,060,684)		(1,158,623)		(27,548)		(4,926,398)		(81,844)		(57,451)		—		(8,312,548)
Written off	(1,938,394)		(850,863)		(4,443)		(1,863,592)		(221,395)		(312,048)		—		(5,190,735)
Exchange differences	847,132		356,124		34,363		(313,508)		2,667		12,504		—		939,282
At December 31, 2023	$	11,114,760	$	5,876,526	$	45,055	$	8,868,771	$	218,500	$	8,118	$	—	$	26,131,730
Accumulated depreciation and impairment loss:
At January 1, 2022	$	3,518,776	$	1,459,157	$	17,926	$	1,930,922	$	152,484	$	123,644	$	169,240	$	7,372,149
Charge for the year	2,087,167		1,088,119		10,582		2,287,110		127,052		136,524		250,334		5,986,888
Additions from acquisition (note 34(C))	2,720,997		2,199,166		—		4,058,977		—		4,246		—		8,983,386
Written back on disposal	—		(24,776)		—		(285,044)		(41,151)		(35,574)		—		(386,545)
Written off	(34,068)		—		—		(176,672)		(5,964)		—		(1,158,041)		(1,374,745)
Impairment loss (note 7(a)(iv))	—		297,061		—		3,308,559		102,776		—		739,214		4,447,610
Exchange differences	26,090		(21,879)		(6,128)		51,607		(13,907)		(12,510)		(747)		22,526
At December 31, 2022 and January 1, 2023	8,318,962		4,996,848		22,380		11,175,459		321,290		216,330		—		25,051,269
Charge for the year	2,786,456		1,282,641		7,981		1,681,221		70,432		51,082		—		5,879,813
Written back on disposal	(370,606)		(1,122,738)		(26,351)		(4,539,440)		(49,500)		(47,692)		—		(6,156,327)
Written off	(1,938,394)		(575,599)		(4,443)		(1,915,113)		(204,433)		(221,632)		—		(4,859,614)
Exchange differences	262,597		242,762		15,160		(90,724)		1,562		7,438		—		438,795
At December 31, 2023	$	9,059,015	$	4,823,914	$	14,727	$	6,311,403	$	139,351	$	5,526	$	—	$	20,353,936
Carrying amounts:
At January 1, 2022	$	5,314,425	$	2,439,265	$	22,048	$	3,651,416	$	287,059	$	329,538	$	993,441	$	13,037,192
At December 31, 2022	$	5,751,118	$	2,479,519	$	14,494	$	4,511,195	$	197,437	$	148,783	$	—	$	13,102,546
At December 31, 2023	$	2,055,745	$	1,052,612	$	30,328	$	2,557,368	$	79,149	$	2,592	$	—	$	5,777,794

(a)Right-of-use assets

The analysis of the carrying amount of right-of-use assets by class of underlying asset is as follows:


	Note	2023		2022
Properties leased for own use, carried at depreciated cost	(i)	$	2,023,753	$	5,739,426
Office equipment, carried at depreciated cost	(ii)	31,992		11,692
		$	2,055,745	$	5,751,118

The analysis of expense items in relation to leases recognized in profit or loss is as follows:


	2023		2022		2021
Depreciation charge of right-of-use assets by class of underlying asset:
- Properties leased for own use	$	2,772,649	$	2,039,815	$	1,535,333
- Office equipment	13,807		47,352		7,233
	$	2,786,456	$	2,087,167	$	1,542,566
Interest on lease liabilities (notes 7(a)(ii) and 10(a))	$	241,497	$	244,085	$	205,915
Expense relating to short-term leases or leases of low-value assets	136,940		831,631		1,019,937

During the years ended December 31, 2023, 2022 and 2021, additions to right-of-use assets of $196,626, $833,538 and $5,370,122, respectively, are mainly resulted from the capitalized lease payment payable under new tenancy agreements.

Details of the maturity analysis of lease liabilities are set out in note 24.

(i)Properties leased for own use

The Group has obtained the right to use some properties as its warehouses and offices through tenancy agreements. The leases typically run for an initial period of 2 to 10 years.

Some leases include an option to renew the lease for an additional period after the end of the contract term. Where practicable, the Group seeks to include such extension options exercisable by the Group to provide operational flexibility. The Group assesses at lease commencement date whether it is reasonably certain to exercise the extension options, and reassesses whether it is reasonably certain to exercise the options if there is a significant event or significant changes in circumstances within its control. If the Group is not reasonably certain to exercise the extension options, the future lease payments during the extension periods are not included in the measurement of lease liabilities. The potential exposure to future lease payments in relation to such leases are assessed as insignificant.

(ii)Office equipment

The Group leases office equipment under a lease expiring in 5 years. The lease does not include an option to renew the lease or purchase the leased equipment at the end of the lease term at a price deemed to be a bargain purchase option. The lease does not include variable lease payments.

(b)Amounts recognized in consolidated statement of cash flows

Amounts included in the consolidated statement of cash flows for leases comprise the following:


	2023		2022		2021
Within operating cash flows	$	(136,940)	$	(831,631)	$	(1,019,937)
Within financing cash flows	(3,476,380)		(2,121,981)		(1,504,946)
	$	(3,613,320)	$	(2,953,612)	$	(2,524,883)

Contract liabilities (Details) - USD ($)	12 Months Ended
Contract liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Contract liabilities [abstract]
Contract liabilities	$ 6,111,017	$ 5,674,290
Movement in contract liabilities
Balance at January 1	5,674,290	9,587,245
Revenue recognized	(1,937,086)	(5,904,877)
Additions from acquisition (note 34(C))	0	416,307
Receipt from customers upon entering sales contracts	2,373,813	1,575,615
Balance at December 31	$ 6,111,017	$ 5,674,290

Accrued expenses and other liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Accrued Expenses And Other Current Liabilities [Abstract]

Schedule of accrued expenses and other liabilities


	2023		2022
Current
Accrued staff costs	$	612,036	$	1,405,316
Accrued expenses	5,336,981		2,949,038
Accrued professional fee	88,211		4,432,425
Value added tax payable	35,480		58,093
Deposit liabilities	868,517		328,559
Consideration payable in relation to the ACT Acquisition (note)	—		958,224
Other payables and accruals	1,233,590		5,479,766
	8,174,815		15,611,421
Non-current
Other non-current liabilities	823,345		949,701
	$	8,998,160	$	16,561,122

Note: The amount refers to the payable to one of the sellers who is an independent third party according to the share purchase agreement as mentioned in note 34, which was fully settled in January 2023.

Intangible assets (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about intangible assets [abstract]

Schedule of intangible assets


	Website and mobile apps		Trademark and technology		Product development cost		Computer software		Customer relationship		Total
Cost:
At January 1, 2022	$	1,351,053	$	26,119,306	$	2,656,881	$	—	$	—	$	30,127,240
Additions	42,968		19,141		484,966		847,478		—		1,394,553
Additions from acquisition (note 34(C))	—		12,900,000		—		811,897		800,000		14,511,897
Disposals	(165,048)		—		(3,131,244)		—		—		(3,296,292)
Exchange differences	(16,656)		(4,950,867)		(10,603)		5,818		—		(4,972,308)
At December 31, 2022 and January 1, 2023	1,212,317		34,087,580		—		1,665,193		800,000		37,765,090
Additions	29,748		—		—		536,775		—		566,523
Written off	(170,897)		—		—		(613,741)		—		(784,638)
Exchange differences	1,071		(602)		—		(5,667)		—		(5,198)
At December 31, 2023	$	1,072,239	$	34,086,978	$	—	$	1,582,560	$	800,000	$	37,541,777
Accumulated amortization and impairment loss:
At January 1, 2022	$	1,109,492	$	4,697,964	$	493,502	$	—	$	—	$	6,300,958
Charge for the year	126,238		757,212		672,641		—		—		1,556,091
Written back on disposal	(83,549)		—		(3,131,244)		—		—		(3,214,793)
Additions from acquisition (note 34(C))	—		—		—		685,508		—		685,508
Impairment loss (note 7(a)(iv))	—		17,147,067		1,962,513		—		—		19,109,580
Exchange differences	(496)		(1,460,221)		2,588		—		—		(1,458,129)
At December 31, 2022 and January 1, 2023	1,151,685		21,142,022		—		685,508		—		22,979,215
Charge for the year	53,961		1,333,180		—		447,420		80,000		1,914,561
Written off	(170,897)		—		—		(613,741)		—		(784,638)
Exchange differences	1,331		(388)		—		7,048		—		7,991
At December 31, 2023	$	1,036,080	$	22,474,814	$	—	$	526,235	$	80,000	$	24,117,129
Carrying amounts:
At January 1, 2022	$	241,561	$	21,421,342	$	2,163,379	$	—	$	—	$	23,826,282
At December 31, 2022	$	60,632	$	12,945,558	$	—	$	979,685	$	800,000	$	14,785,875
At December 31, 2023	$	36,159	$	11,612,164	$	—	$	1,056,325	$	720,000	$	13,424,648

Other non-current assets (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Miscellaneous non-current assets [abstract]
Deposits and prepayments	$ 743,173	$ 1,292,462

Inventories (Tables)

12 Months Ended

Dec. 31, 2023

Classes of current inventories [abstract]

Schedule of inventories


	2023		2022
Consumables and reagent	$	2,471,318	$	3,662,303
Work in progress	104,165		137,106
Finished goods	551,293		734,663
	$	3,126,776	$	4,534,072

Property, plant and equipment (Details) - USD ($)	12 Months Ended
Property, plant and equipment (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	$ 13,102,546	$ 13,037,192
Charge for the year	2,995,067	1,068,535	$ 938,005
Property, plant and equipment at end of period	5,777,794	13,102,546	13,037,192
Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	38,153,815	20,409,341
Additions	541,916	5,781,689
Additions from acquisition (note 34(C))		14,632,568
Disposals	(8,312,548)	(509,459)
Written off	(5,190,735)	(1,642,971)
Exchange differences	939,282	(517,353)
Property, plant and equipment at end of period	26,131,730	38,153,815	20,409,341
Accumulated depreciation and impairment loss
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(25,051,269)	(7,372,149)
Additions from acquisition (note 34(C))		8,983,386
Charge for the year	5,879,813	5,986,888
Written back on disposal	(6,156,327)	(386,545)
Written off	(4,859,614)	(1,374,745)
Impairment loss (note 7(a)(iv))		4,447,610
Exchange differences	438,795	22,526
Property, plant and equipment at end of period	(20,353,936)	(25,051,269)	(7,372,149)
Right-of-use assets
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	5,751,118	5,314,425
Property, plant and equipment at end of period	2,055,745	5,751,118	5,314,425
Right-of-use assets \| Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	14,070,080	8,833,201
Additions	196,626	833,538
Additions from acquisition (note 34(C))		4,623,601
Disposals	(2,060,684)	0
Written off	(1,938,394)	(40,080)
Exchange differences	847,132	(180,180)
Property, plant and equipment at end of period	11,114,760	14,070,080	8,833,201
Right-of-use assets \| Accumulated depreciation and impairment loss
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(8,318,962)	(3,518,776)
Additions from acquisition (note 34(C))		2,720,997
Charge for the year	2,786,456	2,087,167
Written back on disposal	(370,606)	0
Written off	(1,938,394)	(34,068)
Impairment loss (note 7(a)(iv))		0
Exchange differences	262,597	26,090
Property, plant and equipment at end of period	(9,059,015)	(8,318,962)	(3,518,776)
Leasehold improvements
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	2,479,519	2,439,265
Property, plant and equipment at end of period	1,052,612	2,479,519	2,439,265
Leasehold improvements \| Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	7,476,367	3,898,422
Additions	53,521	598,672
Additions from acquisition (note 34(C))		3,102,189
Disposals	(1,158,623)	(30,492)
Written off	(850,863)	0
Exchange differences	356,124	(92,424)
Property, plant and equipment at end of period	5,876,526	7,476,367	3,898,422
Leasehold improvements \| Accumulated depreciation and impairment loss
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(4,996,848)	(1,459,157)
Additions from acquisition (note 34(C))		2,199,166
Charge for the year	1,282,641	1,088,119
Written back on disposal	(1,122,738)	(24,776)
Written off	(575,599)	0
Impairment loss (note 7(a)(iv))		297,061
Exchange differences	242,762	(21,879)
Property, plant and equipment at end of period	(4,823,914)	(4,996,848)	(1,459,157)
Fixtures and furniture
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	14,494	22,048
Property, plant and equipment at end of period	30,328	14,494	22,048
Fixtures and furniture \| Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	36,874	39,974
Additions	5,809	569
Additions from acquisition (note 34(C))		0
Disposals	(27,548)	0
Written off	(4,443)	0
Exchange differences	34,363	(3,669)
Property, plant and equipment at end of period	45,055	36,874	39,974
Fixtures and furniture \| Accumulated depreciation and impairment loss
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(22,380)	(17,926)
Additions from acquisition (note 34(C))		0
Charge for the year	7,981	10,582
Written back on disposal	(26,351)	0
Written off	(4,443)	0
Impairment loss (note 7(a)(iv))		0
Exchange differences	15,160	(6,128)
Property, plant and equipment at end of period	(14,727)	(22,380)	(17,926)
Office equipment, carried at depreciated cost
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	4,511,195	3,651,416
Property, plant and equipment at end of period	2,557,368	4,511,195	3,651,416
Office equipment, carried at depreciated cost \| Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	15,686,654	5,582,338
Additions	285,615	4,160,369
Additions from acquisition (note 34(C))		6,898,517
Disposals	(4,926,398)	(357,127)
Written off	(1,863,592)	(438,530)
Exchange differences	(313,508)	(158,913)
Property, plant and equipment at end of period	8,868,771	15,686,654	5,582,338
Office equipment, carried at depreciated cost \| Accumulated depreciation and impairment loss
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(11,175,459)	(1,930,922)
Additions from acquisition (note 34(C))		4,058,977
Charge for the year	1,681,221	2,287,110
Written back on disposal	(4,539,440)	(285,044)
Written off	(1,915,113)	(176,672)
Impairment loss (note 7(a)(iv))		3,308,559
Exchange differences	(90,724)	51,607
Property, plant and equipment at end of period	(6,311,403)	(11,175,459)	(1,930,922)
Computer equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	197,437	287,059
Property, plant and equipment at end of period	79,149	197,437	287,059
Computer equipment \| Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	518,727	439,543
Additions	345	188,541
Additions from acquisition (note 34(C))		0
Disposals	(81,844)	(65,993)
Written off	(221,395)	(6,320)
Exchange differences	2,667	(37,044)
Property, plant and equipment at end of period	218,500	518,727	439,543
Computer equipment \| Accumulated depreciation and impairment loss
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(321,290)	(152,484)
Additions from acquisition (note 34(C))		0
Charge for the year	70,432	127,052
Written back on disposal	(49,500)	(41,151)
Written off	(204,433)	(5,964)
Impairment loss (note 7(a)(iv))		102,776
Exchange differences	1,562	(13,907)
Property, plant and equipment at end of period	(139,351)	(321,290)	(152,484)
Motor vehicles
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	148,783	329,538
Property, plant and equipment at end of period	2,592	148,783	329,538
Motor vehicles \| Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	365,113	453,182
Additions	0	0
Additions from acquisition (note 34(C))		8,261
Disposals	(57,451)	(55,847)
Written off	(312,048)	0
Exchange differences	12,504	(40,483)
Property, plant and equipment at end of period	8,118	365,113	453,182
Motor vehicles \| Accumulated depreciation and impairment loss
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(216,330)	(123,644)
Additions from acquisition (note 34(C))		4,246
Charge for the year	51,082	136,524
Written back on disposal	(47,692)	(35,574)
Written off	(221,632)	0
Impairment loss (note 7(a)(iv))		0
Exchange differences	7,438	(12,510)
Property, plant and equipment at end of period	(5,526)	(216,330)	(123,644)
Manufacturing equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	0	993,441
Property, plant and equipment at end of period	0	0	993,441
Manufacturing equipment \| Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	0	1,162,681
Additions	0	0
Additions from acquisition (note 34(C))		0
Disposals	0	0
Written off	0	(1,158,041)
Exchange differences	0	(4,640)
Property, plant and equipment at end of period	0	0	1,162,681
Manufacturing equipment \| Accumulated depreciation and impairment loss
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	0	(169,240)
Additions from acquisition (note 34(C))		0
Charge for the year	0	250,334
Written back on disposal	0	0
Written off	0	(1,158,041)
Impairment loss (note 7(a)(iv))		739,214
Exchange differences	0	(747)
Property, plant and equipment at end of period	$ 0	$ 0	$ (169,240)

Lease liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Lease liabilities [abstract]

Schedule of remaining contractual maturities of the lease liabilities

The following table shows the remaining contractual maturities of the Group’s lease liabilities at the end of the reporting periods:


	2023		2022
Within 1 year	$	1,502,173	$	2,882,933
After 1 year but within 2 years	770,839		1,464,200
After 2 years but within 5 years	96,376		1,294,278
After 5 years	—		1,004,752
	867,215		3,763,230
Total	$	2,369,388	$	6,646,163

Accrued expenses and other liabilities

12 Months Ended

Dec. 31, 2023

Accrued Expenses And Other Current Liabilities [Abstract]

Accrued expenses and other liabilities

See accounting policies in note 38(J).


	2023		2022
Current
Accrued staff costs	$	612,036	$	1,405,316
Accrued expenses	5,336,981		2,949,038
Accrued professional fee	88,211		4,432,425
Value added tax payable	35,480		58,093
Deposit liabilities	868,517		328,559
Consideration payable in relation to the ACT Acquisition (note)	—		958,224
Other payables and accruals	1,233,590		5,479,766
	8,174,815		15,611,421
Non-current
Other non-current liabilities	823,345		949,701
	$	8,998,160	$	16,561,122

All of the accrued expenses and other current liabilities are expected to be settled within one year or repayable on demand.

Trade and other receivables and deferred expenses (Tables)

12 Months Ended

Dec. 31, 2023

Trade and other receivables [abstract]

Schedule of trade and other receivables


	2023		2022
Current
Trade receivables, net of loss allowance	$	4,058,007	$	41,691,913
Deposits, prepayments and other receivables
- deposits	887,262		1,119,968
- prepayments	3,298,558		4,965,101
- other receivables	1,099,028		804,045
	5,284,848		6,889,114
Deferred expenses (note)	8,312,890		4,577,255
	17,655,745		53,158,282
Non-current
Deferred expenses (note)	3,530,756		6,307,834
	$	21,186,501	$	59,466,116

Note: Deferred expenses represent the advanced bonus payment to a director and certain employees for retention purpose under various arrangements. These balances are amortized over the period as stated in the employment agreements and recognized as an expense when the Group consumes the benefit arising from the services provided by the director and those employees in exchange for employee benefits. The amounts expected to be amortized within one year are recognized under current assets.

Liabilities for puttable financial instrument

12 Months Ended

Dec. 31, 2023

Liabilities For Puttable Financial Instrument [Abstract]

Liabilities for puttable financial instrument

See accounting policies in note 38(J).

On December 30, 2022, the Group acquired 74.39% of the issued share capital of ACT Genomics. In connection with the ACT Acquisition, a puttable financial instrument had been granted under the shareholders’ agreements to the remaining shareholders of ACT (the “NCI of ACT”), which the Group has an obligation to buy the remaining shares from the NCI of ACT at specified price if the NCI of ACT exercises the option before the contract’s expiry date.

The puttable financial instrument is presented as a current financial liability in the consolidated financial statements due to a potential event could trigger within twelve months from the end of the reporting period.

The movement of the liabilities for puttable financial instrument during years ended December 31, 2023 and 2022 are analyzed as follows:


	2023		2022
Balance at January 1	$	17,138,905	$	—
Issuance of puttable financial instrument	—		17,138,905
Change in fair value recognized in equity	(2,516,376)		—
Balance at December 31	$	14,622,529	$	17,138,905

Income tax (credit)/expense - Deferred tax liability assets (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Represented by:
Deferred tax assets	$ (27,680)	$ (243,449)
Deferred tax liabilities	2,614,823	3,185,440
Deferred tax liability (asset)	$ 2,587,143	$ 2,941,991	$ 579,796	$ (1,951,154)

Interests in equity-accounted investees - Summary of detailed information about financial information of associates (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of associates [line items]
Carrying amount of interests in associates	$ 606,055	$ 788,472
Group's share of total comprehensive income	(62,981,709)	(195,296,319)	$ (173,756,730)
CERBACT Asia Holdings Pte. Ltd
Disclosure of associates [line items]
Carrying amount of interests in associates	606,055	788,472
Group's share of total comprehensive income	$ (188,830)	$ 0

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

Trade and other receivables and deferred expenses (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current
Trade receivables, net of loss allowance	$ 4,058,007	$ 41,691,913
Deposits, prepayments and other receivables
- deposits	887,262	1,119,968
- prepayments	3,298,558	4,965,101
- other receivables	1,099,028	804,045
Deposits, prepayments and other receivables	5,284,848	6,889,114
Deferred expenses	8,312,890	4,577,255
Current	17,655,745	53,158,282
Non-current
Deferred expenses	3,530,756	6,307,834
Trade and other non-current receivables	$ 21,186,501	$ 59,466,116

Financial instruments - Fair values and risk management - Market Risk (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
USD
Disclosure of risk management strategy related to hedge accounting [line items]
Increase in foreign exchange rates	1.00%	1.00%
Effect on profit after tax and retained profits, increase in foreign exchange rates	$ (346,058)	$ (63,061)
(Decrease) in foreign exchange rates	(1.00%)	(1.00%)
Effect on profit after tax and retained profits, decrease in foreign exchange rates	$ 346,058	$ 63,061
RMB
Disclosure of risk management strategy related to hedge accounting [line items]
Increase in foreign exchange rates	5.00%	5.00%
Effect on profit after tax and retained profits, increase in foreign exchange rates	$ (3,478)	$ 48,298
(Decrease) in foreign exchange rates	(5.00%)	(5.00%)
Effect on profit after tax and retained profits, decrease in foreign exchange rates	$ 3,478	$ (48,298)

Preference shares liabilities

12 Months Ended

Dec. 31, 2023

Disclosure of financial liabilities [abstract]

Preference shares liabilities

Prenetics HK entered into a Share Exchange Agreement and Subscription Agreement with, amongst others, the existing shareholders of Prenetics HK and PHCL in May 2021. Under the agreement, 4,154,726 Series A preference shares, 5,338,405 Series B preference shares, 10,532,116 Series C preference shares were exchanged into PHCL’s preference shares at a conversion ratio of 1 to 1, and the contractual terms of the Notes were amended by inserting a new clause so that the Notes are exchangeable into PHCL’s Series D preference shares upon the completion of the Corporate Restructuring. The share exchange and issuance were completed on June 16, 2021. On the same date, PHCL issued 1,650,913 Series E preference shares.

All series of the preference shares share the following features:

•preference shareholders are entitled to the same voting power of the ordinary shares on an as if converted basis and are entitled to a right to vote as a separate class on the special corporate matters;

•8% non-cumulative dividend per annum with distribution priority over the holders of ordinary shares (the “Ordinary Shareholders”). Among the preference shareholders, shareholders of Series C have priority over those of Series B and A, and Series B have priority over Series A;

•the preference shares can be redeemed at the option of the holders upon the occurrence of a Redemption Event, which is defined as the failure to secure an initial public offering or a liquidation event by June 16, 2026. Otherwise, the preference shares will be converted into the ordinary shares of the Company upon the closing of an initial public offering at a then-effective conversion ratio with a down-round protection feature;

•the redemption amount will be based on i) the product of the original subscription price paid and the number of shares to be redeemed for Series A; and ii) the product of the original subscription price paid and the number of share to be redeemed, plus all declared or accrued but unpaid dividends, plus a simple interest of 10% per annum on the subscription price for Series B, Series C and Series D; and iii) the product of the original subscription price paid and the number of share to be redeemed, plus all declared or accrued but unpaid dividends, plus a simple interest of 12% per annum on the subscription price for Series E; and

•upon liquidation, the holders shall be entitled to receive their investment amount prior to and in preference to Ordinary Shareholders and in the following order of priority from the highest to the lowest: Series E, Series D, Series C, Series B and Series A.

Following the share exchange, all series of the preference shares have been reclassified or classified as financial liability under IAS 32, Financial Instruments: Presentation because they contain i) a contractual obligation to deliver cash depending on the outcome of an IPO or a liquidation event that is beyond the control of both the Company and the holders of the shares; and ii) the conversion option does not meet the fixed-for-fixed condition. As such, the redemption feature is considered a non-derivative financial liability being measured at amortized cost (i.e. present value of the redemption amount) and the conversion feature is considered as a derivative financial liability being measured at fair value through profit or loss.

As a result of the aforementioned share exchange, the difference between the carrying amount of Series A, Series B and Series C preference shares and their fair value of the preferred shares liability on the exchange date is recognized in other reserve. For Series D preference shares, there was no difference between the fair value of the convertible securities and the fair value of the liability on the exchange date. For Series E preference shares, they were recorded at fair value on the date of issuance.

The movements of preference shares during the years ended December 31, 2022 and 2023 are as follows:


	Present value of redemption amount		Conversion feature		Total
Balance at January 1, 2022	$	61,373,153	$	425,031,617	$	486,404,770
Changes in the carrying amount of preference shares liabilities (note 10(a))	3,752,758		—		3,752,758
Changes in fair value recognized in profit or loss	—		60,091,353		60,091,353
Reclassification to share capital and share premium upon listing	(65,125,911)		(485,122,970)		(550,248,881)
Balance at December 31, 2022 and 2023	$	—	$	—	$	—

Preference shares liabilities - Movements (Details)	12 Months Ended
Preference shares liabilities - Movements (Details)	Dec. 31, 2023 USD ($)
Disclosure of financial liabilities [line items]
Balance at January 1, 2022	$ 46,744,935
Balance at December 31, 2022 and 2023	26,837,751
Preference shares liabilities
Disclosure of financial liabilities [line items]
Balance at January 1, 2022	486,404,770
Changes in the carrying amount of preference shares liabilities (note 10(a))	3,752,758
Changes in fair value recognized in profit or loss	60,091,353
Reclassification to share capital and share premium upon listing	(550,248,881)
Balance at December 31, 2022 and 2023	0
Financial liabilities at amortized cost \| Preference shares liabilities
Disclosure of financial liabilities [line items]
Balance at January 1, 2022	61,373,153
Changes in the carrying amount of preference shares liabilities (note 10(a))	3,752,758
Changes in fair value recognized in profit or loss	0
Reclassification to share capital and share premium upon listing	(65,125,911)
Balance at December 31, 2022 and 2023	0
Financial liabilities measured at fair value \| Preference shares liabilities
Disclosure of financial liabilities [line items]
Balance at January 1, 2022	425,031,617
Changes in the carrying amount of preference shares liabilities (note 10(a))	0
Changes in fair value recognized in profit or loss	60,091,353
Reclassification to share capital and share premium upon listing	(485,122,970)
Balance at December 31, 2022 and 2023	$ 0

- Definition

The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity’s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity’s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]

+ References + Details

Inventories - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Expenses By Nature Table [Line Items]
Cost of inventories (note 18)	$ 6,320,806	$ 7,129,679	$ 8,948,607
Inventory write-down	3,136,551	2,055,859
Direct costs
Schedule Of Expenses By Nature Table [Line Items]
Cost of inventories (note 18)	$ 9,081,519	$ 57,442,036	$ 52,701,330

Acquisition of ACT Genomics

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about business combination [abstract]

Acquisition of ACT Genomics

See accounting policy in note 38(A)(i)-(iii).

A.Consideration transferred

The following table summarizes the acquisition date fair value of each major class of consideration transferred.


Cash	$	9,041,776
Deferred consideration (note 22)	958,224
Equity instruments (1,326,127 ordinary shares)	39,783,820
Total consideration transferred	$	49,783,820
Net cash outflow arising on acquisition:
Cash consideration	$	9,041,776
Less: cash and cash equivalent balances acquired (note 34(C))	5,623,061
Total net cash outflow arising on acquisition	$	3,418,715

Equity instruments issued

The fair value of the ordinary shares issued was based on the listed share price of the Company at December 30, 2022 of $2 per share (equivalent to $30 per share after reverse stock split).

B.Acquisition-related costs

The Group incurred acquisition-related costs of $1,191,858 on legal fees and due diligence costs. These costs have been included in ‘administrative and other operating expenses’.

C.Identifiable assets acquired and liabilities assumed

The following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition.


Property, plant and equipment (note 13)	$	5,649,182
Intangible assets (note 14)	13,826,389
Interests in equity-accounted investees (note 16)	788,472
Deferred tax assets	235,879
Inventories	1,294,959
Trade receivables (including loss allowance $1,263,570)	2,594,976
Deposits, prepayments and other receivables	2,013,985
Cash and cash equivalents (note 34(A))	5,623,061
Trade payables	(857,537)
Accrued expenses and other current liabilities	(2,763,480)
Contract liabilities (note 23)	(416,307)
Lease liabilities	(2,379,687)
Tax liabilities	(5,713)
Deferred tax liabilities	(2,913,666)
Other non-current liabilities	(223,207)
Total identifiable net assets acquired	$	22,467,306

Measurement of fair values

The valuation technique used for measuring the fair value of material assets acquired was as follow.


Assets acquired			Valuation technique
Property, plant and equipment			Cost technique: The valuation model considers market prices for depreciated replacement cost when appropriate. Depreciated replacement cost reflects functional and economic obsolescence.
Intangible assets			Multi-period excess earnings method: The multi-period excess earnings method considers the present value of net cash flows expected to be generated by the technology and customer relationships, by excluding any cash flows related to contributory assets.

If the acquisition had occurred on January 1, 2022, management estimates that the Group’s consolidated revenue would have been increased by $15,083,979, and consolidated loss for the year would have been increased by $64,938,749.

D.Goodwill

Goodwill arising from the acquisition has been recognized as follows.


	2022
Consideration transferred (note 34(A))	$	49,783,820
Non-controlling interests, based on their proportionate interest in the recognized amounts of the assets and liabilities of ACT Genomics	6,483,762
Fair value of identifiable net assets (note 34(C))	(22,467,306)
Goodwill (note 15)	$	33,800,276

The goodwill is attributable mainly to the skills and technical talent of ACT Genomics’s work force and the synergies expected to be achieved from integrating the company into the Group’s existing business. None of the goodwill recognized is expected to be deductible for tax purposes.

Financial instruments - Fair values and risk management - Movement in the loss allowance account (Details) - Allowance for impairment - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about financial instruments [line items]
Balance at January 1	$ 1,592,119	$ 518,968
Additions from acquisition (note 34(C))	0	1,263,570
Net remeasurement of loss allowance	782,488	(136,493)
Amounts written off	(41,776)	(33,808)
Exchange differences	91,278	(20,118)
Balance at December 31	$ 2,424,109	$ 1,592,119

- Definition

The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose the entity’s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]

+ References + Details

Loss per share

12 Months Ended

Dec. 31, 2023

Earnings per share [abstract]

Loss per share

The calculation of the basic and diluted loss per share have been based on the following loss attributable to equity shareholders and weighted-average number of ordinary shares outstanding.


	2023		2022		2021
			(Restated)		(Restated)
Loss for the year
Loss for the year attributable to equity shareholders of the Company	$	(62,723,871)	$	(190,453,333)	$	(174,009,273)
Number of shares
Weighted-average number of ordinary shares	11,246,010		5,069,315		973,134

At December 31, 2023, 859,331 shares underlying restricted share units and 1,492,307 shares underlying warrants were excluded from the diluted weighted-average number of ordinary shares calculation because their effect would have been anti-dilutive. At December 31, 2022, 1,674,285 shares underlying restricted share units, 1,492,306 shares underlying warrants and 52,619 shares underlying exchangeable notes were excluded from the diluted weighted-average number of ordinary shares calculation because their effect would have been anti-dilutive. At December 31, 2021, 826,695 shares underlying restricted share units and 51,762 shares underlying exchangeable notes were excluded from the diluted weighted-average number of ordinary shares calculation because their effect would have been anti-dilutive.

Acquisition of ACT Genomics - Disclosure of Reconciliation of Changes in Goodwill (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill (note 15)	$ 29,170,123	$ 33,800,276	$ 3,978,065
ACT Genomics Holdings Company Limited
Disclosure of reconciliation of changes in goodwill [line items]
Consideration transferred (note 34(A))		49,783,820
Non-controlling interests, based on their proportionate interest in the recognized amounts of the assets and liabilities of ACT Genomics		6,483,762
Fair value of identifiable net assets (note 34(C))		22,467,306
Goodwill (note 15)		$ 33,800,276

Equity-settled share-based transactions - Schedule of number and aggregate fair value of RSU - Prenetics 2022 (Details) - Restricted share units	Dec. 31, 2023 USD ($) shares $ / shares	Jun. 30, 2023 USD ($) shares $ / shares	Jun. 23, 2023 USD ($) shares $ / shares	Feb. 01, 2023 USD ($) shares $ / shares	Dec. 31, 2022 USD ($) shares $ / shares	Jun. 30, 2022 USD ($) shares $ / shares	May 18, 2022 USD ($) shares $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted (in shares) \| shares	7,928	2,403,529	16,486,108	66,666	946,330	2,446,557	144,522
Closing price per ordinary share less subscription price per (in $ per share) \| $ / shares	$ 3.39	$ 0.79	$ 0.90	$ 1.49	$ 2.00	$ 4.04	$ 7.64
Aggregate fair value of the RSUs (in USD) \| $	$ 26,855	$ 1,903,341	$ 14,874,763	$ 99,332	$ 1,892,660	$ 9,884,090	$ 1,104,148

Loans and borrowings (Tables)

12 Months Ended

Dec. 31, 2023

Borrowings [abstract]

Schedule of reconciliation of liabilities arising from financing activities

The table below details changes in the Group’s liabilities from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are liabilities for which cash flows were, or future cash flows will be, classified in the Group’s consolidated statement of cash flows as cash flows from financing activities.


	Lease liabilities		Trade financing		Preference shares liabilities		Total
	(note 24)		(note 25(a))		(note 26)
Balance at January 1, 2022	$	5,267,210	$	—	$	486,404,770	$	491,671,980
Changes from financing cash flows:
Capital element of lease rentals paid	(1,834,272)		—		—		(1,834,272)
Interest element of lease rentals paid	(244,085)		—		—		(244,085)
Interest paid	—		(172,978)		—		(172,978)
Proceeds from trade financing	—		21,677,075		—		21,677,075
Repayment of trade financing	—		(21,677,075)		—		(21,677,075)
Total changes from financing cash flows	(2,078,357)		(172,978)		—		(2,251,335)
Other changes:
Increase in lease liabilities from entering into new leases	833,538		—		—		833,538
Interest expenses (notes 7(a)(ii) and 10(a))	244,085		172,978		—		417,063
Changes in the carrying amount of preference shares liabilities (note 26)	—		—		3,752,758		3,752,758
Additions from acquisition (note 34(C))	2,379,687		—		—		2,379,687
Fair value loss on preference shares liabilities (note 26)	—		—		60,091,353		60,091,353
Reclassification to share premium (note 26)	—		—		(550,248,881)		(550,248,881)
Total other changes	3,457,310		172,978		(486,404,770)		(482,774,482)
Balance at December 31, 2022 and January 1, 2023	6,646,163		—		—		6,646,163
Changes from financing cash flows:
Capital element of lease rentals paid	(3,234,883)		—		—		(3,234,883)
Interest element of lease rentals paid	(241,497)		—		—		(241,497)
Total changes from financing cash flows	(3,476,380)		—		—		(3,476,380)
Other changes:
Increase in lease liabilities from entering into new leases	196,626		—		—		196,626
Lease modification	(1,238,518)		—		—		(1,238,518)
Interest expenses (notes 7(a)(ii) and 10(a))	241,497		—		—		241,497
Total other changes	(800,395)		—		—		(800,395)
Balance at December 31, 2023	$	2,369,388	$	—	$	—	$	2,369,388

Lease liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Lease liabilities, non-current	$ 867,215	$ 3,763,230
Total	2,369,388	6,646,163
Within 1 year
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Lease liabilities, non-current	1,502,173	2,882,933
After 1 year but within 2 years
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Lease liabilities, non-current	770,839	1,464,200
After 2 years but within 5 years
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Lease liabilities, non-current	96,376	1,294,278
After 5 years
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Lease liabilities, non-current	$ 0	$ 1,004,752

Material accounting policies - Intangible assets (other than goodwill) (Details)	12 Months Ended
	Dec. 31, 2023
Top of range
Disclosure of detailed information about intangible assets [line items]
Consideration refundable period from the date of delivery, services upfront	30 days
Office equipment, carried at depreciated cost \| Bottom
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives	3 years
Office equipment, carried at depreciated cost \| Top of range
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives	5 years
Website and mobile apps
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives	2 years
Trademark and technology \| Bottom
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives	10 years
Trademark and technology \| Top of range
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives	20 years
Product development cost
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives	3 years
Computer software
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives	3 years
Customer relationship
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives	10 years

Related parties (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure Of Material Related Party Transactions [Abstract]

Schedule of transactions with other related parties


	2023		2022		2021
Sales to an equity-accounted investee	$	701,807	$	—	$	—
Services recharge received from an equity-accounted investee	12,857		—		—
Purchase from an equity-accounted investee	—		—		(53,981)
Services provided by a company with control from a director of the Company	—		(30,630)		(90,353)
Legal and professional fee paid on behalf of related companies	—		—		(9,060)

Summary of key management personnel compensation

Key management personnel compensation comprised as following.


	2023		2022		2021
Directors’ fees	$	420,000	$	261,110	$	—
Salaries, wages and other benefits	4,239,821		24,549,012		2,281,701
Contributions to defined contribution retirement plan	14,779		17,538		15,643
Equity-settled share-based payment expenses (note)	10,297,075		30,284,686		21,500,167
	$	14,971,675	$	55,112,346	$	23,797,511

Note: The balances are non-cash transactions for the reporting period. Details of the recognition and the fair value determination are included in note 30.

Consolidated statements of financial position - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Assets
Property, plant and equipment	$ 5,777,794	$ 13,102,546
Intangible assets	13,424,648	14,785,875
Goodwill	29,170,123	33,800,276
Amounts due from equity-accounted investees	98,464,875	788,472
Financial assets at fair value through profit or loss	9,371,064	0
Deferred tax assets	27,680	243,449
Deferred expenses	3,530,756	6,307,834
Other non-current assets	743,173	1,292,462
Non-current assets	160,510,113	70,320,914
Deferred expenses	8,312,890	4,577,255
Inventories	3,126,776	4,534,072
Trade receivables	4,058,007	41,691,913
Deposits, prepayments and other receivables	5,284,848	6,889,114
Amount due from a related company	5,123	0
Amounts due from equity-accounted investees	132,114	0
Financial assets at fair value through profit or loss	11,034,200	17,537,608
Short-term deposits	16,000,000	19,920,160
Cash and cash equivalents	45,706,448	146,660,195
Current assets	93,660,406	241,810,317
Total assets	254,170,519	312,131,231
Liabilities
Deferred tax liabilities	2,614,823	3,185,440
Warrant liabilities	223,850	3,574,885
Lease liabilities	867,215	3,763,230
Other non-current liabilities	823,345	949,701
Non-current liabilities	4,529,233	11,473,256
Trade payables	1,671,019	7,291,133
Accrued expenses and other current liabilities	8,174,815	15,611,421
Contract liabilities	6,111,017	5,674,290
Lease liabilities	1,502,173	2,882,933
Liabilities for puttable financial instrument	14,622,529	17,138,905
Tax payable	7,402,461	8,596,433
Current liabilities	39,484,014	57,195,115
Total liabilities	44,013,247	68,668,371
Equity
Share capital	18,308	13,698
Reserves	206,339,490	237,050,429
Total equity attributable to equity shareholders of the Company	206,357,798	237,064,127
Non-controlling interests	3,799,474	6,398,733
Total equity	210,157,272	243,462,860
Total equity and liabilities	$ 254,170,519	$ 312,131,231

Loans and borrowings - Schedule of consolidated statement of cash flows (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Beginning of the period	$ 6,646,163	$ 491,671,980
Changes from financing cash flows:
Capital element of lease rentals paid	(3,234,883)	(1,834,272)
Interest element of lease rentals paid	(241,497)	(244,085)
Interest paid	0	(172,978)	$ (33)
Proceeds from trade financing		21,677,075
Repayment of trade financing		21,677,075
Total changes from financing cash flows	(3,476,380)	(2,251,335)
Other changes:
Increase in lease liabilities from entering into new leases	196,626	833,538
Interest expenses (notes 7(a)(ii) and 10(a))	241,497	417,063
Changes in the carrying amount of preference shares liabilities (note 26)		3,752,758
Additions from acquisition (note 34(C))		2,379,687
Fair value loss on preference shares liabilities (note 26)		60,091,353
Reclassification to share premium (note 26)		(550,248,881)
Lease modification	(1,238,518)
Total other changes	(800,395)	(482,774,482)
Ending of the period	2,369,388	6,646,163	491,671,980
Lease liabilities
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Beginning of the period	6,646,163	5,267,210
Changes from financing cash flows:
Capital element of lease rentals paid	(3,234,883)	(1,834,272)
Interest element of lease rentals paid	(241,497)	(244,085)
Interest paid		0
Proceeds from trade financing		0
Repayment of trade financing		0
Total changes from financing cash flows	(3,476,380)	(2,078,357)
Other changes:
Increase in lease liabilities from entering into new leases	196,626	833,538
Interest expenses (notes 7(a)(ii) and 10(a))	241,497	244,085
Changes in the carrying amount of preference shares liabilities (note 26)		0
Additions from acquisition (note 34(C))		2,379,687
Fair value loss on preference shares liabilities (note 26)		0
Reclassification to share premium (note 26)		0
Lease modification	(1,238,518)
Total other changes	(800,395)	3,457,310
Ending of the period	2,369,388	6,646,163	5,267,210
Trade financing
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Beginning of the period	0	0
Changes from financing cash flows:
Capital element of lease rentals paid	0	0
Interest element of lease rentals paid	0	0
Interest paid		(172,978)
Proceeds from trade financing		21,677,075
Repayment of trade financing		21,677,075
Total changes from financing cash flows	0	(172,978)
Other changes:
Increase in lease liabilities from entering into new leases	0	0
Interest expenses (notes 7(a)(ii) and 10(a))	0	172,978
Changes in the carrying amount of preference shares liabilities (note 26)		0
Additions from acquisition (note 34(C))		0
Fair value loss on preference shares liabilities (note 26)		0
Reclassification to share premium (note 26)		0
Lease modification	0
Total other changes	0	172,978
Ending of the period	0	0	0
Preference shares liabilities
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Beginning of the period	0	486,404,770
Changes from financing cash flows:
Capital element of lease rentals paid	0	0
Interest element of lease rentals paid	0	0
Interest paid		0
Proceeds from trade financing		0
Repayment of trade financing		0
Total changes from financing cash flows	0	0
Other changes:
Increase in lease liabilities from entering into new leases	0	0
Interest expenses (notes 7(a)(ii) and 10(a))	0	0
Changes in the carrying amount of preference shares liabilities (note 26)		3,752,758
Additions from acquisition (note 34(C))		0
Fair value loss on preference shares liabilities (note 26)		60,091,353
Reclassification to share premium (note 26)		(550,248,881)
Lease modification	0
Total other changes	0	(486,404,770)
Ending of the period	$ 0	$ 0	$ 486,404,770

Intangible assets (Details) - USD ($)	12 Months Ended
Intangible assets (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about intangible assets [line items]
Beginning balance	$ 14,785,875	$ 23,826,282
Ending balance	13,424,648	14,785,875
Acquisition and manufacturing costs
Disclosure of detailed information about intangible assets [line items]
Beginning balance	37,765,090	30,127,240
Additions	566,523	1,394,553
Written off	(784,638)
Additions from acquisition (note 34(C))		14,511,897
Disposals		(3,296,292)
Exchange differences	(5,198)	(4,972,308)
Ending balance	37,541,777	37,765,090
Accumulated depreciation and impairment loss
Disclosure of detailed information about intangible assets [line items]
Beginning balance	(22,979,215)	(6,300,958)
Charge for the year	1,914,561	1,556,091
Written off	784,638
Additions from acquisition (note 34(C))		685,508
Disposals		3,214,793
Impairment loss (note 7(a)(iv))		19,109,580
Exchange differences	7,991	(1,458,129)
Ending balance	(24,117,129)	(22,979,215)
Website and mobile apps
Disclosure of detailed information about intangible assets [line items]
Beginning balance	60,632	241,561
Ending balance	36,159	60,632
Website and mobile apps \| Acquisition and manufacturing costs
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,212,317	1,351,053
Additions	29,748	42,968
Written off	(170,897)
Additions from acquisition (note 34(C))		0
Disposals		(165,048)
Exchange differences	1,071	(16,656)
Ending balance	1,072,239	1,212,317
Website and mobile apps \| Accumulated depreciation and impairment loss
Disclosure of detailed information about intangible assets [line items]
Beginning balance	(1,151,685)	(1,109,492)
Charge for the year	53,961	126,238
Written off	170,897
Additions from acquisition (note 34(C))		0
Disposals		83,549
Impairment loss (note 7(a)(iv))		0
Exchange differences	1,331	(496)
Ending balance	(1,036,080)	(1,151,685)
Trademark and technology
Disclosure of detailed information about intangible assets [line items]
Beginning balance	12,945,558	21,421,342
Ending balance	11,612,164	12,945,558
Trademark and technology \| Acquisition and manufacturing costs
Disclosure of detailed information about intangible assets [line items]
Beginning balance	34,087,580	26,119,306
Additions	0	19,141
Written off	0
Additions from acquisition (note 34(C))		12,900,000
Disposals		0
Exchange differences	(602)	(4,950,867)
Ending balance	34,086,978	34,087,580
Trademark and technology \| Accumulated depreciation and impairment loss
Disclosure of detailed information about intangible assets [line items]
Beginning balance	(21,142,022)	(4,697,964)
Charge for the year	1,333,180	757,212
Written off	0
Additions from acquisition (note 34(C))		0
Disposals		0
Impairment loss (note 7(a)(iv))		17,147,067
Exchange differences	(388)	(1,460,221)
Ending balance	(22,474,814)	(21,142,022)
Product development cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	2,163,379
Ending balance	0	0
Product development cost \| Acquisition and manufacturing costs
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	2,656,881
Additions	0	484,966
Written off	0
Additions from acquisition (note 34(C))		0
Disposals		(3,131,244)
Exchange differences	0	(10,603)
Ending balance	0	0
Product development cost \| Accumulated depreciation and impairment loss
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	(493,502)
Charge for the year	0	672,641
Written off	0
Additions from acquisition (note 34(C))		0
Disposals		3,131,244
Impairment loss (note 7(a)(iv))		1,962,513
Exchange differences	0	2,588
Ending balance	0	0
Computer software
Disclosure of detailed information about intangible assets [line items]
Beginning balance	979,685	0
Ending balance	1,056,325	979,685
Computer software \| Acquisition and manufacturing costs
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,665,193	0
Additions	536,775	847,478
Written off	(613,741)
Additions from acquisition (note 34(C))		811,897
Disposals		0
Exchange differences	(5,667)	5,818
Ending balance	1,582,560	1,665,193
Computer software \| Accumulated depreciation and impairment loss
Disclosure of detailed information about intangible assets [line items]
Beginning balance	(685,508)	0
Charge for the year	447,420	0
Written off	613,741
Additions from acquisition (note 34(C))		685,508
Disposals		0
Impairment loss (note 7(a)(iv))		0
Exchange differences	7,048	0
Ending balance	(526,235)	(685,508)
Customer relationship
Disclosure of detailed information about intangible assets [line items]
Beginning balance	800,000	0
Ending balance	720,000	800,000
Customer relationship \| Acquisition and manufacturing costs
Disclosure of detailed information about intangible assets [line items]
Beginning balance	800,000	0
Additions	0	0
Written off	0
Additions from acquisition (note 34(C))		800,000
Disposals		0
Exchange differences	0	0
Ending balance	800,000	800,000
Customer relationship \| Accumulated depreciation and impairment loss
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	0
Charge for the year	80,000	0
Written off	0
Additions from acquisition (note 34(C))		0
Disposals		0
Impairment loss (note 7(a)(iv))		0
Exchange differences	0	0
Ending balance	$ (80,000)	$ 0

Warrant liabilities - Additional Information (Details) - NASDAQ Intermarket	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Disclosure of warranty liabilities [line items]
Class of warrants or rights exercise price (in $ per share)	$ 8.91
Warrants
Disclosure of warranty liabilities [line items]
Class of warrants or rights issued during the period units (in shares) \| shares	1,492,306
Warrants after reverse stock split
Disclosure of warranty liabilities [line items]
Class of warrants or rights exercise price (in $ per share)	$ 133.65

Income tax (credit)/expense - Deferred tax assets not recognized (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Major components of tax expense (income) [abstract]
Tax losses utilized	$ 97,793,602	$ 62,586,553

Non-controlling interests

12 Months Ended

Dec. 31, 2023

Non-controlling interests [Abstract]

Non-controlling interests

See accounting policies in Note 38(A)(iii).

The following table summaries the information relating each of the Group's subsidiaries that has material non-controlling interests, before any intra-group eliminations.


	2023
ACT Genomics
Non-controlling interests percentage	25.61	%


	2023
Non-current assets	$	28,072,665
Current assets	18,267,042
Non-current liabilities	(3,666,563)
Current liabilities	(7,752,718)

Equity attributable to equity shareholder of the parent Company	25,977,305
Equity attributable to non-controlling interests	8,943,121


	2023
Revenue	$	17,085,906
Expenses	(25,054,425)
Loss for the year	$	(7,968,519)
Loss attributable to equity shareholder of the parent Company	$	(5,927,781)
Loss attributable to non-controlling interests	(2,040,738)
Loss for the year	$	(7,968,519)
Other comprehensive income attributable to equity shareholder of the parent Company	$	534,723
Other comprehensive income attributable to non-controlling interests	184,087
Other comprehensive income for the year	$	718,810
Total comprehensive income attributable to equity shareholder of the parent Company	$	(5,393,058)
Total comprehensive income attributable to non-controlling interests	(1,856,651)
Total comprehensive income for the year	$	(7,249,709)
Net cash outflow from operating activities	$	(10,519,097)
Net cash outflow from investment activities	(522,742)
Net cash outflow from financing activities	(1,469,418)
Net cash outflow	$	(12,511,257)
Dividends paid to non-controlling interests	$	—

Income tax (credit)/expense - Taxation in the consolidated statements of profit or loss represents (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Deferred tax
Origination and reversal of temporary differences	$ (315,796)	$ (279,633)	$ 2,530,047
Tax (credit)/expense	(269,359)	(244,816)	2,568,522
Hong Kong
Current tax expense
Changes in estimates related to prior years	(23,323)	0	0
Deferred tax
Tax (credit)/expense			0
Overseas
Current tax expense
Changes in estimates related to prior years	$ 69,760	$ 34,817	$ 38,475

- Definition

The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]

+ References + Details

Loss per share (Tables)

12 Months Ended

Dec. 31, 2023

Earnings per share [abstract]

Schedule of basic and diluted loss per share


	2023		2022		2021
			(Restated)		(Restated)
Loss for the year
Loss for the year attributable to equity shareholders of the Company	$	(62,723,871)	$	(190,453,333)	$	(174,009,273)
Number of shares
Weighted-average number of ordinary shares	11,246,010		5,069,315		973,134

Other income and other net gains/(losses)

12 Months Ended

Dec. 31, 2023

Analysis of income and expense [abstract]

Other income and other net gains/(losses)


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Government subsidies (note)	$	108,248	$	534,678	$	7,932
Bank interest income	3,923,279		471,878		201
Dividend income	—		9,862		—
Net foreign exchange gains/(losses)	330,193		(663,004)		(51,260)
Impairment loss on amount due from an equity-accounted investee	—		—		(176,227)
Sundry income	145,383		76,443		17,178
	$	4,507,103	$	429,857	$	(202,176)

Note: The Group has recognized various subsidies granted by the governments in different jurisdictions, including:

(i)funding support of $71,657 and $234,470 from the Employment Support Scheme (the “ESS”) under the Anti-epidemic Fund set up by The Government of Hong Kong Special Administrative Region during the years ended December 31, 2023 and 2022, respectively. The purpose of the funding was to provide financial support to enterprises to retain their employees who would otherwise be made redundant. Under the terms of the grant, the Group was required not to make redundancies during the subsidy period and to spend all the funding on paying wages to the employees;

(ii)funding support of $7,932 from the Jobs Support Scheme (the “JSS”) as one of the COVID-19 resilience package granted by the Singapore government during the year ended December 31, 2021. The purpose of the funding was to provide wage support to employers in retaining their local employees (Singapore Citizens and Permanent Residents) during this period of economic uncertainty. Under the terms of the grant, the Singapore government co-funded a proportion of the gross monthly wages paid to each local employee. All active employers, except for government organizations (local and foreign) and representative offices, were eligible for the JSS; and

(iii)funding support of $36,591 and $300,208 from the Job Creation Scheme from the Hong Kong Institute of Human Resource Management (the “HKIHRM”) under the Anti-epidemic Fund set up by The Government of Hong Kong Special Administrative Region during the years ended December 31, 2023 and 2022, respectively. Under the Job Creation Scheme, employers who are HKIHRM members which created job positions are eligible to apply for salary government grants.

Acquisition of ACT Genomics - Additional Information (Details) - USD ($)		12 Months Ended
	Jan. 01, 2022	Dec. 31, 2022	Dec. 30, 2022
Disclosure of detailed information about business combination [line items]
Revenue of combined equity	$ 15,083,979
Profit (loss) of combined equity	$ 64,938,749
ACT Genomics Holdings Company Limited
Disclosure of detailed information about business combination [line items]
Share price (in $ per share)		$ 2
Acquisition related costs		$ 1,191,858
ACT Genomics Holdings Company Limited \| Ordinary shares after reverse stock
Disclosure of detailed information about business combination [line items]
Share price (in $ per share)			$ 30

Capital and reserves - Movement in ordinary shares of the Company (Details)		12 Months Ended
	Nov. 01, 2023	Dec. 31, 2023 USD ($) shares Vote $ / shares	Dec. 31, 2022 USD ($) shares $ / shares	Dec. 31, 2021 USD ($) shares
Disclosure of classes of share capital [line items]
Balance at the beginning		$ 13,698
Cancellation and retirement of repurchased shares		0
Vesting of shares under the restricted share scheme			$ 116,864	$ 4,517
Shares issued upon conversion of exchange loan notes		0	0	$ 0
Issuance of shares for acquisition		0	39,783,820
Issuance of shares for reverse stock split		0
Balance at the end		$ 18,308	$ 13,698
Par value per share ($ per share) \| $ / shares		$ 1
Stockholders equity note stock split conversion ratio	0.0667	0.0667
Class A ordinary shares
Disclosure of classes of share capital [line items]
Par value per share ($ per share) \| $ / shares		$ 0.0015
Class B ordinary shares
Disclosure of classes of share capital [line items]
Par value per share ($ per share) \| $ / shares		$ 0.0015
Ordinary shares
Disclosure of classes of share capital [line items]
Number of shares authorised (in shares) \| shares		33,333,334	33,333,334
Authorized share capital		$ 50,000	$ 50,000
Par value per share ($ per share) \| $ / shares			$ 0.0001
Ordinary shares \| Class A ordinary shares
Disclosure of classes of share capital [line items]
Number of shares authorised (in shares) \| shares		30,000,001	30,000,001
Authorized share capital		$ 45,000	$ 45,000
Balance at the beginning (in shares) \| shares		8,484,616	0
Balance at the beginning		$ 12,727	$ 0
Issuance of prenetics ordinary shares as part of reverse recapitalization (in shares) \| shares		0	6,751,061
Issuance of Prenetics Ordinary Shares as part of Reverse Recapitalization		$ 0	$ 10,127
Number of cancellation and retirement of repurchased shares (in shares) \| shares		(112,317)	0
Cancellation and retirement of repurchased shares		$ 168	$ 0
Share issued for vesting of restricted share units (in shares) \| shares		513,345	523,519
Vesting of shares under the restricted share scheme		$ 770	$ 785
Share issued upon conversion of exchange loan notes (in shares) \| shares		52,620	52,619
Shares issued upon conversion of exchange loan notes		$ 79	$ 79
Post reverse stock split (in shares) \| shares		35,754	0
Issuance of shares for reverse stock split		$ 54	$ 0
Balance at the end (in shares) \| shares		10,624,208	8,484,616	0
Balance at the end		$ 15,937	$ 12,727	$ 0
Par value per share ($ per share) \| $ / shares			$ 0.0001
Number of votes per share \| Vote		1
Ordinary shares \| Class A ordinary shares \| Insighta
Disclosure of classes of share capital [line items]
Number of instruments or interests issued or issuable (in shares) \| shares		1,481,481	0
Issuance of shares for acquisition		$ 2,222	$ 0
Ordinary shares \| Class A ordinary shares \| ACT
Disclosure of classes of share capital [line items]
Number of instruments or interests issued or issuable (in shares) \| shares		168,709	1,157,417
Issuance of shares for acquisition		$ 253	$ 1,736
Ordinary shares \| Class B ordinary shares
Disclosure of classes of share capital [line items]
Number of shares authorised (in shares) \| shares		3,333,333	3,333,333
Authorized share capital		$ 5,000	$ 5,000
Balance at the beginning (in shares) \| shares		647,591	0
Balance at the beginning		$ 971	$ 0
Issuance of prenetics ordinary shares as part of reverse recapitalization (in shares) \| shares		0	647,591
Issuance of Prenetics Ordinary Shares as part of Reverse Recapitalization		$ 0	$ 971
Share issued for vesting of restricted share units (in shares) \| shares		933,380	0
Vesting of shares under the restricted share scheme		$ 1,400	$ 0
Post reverse stock split (in shares) \| shares		1	0
Issuance of shares for reverse stock split		$ 0	$ 0
Balance at the end (in shares) \| shares		1,580,972	647,591	0
Balance at the end		$ 2,371	$ 971	$ 0
Par value per share ($ per share) \| $ / shares			$ 0.0001
Number of votes per share \| Vote		20
Ordinary shares after reverse stock
Disclosure of classes of share capital [line items]
Par value per share ($ per share) \| $ / shares		$ 0.0015
Ordinary shares after reverse stock \| Class A ordinary shares
Disclosure of classes of share capital [line items]
Par value per share ($ per share) \| $ / shares		0.0015
Ordinary shares after reverse stock \| Class B ordinary shares
Disclosure of classes of share capital [line items]
Par value per share ($ per share) \| $ / shares		$ 0.0015

Inventories (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Classes of current inventories [abstract]
Consumables and reagent	$ 2,471,318	$ 3,662,303
Work in progress	104,165	137,106
Finished goods	551,293	734,663
Inventories	$ 3,126,776	$ 4,534,072

Reverse Recapitalization

12 Months Ended

Dec. 31, 2023

Reverse Recapitalization [Abstract]

Reverse recapitalization

Reverse Recapitalization

As disclosed in note 1, the Reverse Recapitalization has been accounted for with reference to the principles of reverse acquisitions with PHCL being the accounting acquirer and Artisan the accounting acquiree. Accordingly, except for the capital structure, these financial statements have been presented as a continuation of the consolidated financial information of PHCL Group with:

•the assets and liabilities of PHCL Group recognized and measured at their carrying amounts immediately prior to the Reverse Recapitalization;

•the retained earnings and other equity balances of PHCL Group recognized at amounts immediately prior to the Reverse Recapitalization; and

•the financial information for periods prior to the Reverse Recapitalization being that of PHCL Group.

As Artisan, the accounting acquiree, does not meet the definition of a business for the purposes of IFRS 3, the Reverse Recapitalization is determined to be an acquisition of the net assets of Artisan together with an equity-settled share-based payment which is regarded as an issuance of certain of the Company’s Class A ordinary shares in exchange for a stock exchange listing service. The stock exchange listing service has been recorded in profit or loss and measured as the excess of fair value of the Company’s Class A ordinary shares issued to acquire Artisan over the fair value of Artisan’s identifiable net assets acquired, with the amount expensed as incurred:


Fair value of Artisan’s identifiable net assets acquired comprising			$	23,599,605
Prepayments	$	538,315
Cash and cash equivalent	30,363,822
Accrued expenses	(231,109)
Warrants liabilities (note (i))	(6,186,423)
Derivative liabilities (note (ii))	(885,000)
Less: Fair value of consideration comprising:
14,523,244 Company’s Class A ordinary shares			(113,146,206)
Share-based payment expense on listing			$	(89,546,601)

Notes:

(i)The warrants liabilities acquired include those in relation to the warrants issued by Artisan to Artisan’s public investors and Artisan LLC, the sponsor. The holders of Artisan’s warrants (including public investors and the sponsor) received one warrant of the Company for each Artisan’s warrant, resulting in the issuance of 100,000 warrants of the Company (see note 27).

(ii)Prior to the initial public offering of Artisan, institution investors (“FPA Investors”) agreed to purchase an aggregate of 6,000,000 Class A ordinary shares of Artisan and 1,500,000 redeemable warrants of Artisan at a price of $10 per Class A ordinary share and 1⁄4 warrant of Artisan in a private placement to close immediately prior to the closing of Artisan merging with one or more entities. The investment commitments from FPA Investors represents a derivative liability of Artisan measured at FVTPL before the Initial Merger. As part of the Reverse Recapitalization, prior to the Initial Merger, the agreements with FPA Investors were amended such that FPA Investors committed to purchase a variable number of Class A ordinary shares and warrants of the Company at an aggregate price of $585,000 immediately prior to the closing of the Acquisition Merger. On May 18, 2022, the derivative liability was settled by issuing 400,000 Class A ordinary shares and 100,000 warrants of the Company to FPA Investors (see note 27).

The Reverse Recapitalization has also involved the following transactions:

•For additional capitalization, the Company issued 372,000 Class A ordinary shares to PIPE Investors on May 18, 2022 (see note 29(b)), pursuant to the original subscription agreements dated on September 15, 2021 which was subsequently amended in 2022.

In the subscription agreements dated on September 15, 2021, PIPE Investors committed to purchase Class A ordinary shares of the Company at a price of $10 per share (equivalent to $150 per share after reverse stock split) upon listing. The subscription agreements were amended on March 30, 2022 such that PIPE Investors committed to purchase a variable number of Class A ordinary shares of the Company at an aggregate price of $55,800,000 upon listing. The amendment of the subscription agreements with PIPE Investors results in recognition of a derivative liability measured at fair value through profit or loss, with a debit in equity. Upon completion of the Reverse Recapitalization, the derivative liability was settled by issuing 516,000 Class A ordinary shares of the Company to PIPE Investors.

•Professional services expenditure of $18,231,775 were incurred to facilitate listing on NASDAQ, with $3,529,904 and $14,701,871 recognized as administrative and other operating expenses in the profit or loss for the years ended December 31, 2022 and 2021, respectively.

Reporting entity	12 Months Ended
Reporting entity	Dec. 31, 2023
Disclosure Of General Information About Reporting Entity [Abstract]
Reporting entity	Reporting entity Prenetics Global Limited (the “Company”), is a company incorporated in Cayman Islands. The Company was formed to facilitate the public listing and additional capitalization (referred to collectively as the “Reverse Recapitalization”) of Prenetics Holding Company Limited, (“PHCL”) and its subsidiaries (the “PHCL Group”). The Company and its subsidiaries (collectively, the “Group”) focus on providing healthcare solutions through three pillars — prevention, diagnostics and personalized care. The Group’s preventive health testing services are genetic testing (under the brand-named CircleDNA) for general health purposes. CircleDNA utilizes a whole exome sequencing technology that conducts a full scan on individuals’ protein-coding genes, analyzing genetic variations across different categories and providing personalized reports with a saliva sample. The Group also engages in research and development activities to advance its preventive, diagnostic and personalized healthcare solutions. The Reverse Recapitalization (see note 31) was effectuated by: •a special purpose acquisition company (“SPAC”) Artisan Acquisition Corp. (“Artisan”), incorporated in the Cayman Islands and listed on the Nasdaq Stock Market (“NASDAQ”), merging on May 17, 2022 with AAC Merger Limited, incorporated in the Cayman Islands and a directly wholly-owned subsidiary of the Company; with AAC Merger Limited surviving and remaining as a wholly-owned subsidiary of the Company (“Initial Merger”); •PGL Merger Limited, incorporated in the Cayman Islands and a directly wholly-owned subsidiary of the Company, merging with PHCL on May 18, 2022; with PHCL surviving and becoming a wholly-owned subsidiary of the Company (“Acquisition Merger”); •additional capitalization by way of issuing the Company’s shares to certain third-party investors (“PIPE Investors”) on May 18, 2022, pursuant to investment commitments in subscribing and purchasing for the Class A Ordinary Shares of the Company, concurrently with the execution of the Acquisition Merger; and •the Company becoming a publicly traded company on NASDAQ on May 18, 2022. The Reverse Recapitalization has been accounted for with reference to the principles of reverse acquisitions in IFRS 3, Business combinations, (“IFRS 3”) with PHCL being the accounting acquirer and Artisan the accounting acquiree. Accordingly, these consolidated financial statements have been presented as a continuation of the consolidated financial information of the PHCL Group, except for the capital structure (see note 31). On December 30, 2022, the Group acquired 74.39% of the issued share capital of ACT Genomics Holdings Company Limited (“ACT Genomics”), and obtained control of ACT Genomics (the “ACT Acquisition”). ACT Genomics is an innovation-driven cancer solution provider, which specializing in precision oncology, and qualifies as a business as defined in IFRS 3. The ACT Acquisition is expected to allow the Group to accelerate the utilization of genetic information throughout a cancer patient’s journey and to deliver the information needed to enable best-in-class personalized cancer care (see note 34). On July 20, 2023, the Group acquired 50% shareholdings of an equity-accounted investee, Insighta Holdings Limited ("Insighta"). Details of the interests in equity-accounted investees are included in note 16.

Operating segments (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of operating segments [abstract]

Schedule of results of each reportable segment


	Prevention		Diagnostics		Unallocated		Total from continuing operations		Prevention and diagnostics (discontinued) (note 7)		Total
	(Restated)		(Restated)		(Restated)				(Restated)
2023
Revenue	$	6,155,140	$	15,587,535	$	—	$	21,742,675	$	13,461,964	$	35,204,639
Gross profit	3,115,480		7,656,524		(1,942,117)		8,829,887		6,105,445		14,935,332
2022
Revenue	13,163,841		—		—		13,163,841		262,597,457		275,761,298
Gross profit	4,391,992		—		(773,697)		3,618,295		127,936,591		131,554,886
2021
Revenue	12,532,744		—		—		12,532,744		263,320,009		275,852,753
Gross profit	4,392,094		—		(789,497)		3,602,597		102,528,614		106,131,211

Schedule of revenue and non-current assets by regions

Revenue


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Hong Kong	$	8,963,411	$	13,163,841	$	12,532,744
United Kingdom	2,269,534		—		—
Taiwan	9,325,494		—		—
Rest of the world	1,184,236		—		—
	$	21,742,675	$	13,163,841	$	12,532,744
Discontinued operation
Hong Kong	$	12,915,851	$	197,770,303	$	112,393,676
United Kingdom	546,113		64,827,154		150,926,333
	$	13,461,964	$	262,597,457	$	263,320,009

(ii)Non-current assets


	2023		2022
Hong Kong	$	147,559,245	$	67,151,416
United Kingdom	212,894		1,816,121
Taiwan	2,385,846		—
Rest of the world	953,384		321,456
Total non-current assets	$	151,111,369	$	69,288,993

Non-current assets exclude financial assets at fair value through profit or loss and deferred tax assets.

Interests in equity-accounted investees

12 Months Ended

Dec. 31, 2023

Disclosure of associates [abstract]

Interests in equity-accounted investees

See accounting policies in notes 38(A)(iv)-(v) and (L)(i).


	2023		2022
Interest in a joint venture	$	97,858,820	$	—
Interests in associates	606,055		788,472
	$	98,464,875	$	788,472

On July 20, 2023, the Group acquired 50% shareholdings of an equity-accounted investee, Insighta. This involved a total consideration of $80,000,000 contribution in cash to the joint venture and an issuance of 1,481,481 Class A ordinary shares. The fair value of the ordinary shares issued was based on the listed share price of the Company at July 20, 2023 of $0.83 per share (equivalent to $12.51 per share after reverse stock split). The joint venture partner entered into a license agreement with the joint venture that will be automatically terminated upon the occurrence of certain events, including the cessation of business and liquidation of the joint venture.

Particulars of equity-accounted investees of the Group are as follows:


Name of an equity-accounted investee	Place of incorporation/ operation	Particular of issued and paid-up capital	Proportion of nominal value of issue capital held by the Company				Principal activity
			2023		2022
			Directly	Indirectly	Directly	Indirectly
			%	%	%	%
Insighta	Cayman Islands	2,000,000 ordinary shares	50	—	—	—	Multi-cancer genetic testing services
アクトメッド株式会社 (“ACTmed Co., Ltd.”)	Japan	1,347 ordinary shares	—	24.85	—	24.85	Precise cancer genetic testing services
CERBACT Asia Holdings Pte. Ltd. (“CERBACT”)	Singapore	100 ordinary shares	—	26.04	—	26.04	Investment holdings

Insighta

Insighta represents a joint venture in which the Group has a 50 percent ownership interest and joint control under a transactional agreement, while Insighta is not publicly listed.

The Group has strategically entered the precision oncology diagnostics market through the establishment of Insighta.

The following table summarizes the financial information of Insighta, from the period of July 20, 2023 to December 31, 2023, as included in its own financial statements, adjusted for fair value adjustments at acquisition and differences

in accounting policies. The table also reconciles the summarized financial information to the carrying amount of the Group's interest in Insighta.


	2023
Non-current assets	$	132,725,811
Current assets (including cash and cash equivalents $79,108,498)	79,310,442
Non-current liabilities	(15,192,930)
Other payables, accruals and contract liabilities	(200,052)
Amount due to a related company	(925,631)
Net assets (100%)	195,717,640
Group's share of net assets (50%)	97,858,820
Other income	580,440
Interest income	927,019
Depreciation and amortization	(2,141,759)
Other expenses	(1,054,858)
Income tax expense	349,018
Loss and total comprehensive income (100%)	$	(1,340,140)
Group's share of loss and total comprehensive income (50%)	$	(670,070)
Dividends received by the Group	$	—

ACTmed Co., Ltd

ACTmed Co., Ltd. represents an associate and is not publicly listed.

At December 31, 2022, the carrying amount of the Group’s interests in the associate is nil as the Group’s share of loss has exceeded its investment in the associate. The Group will not resume recognition of its share of any future profits in the associate until its share of such profits equals the cumulative share of losses not recognized in past years.

CERBACT

CERBACT represents an associate and was incorporated on July 12, 2021 as a limited liability company in Singapore. CERBACT is not individually material to the Group and is not publicly listed.

Aggregate information of associates that are not individually material:


	2023		2022
Carrying amount of interests in associates	$	606,055	$	788,472
Group's share of total comprehensive income	(188,830)		—

Interests in equity-accounted investees - Summary of detailed information about interest in associates (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Disclosure of associates [abstract]
Interest in a joint venture	$ 97,858,820	$ 0
Interests in associates	606,055	788,472
Other equity interest	$ 98,464,875	$ 788,472

Lease liabilities

12 Months Ended

Dec. 31, 2023

Lease liabilities [abstract]

Lease liabilities

See accounting policy in note 38(M).

The following table shows the remaining contractual maturities of the Group’s lease liabilities at the end of the reporting periods:


	2023		2022
Within 1 year	$	1,502,173	$	2,882,933
After 1 year but within 2 years	770,839		1,464,200
After 2 years but within 5 years	96,376		1,294,278
After 5 years	—		1,004,752
	867,215		3,763,230
Total	$	2,369,388	$	6,646,163

Loss per share (Details) - USD ($)	12 Months Ended
Loss per share (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Loss for the year
Loss for the year attributable to equity shareholders of the Company	$ 62,723,871	$ 190,453,333	$ 174,009,273
Number of shares
Weighted-average number of ordinary shares (per share)	11,246,010	5,069,315	973,134

Capital and reserves (Tables)

12 Months Ended

Dec. 31, 2023

Miscellaneous equity [abstract]

Summary of issued share capital per class A and B

(a)Movement in ordinary shares of PHCL

Authorized and issued share capital


		2023			2022
	Note	No. of shares			No. of shares
Authorized ordinary shares of $1 each	(ii)	50,000	$	50,000	50,000	$	50,000
Ordinary shares, issued and fully paid:
Balance at January 1		1	$	1	14,932,033	$	1,493
Shares issued upon conversion of exchange loan notes	(iii)	—	—		1	1
Exchange for Prenetics Ordinary Shares as part of Reverse Recapitalization	(v)	—	—		(14,932,033)	(1,493)
Balance at December 31	(iv)	1	$	1	1	$	1
Total share capital			$	1		$	1

Notes:

(i)The Ordinary Shareholders are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of PHCL. All ordinary shares rank equally with regard to the Group’s residual assets.

(ii)As specified in the written plan of merger approved by special resolution of the shareholders of PHCL at an extraordinary general meeting of the shareholders of PHCL on May 6, 2022, the authorized share capital of PHCL had been redesignated to $50,000 divided into 50,000 ordinary shares of a par value of $1 each.

(iii)On May 18, 2022, 1 ordinary share valued at $1 was issued upon the closing of the Acquisition Merger.

(iv)At December 31, 2022, the entire amount standing to the reclassification to share premium at $17,126,369 due to the Group’s restructuring.

(v)On May 18, 2022, the ordinary shares of PHCL were canceled in exchange for the right to receive Class A or Class B ordinary shares of the Company equal to the exchange ratio of 2.03 for each ordinary share of PHCL.

Movement in ordinary shares of the Company

Authorized and issued share capital


		2023			2022
	Note	No. of shares			No. of shares
Authorized Class A ordinary shares of $0.0015 each	(i)	30,000,001	$	45,000	30,000,001	$	45,000
Authorized Class B ordinary shares of $0.0015 each	(i)	3,333,333	5,000		3,333,333	5,000
		33,333,334	$	50,000	33,333,334	$	50,000
Class A ordinary shares, issued and fully paid:
As of the beginning of the year		8,484,616	$	12,727	—	$	—
Issuance of Prenetics Ordinary Shares as part of Reverse Recapitalization		—	—		6,751,061	10,127
Cancellation and retirement of repurchased shares		(112,317)	(168)		—	—
Share issued for vesting of restricted share units		513,345	770		523,519	785
Share issued upon conversion of exchange loan notes		52,620	79		52,619	79
Share issued for the investment in Insighta		1,481,481	2,222		—	—
Share issued for the ACT Acquisition		168,709	253		1,157,417	1,736
Adjustment for reverse stock split	(iv)	35,754	54		—	—
At the end of the year	(ii)	10,624,208	$	15,937	8,484,616	$	12,727
Class B ordinary shares, issued and fully paid:
As of the beginning of the year		647,591	$	971	—	$	—
Share issued for vesting of restricted share units		933,380	1,400		—	—
Issuance of Prenetics Ordinary Shares as part of Reverse Recapitalization		—	—		647,591	971
Adjustment for reverse stock split	(iv)	1	—		—	—
Balance at December 31	(iii)	1,580,972	$	2,371	647,591	$	971
Total share capital			$	18,308		$	13,698

Notes:

(i)The authorized share capital of the Company is $50,000 divided into 33,333,334 shares with a par value of $0.0001 each (equivalent to $0.0015 each after reverse stock split), of which (i) 30,000,001 shares shall be designated as Class A Ordinary Shares; (ii) 3,333,333 shares shall be designated as convertible Class B Ordinary Shares. The share capital would reflect the par value with the excess recorded as share premium.

(ii)Class A ordinary shareholders are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company. All ordinary shares rank equally with regard to the Group’s residual assets.

(iii)Class B ordinary shareholders are entitled to receive dividends as declared from time to time and are entitled to twenty vote per share at meetings of the Company. All ordinary shares rank equally with regard to the Group’s residual assets.

(iv)In November 2023, the Company approved a reverse stock split of issued and unissued ordinary shares at a ratio of 1-for-15. (see note 2)

Financial instruments - Fair values and risk management - Group's exposure at the end of the reporting period to currency risk, Sensitivity analysis (Details) - Currency risk	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
USD
Disclosure of detailed information about financial instruments [line items]
Net exposure	$ 41,470,331	$ 7,551,223
Average foreign exchange rate	7.82	7.83
Closing foreign exchange rate	7.81	7.78
USD \| Trade receivables
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk	$ 50,696	$ 79,220
USD \| Deposits, prepayments and other receivables
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk	76,586	2,972,471
USD \| Cash and cash equivalents
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk	41,388,803	12,225,385
USD \| Trade payables
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk	(45,754)	(3,984,494)
USD \| Accrued expenses and other liabilities
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk	0	(3,741,359)
RMB
Disclosure of detailed information about financial instruments [line items]
Net exposure	$ 83,342	$ (1,156,840)
Average foreign exchange rate	1.10	1.17
Closing foreign exchange rate	1.10	1.11
RMB \| Trade receivables
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk	$ 0	$ 0
RMB \| Deposits, prepayments and other receivables
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk	0	872,455
RMB \| Cash and cash equivalents
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk	253,839	14
RMB \| Trade payables
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk	(167,889)	(2,029,309)
RMB \| Accrued expenses and other liabilities
Disclosure of detailed information about financial instruments [line items]
Maximum exposure to credit risk	$ (2,608)	$ 0

Preference shares liabilities - Additional information (Details) - Prenetics HK		1 Months Ended
	Jun. 16, 2021 shares	May 31, 2021 shares
Disclosure of financial liabilities [line items]
Percentage of non-cumulative dividend (%)		8.00%
Preference shares liabilities \| Share exchange agreement and subscription agreement
Disclosure of financial liabilities [line items]
Conversion ratio		1
Preference shares liabilities \| Series A preference shares \| Share exchange agreement and subscription agreement
Disclosure of financial liabilities [line items]
Number of shares exchanged (in shares)		4,154,726
Preference shares liabilities \| Series B preference shares \| Share exchange agreement and subscription agreement
Disclosure of financial liabilities [line items]
Number of shares exchanged (in shares)		5,338,405
Percentage of simple interest on subscription price for redemption (%)		10.00%
Preference shares liabilities \| Series C preference shares \| Share exchange agreement and subscription agreement
Disclosure of financial liabilities [line items]
Number of shares exchanged (in shares)		10,532,116
Percentage of simple interest on subscription price for redemption (%)		10.00%
Preference shares liabilities \| Series D preference shares \| Share exchange agreement and subscription agreement
Disclosure of financial liabilities [line items]
Percentage of simple interest on subscription price for redemption (%)		10.00%
Preference shares liabilities \| Series E preferred shares \| Share exchange agreement and subscription agreement
Disclosure of financial liabilities [line items]
Number of shares issued (in shares)	1,650,913
Percentage of simple interest on subscription price for redemption (%)		12.00%

Operating segments - Revenue (Details) - USD ($)	12 Months Ended
Operating segments - Revenue (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of geographical areas [line items]
Revenue	$ 21,742,675	$ 13,163,841	$ 12,532,744
Non-current assets	151,111,369	69,288,993
Hong Kong
Disclosure of geographical areas [line items]
Revenue	8,963,411	13,163,841	12,532,744
Non-current assets	147,559,245	67,151,416
United Kingdom
Disclosure of geographical areas [line items]
Revenue	2,269,534	0	0
Non-current assets	212,894	1,816,121
Taiwan
Disclosure of geographical areas [line items]
Revenue	9,325,494	0	0
Non-current assets	2,385,846	0
Rest of the world
Disclosure of geographical areas [line items]
Revenue	1,184,236	0	0
Non-current assets	953,384	321,456
Hong Kong
Disclosure of geographical areas [line items]
Revenue	13,461,964	262,597,457	263,320,009
Hong Kong \| Hong Kong
Disclosure of geographical areas [line items]
Revenue	12,915,851	197,770,303	112,393,676
Hong Kong \| United Kingdom
Disclosure of geographical areas [line items]
Revenue	$ 546,113	$ 64,827,154	$ 150,926,333

- Definition

The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 28
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 23
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2023-03-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 32
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard
-URIDate 2023-03-23

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2023-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2023-03-23

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 33
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2023-03-23

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 34
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard
-URIDate 2023-03-23

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 82
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2023-03-23

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 103
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard
-URIDate 2023-03-23

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 102
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard
-URIDate 2023-03-23

+ Details

Intangible assets

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about intangible assets [abstract]

Intangible assets

See accounting policies in notes 38(I) and (L)(ii).


	Website and mobile apps		Trademark and technology		Product development cost		Computer software		Customer relationship		Total
Cost:
At January 1, 2022	$	1,351,053	$	26,119,306	$	2,656,881	$	—	$	—	$	30,127,240
Additions	42,968		19,141		484,966		847,478		—		1,394,553
Additions from acquisition (note 34(C))	—		12,900,000		—		811,897		800,000		14,511,897
Disposals	(165,048)		—		(3,131,244)		—		—		(3,296,292)
Exchange differences	(16,656)		(4,950,867)		(10,603)		5,818		—		(4,972,308)
At December 31, 2022 and January 1, 2023	1,212,317		34,087,580		—		1,665,193		800,000		37,765,090
Additions	29,748		—		—		536,775		—		566,523
Written off	(170,897)		—		—		(613,741)		—		(784,638)
Exchange differences	1,071		(602)		—		(5,667)		—		(5,198)
At December 31, 2023	$	1,072,239	$	34,086,978	$	—	$	1,582,560	$	800,000	$	37,541,777
Accumulated amortization and impairment loss:
At January 1, 2022	$	1,109,492	$	4,697,964	$	493,502	$	—	$	—	$	6,300,958
Charge for the year	126,238		757,212		672,641		—		—		1,556,091
Written back on disposal	(83,549)		—		(3,131,244)		—		—		(3,214,793)
Additions from acquisition (note 34(C))	—		—		—		685,508		—		685,508
Impairment loss (note 7(a)(iv))	—		17,147,067		1,962,513		—		—		19,109,580
Exchange differences	(496)		(1,460,221)		2,588		—		—		(1,458,129)
At December 31, 2022 and January 1, 2023	1,151,685		21,142,022		—		685,508		—		22,979,215
Charge for the year	53,961		1,333,180		—		447,420		80,000		1,914,561
Written off	(170,897)		—		—		(613,741)		—		(784,638)
Exchange differences	1,331		(388)		—		7,048		—		7,991
At December 31, 2023	$	1,036,080	$	22,474,814	$	—	$	526,235	$	80,000	$	24,117,129
Carrying amounts:
At January 1, 2022	$	241,561	$	21,421,342	$	2,163,379	$	—	$	—	$	23,826,282
At December 31, 2022	$	60,632	$	12,945,558	$	—	$	979,685	$	800,000	$	14,785,875
At December 31, 2023	$	36,159	$	11,612,164	$	—	$	1,056,325	$	720,000	$	13,424,648

Goodwill - Summary of assumptions used in the estimation of the recoverable amount (Details)	Dec. 31, 2022
Prevention Emea Within Prevention Segment
Disclosure of reconciliation of changes in goodwill [line items]
Pre-tax discount rate (%)	16.80%
Terminal value growth rate (%)	3.20%
Average revenue growth rate (%)	25.10%
Diagnostics Emea Within Diagnostics Segment
Disclosure of reconciliation of changes in goodwill [line items]
Pre-tax discount rate (%)	16.80%

Short-term deposits and cash and cash equivalents - Schedule of cash and cash equivalents (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash and cash equivalents [abstract]
Bank balances	$ 45,701,633	$ 146,656,326
Cash on hand	4,815	3,869
Cash and cash equivalents	$ 45,706,448	$ 146,660,195	$ 35,288,952	$ 14,489,880

Functional and presentation currency	12 Months Ended
Functional and presentation currency	Dec. 31, 2023
Functional And Presentation Currency [Abstract]
Functional and presentation currency	Functional and presentation currency These consolidated financial statements are presented in United States dollars (“USD”), which is the Company’s functional currency.

Property, plant and equipment - Schedule of amounts included in the consolidated statement of cash flows (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [abstract]
Within operating cash flows	$ (136,940)	$ (831,631)	$ (1,019,937)
Within financing cash flows	(3,476,380)	(2,121,981)	(1,504,946)
Total	$ (3,613,320)	$ (2,953,612)	$ (2,524,883)

Discontinued operations - Results of discontinued operation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of analysis of single amount of discontinued operations [line items]
Revenue	$ 21,742,675	$ 13,163,841	$ 12,532,744
Direct costs	(12,912,788)	(9,545,546)	(8,930,147)
Gross profit	8,829,887	3,618,295	3,602,597
Other income and other net gains/(losses)	4,507,103	429,857	(202,176)
Selling and distribution expenses	(8,243,379)	(4,738,099)	(5,738,682)
Research and development expenses	(11,661,760)	(5,988,905)	(6,391,491)
Administrative and other operating expenses	(41,438,301)	(59,341,636)	(47,932,095)
Operating loss from continuing operations	(51,906,718)	(66,020,488)	(56,661,847)
Other finance costs	(119,662)	(3,994,755)	(5,052,076)
Gain on bargain purchase	0	0	117,238
Loss before taxation	(56,669,031)	(225,820,154)	(216,553,522)
Income tax credit/(expense)	116,482	(7,391,920)	(1,164,222)
(Loss)/profit from discontinued operation, net of tax	$ (8,377,660)	$ 35,121,951	$ 45,105,202
(Loss)/earnings per share
Basic ($ per share)	$ (0.74)	$ 6.93	$ 3.09
Diluted ($ per share)	$ (0.74)	$ 6.93	$ 3.09
Hong Kong
Disclosure of analysis of single amount of discontinued operations [line items]
Revenue	$ 13,461,964	$ 262,597,457	$ 263,320,009
Direct costs	(7,356,519)	(134,660,866)	(160,791,395)
Gross profit	6,105,445	127,936,591	102,528,614
Other income and other net gains/(losses)	289,614	(25,214)	341,124
Selling and distribution expenses	(631,812)	(8,563,337)	(16,193,640)
Research and development expenses	(1,188,677)	(9,530,323)	(4,172,461)
Restructuring costs	0	(30,378,741)	0
Administrative and other operating expenses	(12,946,412)	(36,721,676)	(36,059,318)
Operating loss from continuing operations	(8,371,842)	42,717,300	46,444,319
Other finance costs	(122,300)	(203,429)	(185,954)
Write-off on amount due from a shareholder	0	0	(106,179)
Gain on bargain purchase	0	0	117,238
Loss before taxation	$ (8,494,142)	$ 42,513,871	$ 46,269,424

Interests in equity-accounted investees - Summary of interests in associates (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Jul. 20, 2023
Insighta
Disclosure of associates [line items]
Number of shares issued (in shares)			2,000,000
Insighta \| Direct beneficial interest (%)
Disclosure of associates [line items]
Proportion of nominal value of issue capital held by the Company (%)	50.00%	0.00%
Insighta \| Indirect beneficial interest (%)
Disclosure of associates [line items]
Proportion of nominal value of issue capital held by the Company (%)	0.00%	0.00%
ACTmed Co., Ltd
Disclosure of associates [line items]
Number of shares issued (in shares)			1,347
ACTmed Co., Ltd \| Direct beneficial interest (%)
Disclosure of associates [line items]
Proportion of nominal value of issue capital held by the Company (%)	0.00%	0.00%
ACTmed Co., Ltd \| Indirect beneficial interest (%)
Disclosure of associates [line items]
Proportion of nominal value of issue capital held by the Company (%)	24.85%	24.85%
CERBACT Asia Holdings Pte. Ltd
Disclosure of associates [line items]
Number of shares issued (in shares)			100
CERBACT Asia Holdings Pte. Ltd \| Direct beneficial interest (%)
Disclosure of associates [line items]
Proportion of nominal value of issue capital held by the Company (%)	0.00%	0.00%
CERBACT Asia Holdings Pte. Ltd \| Indirect beneficial interest (%)
Disclosure of associates [line items]
Proportion of nominal value of issue capital held by the Company (%)	26.04%	26.04%

Discontinued operations - Other income and other gain (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of analysis of single amount of discontinued operations [line items]
Interest income	$ 3,923,279	$ 471,878	$ 201
Net foreign exchange gains/(losses)	330,193	(663,004)	(51,260)
Sundry income	145,383	76,443	17,178
Other income and other net gain/(losses)	4,507,103	429,857	(202,176)
Hong Kong
Disclosure of analysis of single amount of discontinued operations [line items]
Interest income	19,297	311	3,779
Net foreign exchange gains/(losses)	(25,049)	(25,721)	336,285
Sundry income	295,366	196	1,060
Other income and other net gain/(losses)	$ 289,614	$ (25,214)	$ 341,124

Reverse Recapitalization - Summary of fair value of Artisan's identifiable net assets acquired (Details)	Dec. 31, 2023 USD ($) shares $ / shares shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Disclosure Of Reverse Recapitalization [Line Items]
Cash and cash equivalent	$ 45,706,448	$ 146,660,195	$ 35,288,952	$ 14,489,880
Less: Fair value of consideration comprising:
Class of warrants received during the period \| shares	1
Class A ordinary shares
Disclosure Of Reverse Recapitalization [Line Items]
Number of instruments or interests issued or issuable (in shares) \| shares	14,523,244
Warrants
Less: Fair value of consideration comprising:
Number of warrants issued (in shares) \| shares	100,000
Artisan
Disclosure Of Reverse Recapitalization [Line Items]
Fair value of Artisan’s identifiable net assets acquired comprising	$ 23,599,605
Prepayments	538,315
Cash and cash equivalent	30,363,822
Accrued expenses	(231,109)
Warrants Liabilities	(6,186,423)
Derivative financial liabilities	(885,000)
Less: Fair value of consideration comprising:
14,523,244 Company’s Class A ordinary shares	(113,146,206)
Share-based payment expense on listing	$ (89,546,601)
Artisan \| Class A ordinary shares
Less: Fair value of consideration comprising:
Number of shares issued (in shares) \| shares	6,000,000
Sale of stock price per share ($ per shares) \| $ / shares	$ 10
Artisan \| Redeemable Warrants
Less: Fair value of consideration comprising:
Number of warrants issued (in shares) \| shares	1,500,000
FPA Investors \| Reverse Recapitalization
Less: Fair value of consideration comprising:
Sale of stock price per share ($ per shares) \| $ / shares	$ 585,000
FPA Investors \| Class A ordinary shares
Less: Fair value of consideration comprising:
Shares issued upon conversion (in shares) \| shares	400,000
FPA Investors \| Warrants \| Warrants
Less: Fair value of consideration comprising:
Number of warrant issued upon conversion (in shares) \| shares	100,000

Loss before taxation - Other items (Details) - USD ($)	12 Months Ended
Loss before taxation - Other items (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Continuing operations
Cost of inventories (note 18)	$ 6,320,806	$ 7,129,679	$ 8,948,607
Depreciation of (note 13)
- property, plant and equipment#	2,995,067	1,068,535	938,005
- right-of-use assets#	1,761,394	950,477	625,284
Amortization of intangible assets# (note 14)	1,914,561	57,846	67,433
Write-off on property, plant and equipment	331,121	0	0
Auditor’s remuneration	1,244,315	1,319,047	1,052,910
Miscellaneous laboratory charges	2,200	268	13,953
Direct costs
Continuing operations
Cost of inventories (note 18)	9,081,519	57,442,036	52,701,330
Depreciation of (note 13)
Total depreciation and amortization charges	1,435,709	501,786	430,359
Research and development expenses
Depreciation of (note 13)
Total depreciation and amortization charges	584,545	132,156	55,519
Administrative and other operating expenses
Depreciation of (note 13)
Total depreciation and amortization charges	4,650,768	1,442,916	1,144,844
Total depreciation and amortization charges
Depreciation of (note 13)
Total depreciation and amortization charges	$ 6,671,022	$ 2,076,858	$ 1,630,722

Goodwill - Summary of goodwill balance allocated to CGU's (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill	$ 29,170,123	$ 33,800,276	$ 3,978,065
Cancer genetic testing services within the Diagnostics segment
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill	28,319,438	30,639,976
Sales of medical diagnostics products within the Diagnostics segment
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill	$ 850,685	$ 3,160,300

Loss before taxation

12 Months Ended

Dec. 31, 2023

Profit Or Loss Before Tax [Abstract]

Loss before taxation

Loss before taxation is arrived at after charging:

(a)Other finance costs

See accounting policies in notes 38(E) and (J).


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Interest expenses on lease liabilities (notes 13(a) and 25(b))	$	119,197	$	40,656	$	42,196
Interest expenses on trade financing (note 25(b))	—		172,978		—
Changes in the carrying amount of preference shares liabilities (note 26)	—		3,752,758		5,009,847
Other interest expenses	465		28,363		33
	$	119,662	$	3,994,755	$	5,052,076

(b)Staff costs


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Salaries, wages and other benefits	$	27,745,031	$	21,058,447	$	13,246,763
Contributions to defined contribution retirement plan	718,933		369,102		344,926
Equity-settled share-based payment expenses	10,495,706		25,913,717		20,426,026
	$	38,959,670	$	47,341,266	$	34,017,715
Represented by:
Direct costs	$	1,997,360	$	282,918	$	345,183
Selling and distribution expenses	3,891,109		1,593,735		1,144,714
Research and development expenses	10,226,280		5,637,295		6,147,814
Administrative and other operating expenses	22,844,921		39,827,318		26,380,004
Total staff costs	$	38,959,670	$	47,341,266	$	34,017,715

(c)Other items


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Cost of inventories (note 18)	$	6,320,806	$	7,129,679	$	8,948,607
Depreciation of (note 13)
- property, plant and equipment#	2,995,067		1,068,535		938,005
- right-of-use assets#	1,761,394		950,477		625,284
Amortization of intangible assets# (note 14)	1,914,561		57,846		67,433
Write-off on property, plant and equipment	331,121		—		—
Auditor’s remuneration	1,244,315		1,319,047		1,052,910
Miscellaneous laboratory charges	2,200		268		13,953
# Represented by:
Direct costs	$	1,435,709	$	501,786	$	430,359
Research and development expenses	584,545		132,156		55,519
Administrative and other operating expenses	4,650,768		1,442,916		1,144,844
Total depreciation and amortization charges	$	6,671,022	$	2,076,858	$	1,630,722

Liabilities for puttable financial instrument - Schedule of liabilities for puttable financial instrument (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Liabilities For Puttable Financial Instrument [Abstract]
Balance at January 1	$ 17,138,905	$ 0
Issuance of puttable financial instrument	0	17,138,905
Change in fair value recognized in equity	(2,516,376)	0
Balance at December 31	$ 14,622,529	$ 17,138,905

Income tax (credit)/expense - Reconciliation of effective tax rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Continuing operations
Loss before taxation	$ (56,669,031)	$ (225,820,154)	$ (216,553,522)
Notional tax on loss before taxation, calculated at the applicable rate	(8,935,753)	(24,306,622)	(13,864,746)
Tax effect of non-deductible expenses	3,917,601	24,387,021	17,502,323
Tax effect of non-taxable income	(1,136,909)	(163,797)	(846,573)
Tax effect on utilization of previously unrecognized tax losses	(70,806)	0	(579,657)
Tax effect of tax losses not recognized	6,186,067	101,854	0
Tax effect of previously unrecognized temporary differences recognized in current year	(272,720)	(263,272)	360,922
Others	43,161	0	(3,747)
Tax (credit)/expense	$ (269,359)	$ (244,816)	$ 2,568,522

Equity-settled share-based transactions - Schedule of details of the restricted share units outstanding PHCL 2021 Plan (Details) - Restricted share units	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Restricted share units granted (in shares)	834,947	1,690,766	14,748,217
Directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Restricted share units granted (in shares)	821,111	1,636,011
Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Restricted share units granted (in shares)	2,126	43,045
Third parties
Disclosure of terms and conditions of share-based payment arrangement [line items]
Restricted share units granted (in shares)	11,710	11,710

Equity-settled share-based transactions - PHCL 2021 Plan, Narrative (Details) - Restricted share units									12 Months Ended
	Dec. 31, 2023 shares	Jun. 30, 2023 shares	Jun. 23, 2023 shares	Feb. 01, 2023 shares	Dec. 31, 2022 shares	Jun. 30, 2022 shares	May 18, 2022 shares	Jun. 16, 2021	Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of restricted shares granted (in shares)	7,928	2,403,529	16,486,108	66,666	946,330	2,446,557	144,522
2021 Share Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of restricted shares granted (in shares)								3,933,063	63,934

Liabilities for puttable financial instrument - Additional Information (Details) - ACT Genomics Holdings Company Limited	Dec. 30, 2022
Disclosure of reconciliation of liabilities arising from puttable financial instrument [Line Items]
Percentage of equity interest acquired (%)	74.39%
Puttable, Bond Granted
Disclosure of reconciliation of liabilities arising from puttable financial instrument [Line Items]
Percentage of equity interest acquired (%)	74.39%

Other non-current assets

12 Months Ended

Dec. 31, 2023

Miscellaneous non-current assets [abstract]

Other non-current assets

See accounting policies in notes 38(J)(i)-(ii) and (L)(i).


	2023		2022
Deposits and prepayments	$	743,173	$	1,292,462

The balances are classified as non-current assets as they are either expected to be (i) recovered or recognized as expense after one year, or (ii) capitalized as property, plant and equipment after the end of the reporting period.

Goodwill (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of reconciliation of changes in goodwill [abstract]

Summary of goodwill


At January 1, 2022	$	3,978,065
Additions from acquisition (note 34(D))	33,800,276
Impairment loss (note 7(a)(iv))	(3,272,253)
Exchange differences	(705,812)
At December 31, 2022 and January 1, 2023	33,800,276
Adjustment of non-controlling interests	(729,885)
Impairment loss	(3,900,268)
At December 31, 2023	$	29,170,123

Summary of goodwill balance allocated to the CGUs

Below is the summary of ACT Genomics goodwill balance allocated to the Group’s CGUs:


	2023		2022
Cancer genetic testing services within the Diagnostics segment	$	28,319,438	$	30,639,976
Sales of medical diagnostics products within the Diagnostics segment	850,685		3,160,300
	$	29,170,123	$	33,800,276


	2023		2022
CGU of cancer genetic testing services
Pre-tax discount rate	21.9	%	19.5	%
Terminal value growth rate	3.0	%	3.0	%
Average revenue growth rate	24.7	%	31.1	%
CGU of sales of medical diagnostics products
Pre-tax discount rate	21.7	%	19.6	%
Terminal value growth rate	3.0	%	3.0	%
Average revenue growth rate	12.0	%	18.3	%


	2022
CGU Prevention EMEA
Pre-tax discount rate	16.8	%
Terminal value growth rate	3.2	%
Average revenue growth rate	25.1	%
CGU Diagnostics EMEA
Pre-tax discount rate	16.8	%
Terminal value growth rate	N/A
Average revenue growth rate	N/A

Preference shares liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of financial liabilities [abstract]

Schedule of movements in preference shares liabilities

The movements of preference shares during the years ended December 31, 2022 and 2023 are as follows:


	Present value of redemption amount		Conversion feature		Total
Balance at January 1, 2022	$	61,373,153	$	425,031,617	$	486,404,770
Changes in the carrying amount of preference shares liabilities (note 10(a))	3,752,758		—		3,752,758
Changes in fair value recognized in profit or loss	—		60,091,353		60,091,353
Reclassification to share capital and share premium upon listing	(65,125,911)		(485,122,970)		(550,248,881)
Balance at December 31, 2022 and 2023	$	—	$	—	$	—

Goodwill - Additional Information (Details)	3 Months Ended	12 Months Ended
Goodwill - Additional Information (Details)	Sep. 30, 2022 USD ($)	Dec. 31, 2023 USD ($) cashGeneratingUnit	Dec. 31, 2022 USD ($) cashGeneratingUnit
Disclosure of reconciliation of changes in goodwill [line items]
Cash flow projections period			6 years
Additional information for cash flow projection period			5 years
Number Of Cash Generating Units \| cashGeneratingUnit		2	2
Impairment loss recognised in profit or loss, goodwill		$ 3,900,268	$ 3,272,253
Cancer Genetic Testing Services and sales of medical diagnostics products within the diagnostics segment
Disclosure of reconciliation of changes in goodwill [line items]
Impairment loss recognised in profit or loss, goodwill			$ 0
CGU Prevention EMEA
Disclosure of reconciliation of changes in goodwill [line items]
Impairment loss recognised in profit or loss, goodwill	$ 703,534
CGU Diagnostics EMEA
Disclosure of reconciliation of changes in goodwill [line items]
Impairment loss recognised in profit or loss, goodwill	$ 2,568,719

Accounting policies, changes in accounting estimates and errors (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of expected impact of initial application of new standards or interpretations [abstract]

Disclosure of initial application of standards or interpretations

Up to the date of issue of these consolidated financial statements, the IASB has issued a number of new or amended standards, which are not yet effective for the year ended December 31, 2023 and which have not been adopted in these consolidated financial statements.


			Effective for accounting periods beginning on or after
IFRS 17, Insurance Contracts, and amendments to IFRS 17, Insurance Contracts			January 1, 2023
Amendments to IAS 1 and IFRS Practice Statement 2, Disclosure of Accounting Policies			January 1, 2023
Amendments to IAS 8, Definition of Accounting Estimates			January 1, 2023
Amendments to IAS 12, Deferred Tax related to Assets and Liabilities arising from a Single Transaction			January 1, 2023
Amendments to IFRS 16, Lease Liabilities in a Sale and Leaseback			January 1, 2024
Amendments to IAS 1, Non-current Liabilities with Covenants			January 1, 2024
Amendments to IAS 1, Classification of Liabilities as Current or Non-current			January 1, 2024
Amendments to IAS21, The effects of changes in foreign exchange rates, Lack of exchangeability			January 1, 2025
IFRS 18, Presentation and Disclosure in Financial Statements			January 1, 2027

Operating segments

12 Months Ended

Dec. 31, 2023

Disclosure of operating segments [abstract]

Operating segments

a.Basis for segmentation

The Group manages its businesses by divisions, which are organized by a mixture of both business lines (products and services) and geographical locations. The Group has identified the following two reportable segments in a manner consistent with the way in which information is reported internally to the Group’s chief operating decision maker (the “CODM”) for the purposes of resource allocation and performance assessment.

The Group’s operating and reportable segments are as follows:

1.Prevention being the design and sale of genetics testing (including update services) and stool-based DNA tests for early colorectal cancer screening.

2.Diagnostic being the sale of precision oncology testing services.

b.Information about reportable segment

Information related to each reportable segment is set out below. Performance is measured based on gross profit, as included in the internal management reports that are reviewed by the CODM. The CODM does not evaluate operating segments using asset information.


	Prevention		Diagnostics		Unallocated		Total from continuing operations		Prevention and diagnostics (discontinued) (note 7)		Total
	(Restated)		(Restated)		(Restated)				(Restated)
2023
Revenue	$	6,155,140	$	15,587,535	$	—	$	21,742,675	$	13,461,964	$	35,204,639
Gross profit	3,115,480		7,656,524		(1,942,117)		8,829,887		6,105,445		14,935,332
2022
Revenue	13,163,841		—		—		13,163,841		262,597,457		275,761,298
Gross profit	4,391,992		—		(773,697)		3,618,295		127,936,591		131,554,886
2021
Revenue	12,532,744		—		—		12,532,744		263,320,009		275,852,753
Gross profit	4,392,094		—		(789,497)		3,602,597		102,528,614		106,131,211

c.Geographic information

The following table presents a summary of revenue by region based on the location of domiciliation and the amounts of non-current assets based on the location of the asset. The Group geographically categorizes a sale based on the region in which the entity is domiciled in.

(i)Revenue


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Hong Kong	$	8,963,411	$	13,163,841	$	12,532,744
United Kingdom	2,269,534		—		—
Taiwan	9,325,494		—		—
Rest of the world	1,184,236		—		—
	$	21,742,675	$	13,163,841	$	12,532,744
Discontinued operation
Hong Kong	$	12,915,851	$	197,770,303	$	112,393,676
United Kingdom	546,113		64,827,154		150,926,333
	$	13,461,964	$	262,597,457	$	263,320,009

(ii)Non-current assets


	2023		2022
Hong Kong	$	147,559,245	$	67,151,416
United Kingdom	212,894		1,816,121
Taiwan	2,385,846		—
Rest of the world	953,384		321,456
Total non-current assets	$	151,111,369	$	69,288,993

Non-current assets exclude financial assets at fair value through profit or loss and deferred tax assets.

d.Major customers

No single customer from continuing operations contributed 10% or more to the Group's revenue from continuing operations in 2023, 2022 and 2021.

Material accounting policies

12 Months Ended

Dec. 31, 2023

Disclosure Of Summary Of Material Accounting Policies [Abstract]

Changes in material accounting policies

Material accounting policy information

The Group also adopted Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2) from January 1, 2023. Although the amendments did not result in any changes to the accounting policies themselves, they impacted the accounting policy information disclosed in the consolidated financial statements.

The amendments require the disclosure of 'material', rather than 'significant', accounting policies. The amendments also provide guidance on the application of materiality to disclosure of accounting policies, assisting entities to provide useful, entity-specific accounting policy information that users need to understand other information in the consolidated financial statements.

Management reviewed the accounting policies and made updates to the information disclosed in note 38 Material accounting policies (2022: Significant accounting policies) in certain instances in line with the amendments.

Material accounting policies

The Group has consistently applied the following accounting policies to all periods presented in these consolidated financial statements.

In addition, the Group adopted Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2) from January 1, 2023. The amendments require the disclosure of 'material', rather than 'significant', accounting policies. Although the amendments did not result in any changes to the accounting policies themselves, they impacted the accounting policy information disclosed in note 38 in certain instances (see note 5 for further information).

Certain comparative amounts in the statement of profit or loss and other comprehensive income have been re-presented, as a result of operations discontinued during the current year (see note 7).

A Basis of consolidation

(i)Business combinations

The Group accounts for business combinations using the acquisition method when the acquired set of activities and assets meets the definition of a business and control is transferred to the Group. In determining whether a particular set of activities and assets is a business, the Group assesses whether the set of assets and activities acquired includes, at a minimum, an input and substantive process and whether the acquired set has the ability to produce outputs.

The Group has an option to apply a ‘concentration test’ that permits a simplified assessment of whether an acquired set of activities and assets is not a business. The optional concentration test is met if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.

The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognized in profit or loss immediately. Transaction costs are expensed as incurred, except if related to the issue of equity securities.

(ii)Subsidiaries

Subsidiaries are entities controlled by the Group. The Group ‘controls’ an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

An investment in a subsidiary is consolidated into the consolidated financial statements from the date that control commences until the date that control ceases. Intra-group balances, transactions and cash flows and any unrealized profits arising from intra-group transactions are eliminated in full in preparing the consolidated financial statements. Unrealized losses resulting from intra-group transactions are eliminated in the same way as unrealized gains but only to the extent that there is no evidence of impairment.

(iii)Non-controlling interests

Non-controlling interests are measured initially at their proportionate share of the acquiree’s identifiable net assets at the date of acquisition.

Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

(iv)Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealized income and expenses (except for foreign currency transaction gains or losses) arising from intra-group transactions, are eliminated. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment.

Interests in associates and the joint venture are accounted for under the equity method. They are initially recognized at cost, which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the Group's share of the profit or loss and other comprehensive income of equity-accounted investees, until the date on which significant influence or joint control ceases.

(v)Interests in equity-accounted investees

The Group’s interests in equity-accounted investees comprise interests in associates.

Associates are those entities in which the Group has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the Group has joint control, whereby the Group has rights to the net assets of the arrangement, rather than rights to its assets and obligations for its liabilities.

B Foreign currency

(i)Foreign currency transactions

The Group is exposed to transactional foreign currency risk to the extent that there is a mismatch between the currencies in which sales, purchases and receivables are denominated and the respective functional currencies of Group companies. The functional currencies of Group companies are primarily the Hong Kong dollar (“HKD”), the New Taiwan dollar ("TWD") and British Pound (“GBP”). The currencies in which these transactions are primarily denominated are HKD, GBP, USD and RMB.

Transactions in foreign currencies are translated into the respective functional currencies of Group companies at the exchange rates at the dates of the transactions.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Foreign currency differences are generally recognized in profit or loss and presented within profit or loss.

(ii)Foreign operations

The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated into USD at the exchange rates at the reporting date. The income and expenses of foreign operations are translated into USD at the exchange rates at the dates of the transactions.

Foreign currency differences are recognized in other comprehensive income and accumulated in the translation reserve, except to the extent that the translation difference is allocated to non-controlling interests.

When a foreign operation is disposed of in its entirety or partially such that control, significant influence or joint control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal. If the Group disposes of part of its interest in a subsidiary but retains control, then the relevant proportion of the cumulative amount is reattributed to non-controlling interests. When the Group disposes of only part of an associate or joint venture while retaining significant influence or joint control, the relevant proportion of the cumulative amount is reclassified to profit or loss.

C Revenue and other income

Income is classified by the Group as revenue when it arises from the sale of goods or the provision of services in the ordinary course of the Group’s business.

Revenue is measured based on the amount of consideration to which the Group is expected to be entitled in exchange for transferring goods or services to a customer, excluding amounts collected on behalf of third parties. The Group recognizes revenue when (or as) it transfers control over a product or service to customer. An asset is transferred when (or as) the customer obtains control of the asset.

The Group transfers control of a good or service at a point in time unless one of the following overtime criteria is met:

(a)the customer simultaneously receives and consumes the benefits provided as the Group performs;

(b)the Group’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or

(c)the Group’s performance does not create an asset with an alternative use and the Group has an enforceable right to payment for performance completed to date.

The Group provides i) preventive services which are genetic testing services to individuals and corporates for their employees and customers; and ii) diagnostic services which are precision oncology services.

The Group collects consideration for preventive services to individuals and corporations upfront, and such consideration received usually becomes non-refundable up to 30 days from the date of delivery of the kits to the individuals or corporations, or the date of purchase. The upfront consideration received is initially recognized as deposit liabilities and subsequently reclassified to contract liabilities when the amount becomes non-refundable. Such amount does not include any variable consideration.

The Group collects consideration for diagnostic services to patients from public hospitals upfront, and such consideration received usually becomes non-refundable from the date of receipt of patients’ specimen, or the date of purchase. The upfront consideration received is recognized as contract liabilities when the amount becomes non-refundable. Such amount does not include any variable consideration.

The Group determines that its sales contracts do not have a significant financing component when the upfront consideration becomes non-refundable as customers have discretion to decide when the tests are performed during the contract term.

(i)Performance obligations

Generally, the Group fulfilled its performance obligations for preventive and diagnostic services at a point in time upon delivery of the testing results or reports to customers except for one category of the genetic testing kits under the preventive services which includes an additional distinct performance obligation being the subscription of free future updates to new features, reports and categories (collectively the “update services”).

The update services are considered distinct from the testing results or reports received by customers as those customers can benefit from the information provided in the testing results without the update services, the update services would not significantly modify the testing results, and there is not any significant interdependency between the testing results and the update services.

For genetic testing kits which contain the update services, the Group allocates revenue to the testing results and the update services on a relative standalone selling price basis. When estimating standalone prices, the Group considers all information that is reasonably available which includes market conditions, company-specific information about the customers, pricing strategies and practices, cost incurred to provide the service and industry pricing. The Group has estimated the standalone selling price of the update services based on the expected cost plus a margin.

(ii)Revenue breakage

Provision of preventive services require individuals to provide specimen samples to the Group before it can proceed with the necessary laboratory procedures. Sales contracts relating to testing kits sold directly to individuals normally require specimen samples to be sent back to the Group within one year (the “sample return period”) from the date of purchase depending on the jurisdictions in which the kits are purchased by customers. If these customers do not return their specimen samples within the sample return period, the Group has no further obligation to provide the service. Sales contracts relating to kits sold to corporations normally do not include specified sample return periods.

For certain non-refundable sale contracts, the Group does not have sufficient and relevant historical experience to form a reasonable expectation about the amount of breakage revenue to which the Group is expected to be entitled. This would be the case for certain preventive testing kits sold to corporations such as insurance companies that would ultimately be passed on to its end users at the corporations’ discretion, where there is no stated sample return period and the Group has no visibility as to whether and when the kits are distributed to end users. This would also be the case for certain diagnostic testing kits sold to individuals with respect to COVID-19. For those sales contracts, revenue is recognized at the earlier point in time of i) the relevant services are rendered and the testing results are issued; or ii) when the likelihood of end users returning their specimen samples becomes remote.

Otherwise, the Group generally has sufficient and relevant historical experience for other sales contracts such that the Group expects to be entitled to a breakage amount in relation to non-refundable and unexercised rights. For these sales contracts, the Group estimates and recognizes the expected breakage amount as revenue in proportion to the pattern of rights exercised by customers on a portfolio basis to the extent that it is considered highly probable that a significant reversal will not occur in the future.

The Group updates its breakage estimate regularly and if necessary, adjusts the deferred revenue balance accordingly. If actual return patterns vary from the estimate, actual breakage revenue may differ from the amounts recorded. The Group recognized breakage revenue from unreturned kits of $502,707, $230,107 and $347,894 for the years ended December 31, 2023, 2022 and 2021, respectively.

(iii)Interest income

Interest income is recognized as it accrues using the effective interest method.

(iv)Government subsidies

Government subsidies are initially recognized as deferred income at fair value if there is reasonable assurance that they will be received and that the Group will comply with the conditions with the grant. Grants that compensate the Group for expenses incurred are recognized as other income on a systematic basis in the same periods in which the expenses are recognized.

D Employee benefits

(i)Short-term employee benefits

Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

(ii)Share-based payment arrangements

The grant-date fair value of equity-settled share-based payment arrangements granted to certain employees, directors and third parties is generally recognized as an expense, with a corresponding increase in equity, over the vesting period of the RSUs. The amount recognized as an expense is adjusted to reflect the number of RSUs for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the number RSUs that meet the related service and non-market performance conditions at the vesting date.

(iii)Defined contribution plans

Obligations for contributions to defined contribution plans are expensed as the related service is provided.

E Other finance costs

The Group’s other finance costs include:

-interest expense;

-interest expenses on lease liabilities;

-imputed interest on deferred consideration; and

-changes in the carrying amount of preference shares liabilities.

Interest expense is recognized using the effective interest method.

The ‘effective interest rate’ is the rate that exactly discounts estimated future cash payments through the expected life of the financial instrument to the amortized cost of the financial liability.

F Income tax

Income tax expense comprises current and deferred tax. It is are recognized in profit or loss.

(i)Current tax

Current tax comprises the expected tax payable on the taxable income for the year and any adjustment to the tax payable in respect of previous years. The amount of current tax payable is the best estimate of the tax amount expected to be paid that reflects uncertainty related to income taxes, if any. It is measured using tax rates enacted or substantively enacted at the reporting date.

(ii)Deferred tax

Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for:

-temporary differences on the initial recognition of assets or liabilities in a transaction that

◦is not a business combination; and

◦at the time of the transaction (i) affects neither accounting nor taxable profit or loss and (ii) does not give rise to equal taxable and deductible temporary differences.

-taxable temporary differences arising on the initial recognition of goodwill.

Deferred tax assets are recognized for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Future taxable profits are determined based on the reversal of relevant taxable temporary differences. If the amount of taxable temporary differences is insufficient to recognize a deferred tax asset in full, then future taxable profits, adjusted for reversals of existing temporary differences, are considered, based on the business plans for individual subsidiaries in the Group. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized; such reductions are reversed when the probability of future taxable profits improves.

The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Group expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset only if certain criteria are met.

G Inventories

Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on the first-in,first-out allocation method.

H Property, plant and equipment

(i)Recognition and measurement

Items of property, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognized in profit or loss.

(ii)Subsequent expenditure

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Group.

(iii)Depreciation

Depreciation is calculated to write off the cost of items of property, plant and equipment less their estimated residual values using the straight-line method over their estimated useful lives, and is generally recognized in profit or loss.

The estimated useful lives of property, plant and equipment for current and comparative periods are as follows:


– Properties leased for own use			Over the unexpired lease period

– Office equipment leased for own use			Over the unexpired lease period

– Leasehold improvements			Shorter period of the lease term or the useful life

– Fixtures and furniture			3 - 5 years

– Office and lab equipment			3 - 5 years

– Computer equipment			3 years

– Motor vehicles			3 - 5 years

– Manufacturing equipment			3 - 5 years

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

I Intangible assets and goodwill

(i)Recognition and measurement

Goodwill

Goodwill arising on the acquisition of subsidiaries is measured at cost less accumulated impairment losses.

Research and development

Expenditure on research activities is recognized in profit or loss as incurred.

Other intangible assets

Other intangible assets, including website and mobile apps, trademark and technology and product development cost, computer software and customer relationship, that are acquired by the Group and have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses.

(ii)Subsequent expenditure

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates.

(iii)Amortization

Amortization is calculated to write off the cost of intangible assets less their estimated residual values using the straight-line method over their estimated useful lives, and is generally recognized in profit or loss. Goodwill is not amortized.

The estimated useful lives for current and comparative periods are as follows:


– Website and mobile apps			2 years
– Trademark and technology			10 - 20 years
– Products development cost			3 years
– Computer software			3 years
– Customer relationship			10 years

Amortization methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

J Financial instruments

(i)Recognition and initial measurement

Trade receivables are initially recognized when they are originated. All other financial assets and financial liabilities are initially recognized when the Group becomes a party to the contractual provisions of the instrument.

A financial asset (unless it is a trade receivable without a significant financing component) or financial liability is initially measured at fair value plus or minus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition or issue. A trade receivable without a significant financing component is initially measured at the transaction price.

(ii)Classification and subsequent measurement

Financial assets - classification

On initial recognition, a financial asset is classified as subsequently measured at amortized cost or FVTPL.

Financial assets are not reclassified subsequent to their initial recognition unless the Group changes its business model for managing financial assets, in which case all affected financial assets are reclassified on the first day of the first reporting period following the change in the business model.

A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:

-it is held within a business model whose objective is to hold assets to collect contractual cash flows; and

-its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest ("SPPI") on the principal amount outstanding.

All financial assets not classified as measured at amortized cost as described above are measured at FVTPL. This includes all derivative financial assets.

Financial assets – Business model assessment

The business models of the Group are as follows.

Held to collect

The Group holds financial assets which arise from its principal operations. The objective of the business model for these financial instruments is to collect the amounts due from the Group’s receivables and to earn contractual interest income on the amounts collected.

Held to collect and sell

The Group holds a portfolio of corporate debt securities for liquidity management purposes.

Financial assets – Assessment whether contractual cash flows are solely payments of principal and interest

In assessing whether the contractual cash flows are SPPI, the Group considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Group considers:

-contingent events that would change the amount or timing of cash flows;

-terms that may adjust the contractual coupon rate, including variable-rate features;

-prepayment and extension features; and

-terms that limit the Group’s claim to cash flows from specified assets (e.g. non-recourse features).

A prepayment feature is consistent with the SPPI criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding.

Financial assets – Subsequent measurement and gains and losses

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss.

Financial assets at amortized cost

These assets are subsequently measured at amortized cost using the effective interest method. The gross carrying amount is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss.

Financial liabilities – Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortized cost or FVTPL. A financial liability is classified as at FVTPL if it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss.

Liabilities for puttable financial instrument – Classification, subsequent measurement and gains and losses

Liabilities for puttable financial instrument are an obligation arising from put options written to non-controlling shareholders of subsidiaries, which will be settled based on the fair value of the shares held by the non-controlling shareholders, results in a gross financial liability. The gross financial liability is initially recognized and measured at amortize cost with the corresponding debit to the “other reserve”. In subsequent periods, the changes of fair value is recognized in ‘other reserve’.

K Share capital

(i)Ordinary shares

Incremental costs directly attributable to the issue of ordinary shares are recognized as a deduction from equity.

(ii)Preference shares

The Group’s redeemable preference shares are classified as financial liabilities, because they bear non-discretionary dividends and are redeemable in cash by the holders. Non-discretionary dividends thereon are recognized as interest expense in profit or loss as accrued.

Non-redeemable preference shares are classified as equity, because they bear discretionary dividends, do not contain any obligations to deliver cash or other financial assets and do not require settlement in a variable number of the Group’s equity instruments. Discretionary dividends thereon are recognized as equity distributions on approval by the Company’s shareholders.

(iii)Repurchase and reissue of ordinary shares (treasury shares)

When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares and are presented in the treasury share reserve. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity and the resulting surplus or deficit on the transaction is presented within share premium.

L Impairment

(i)Non-derivative financial assets

Financial instruments

The Group recognizes loss allowances for ECLs on financial assets measured at amortized cost.

The Group measures loss allowances at an amount equal to lifetime ECLs, except for bank balances for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition, which are measured at 12-month ECLs.

Loss allowances for trade receivables are always measured at an amount equal to lifetime ECLs.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Group considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the Group’s historical experience and informed credit assessment, that includes forward-looking information.

The Group assumes that the credit risk on a financial asset has increased significantly if it is more than 30 days past due.

The Group considers a financial asset to be in default when:

-the debtor is unlikely to pay its credit obligations to the Group in full, without recourse by the Group to actions such as realizing security (if any is held); or

-the financial asset is more than 90 days past due.

Lifetime ECLs are the ECLs that result from all possible default events over the expected life of a financial instrument.

12-month ECLs are the portion of ECLs that result from default events that are possible within the 12 months after the reporting date (or a shorter period if the expected life of the instrument is less than 12 months).

The maximum period considered when estimating ECLs is the maximum contractual period over which the Group is exposed to credit risk.

Measurement of ECLs

ECLs are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the entity in accordance with the contract and the cash flows that the Group expects to receive).

ECLs are discounted at the effective interest rate of the financial asset.

Credit-impaired financial assets

At each reporting date, the Group assesses whether financial assets carried at amortized cost are credit-impaired. A financial asset is ‘credit-impaired’ when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit-impaired includes the following observable data:

-significant financial difficulty of the debtor;

-a breach of contract such as a default or being more than 90 days past due;

-the restructuring of a loan or advance by the Group on terms that the Group would not consider otherwise;

-it is probable that the debtor will enter bankruptcy or other financial reorganization; or

-the disappearance of an active market for a security because of financial difficulties.

Presentation of allowance for ECL in the statement of financial position

Loss allowances for financial assets measured at amortized cost are deducted from the gross carrying amount of the assets

Write-off

The gross carrying amount of a financial asset is written off when the Group has no reasonable expectations of recovering a financial asset in its entirety or a portion thereof. For individual customers, the Group has a policy of writing off the gross carrying amount when the financial asset is 180 days past due based on historical experience of recoveries of similar assets. For corporate customers, the Group individually makes an assessment with respect to the timing and amount of write-off based on whether there is a reasonable expectation of recovery. The Group expects no significant recovery from the amount written off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Group’s procedures for recovery of amounts due.

(ii)Non-financial assets

At each reporting date, the Group reviews the carrying amounts of its non-financial assets (other than inventories and deferred tax assets) to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. Goodwill is tested annually for impairment.

For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs. Goodwill arising from a business combination is allocated to CGUs or groups of CGUs that are expected to benefit from the synergies of the combination.

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs of disposal. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU.

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its recoverable amount.

Impairment losses are recognized in profit or loss. They are allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets in the CGU on a pro rata basis.

An impairment loss in respect of goodwill is not reversed. For other assets, an impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

M Leases

At inception of a contract, the Group assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

As a lessee

The Group recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term, unless the lease transfers ownership of the underlying asset to the Group by the end of the lease term or the cost of the right-of-use asset reflects that the Group will exercise a purchase option. In that case the right-of-use asset will be depreciated over the useful life of the underlying asset, which is determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group’s incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.

The Group determines its incremental borrowing rate by obtaining interest rates from various external financing sources and makes certain adjustments to reflect the terms of the lease and type of the asset leased.

Lease payments included in the measurement of the lease liability comprise fixed payments, including in-substance fixed payments.

The lease liability is measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if the Group changes its assessment of whether it will exercise a termination option.

The Group presents right-of-use assets that do not meet the definition of investment property in ‘property, plant and equipment’ and lease liabilities in ‘lease liabilities’ in the statement of financial position.

Short-term leases and leases of low-value assets

The Group has elected not to recognize right-of-use assets and lease liabilities for leases of low-value assets and short-term leases, including IT equipment. The Group recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

N Fair value measurement

‘Fair value’ is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or, in its absence, the most advantageous market to which the Group has access at that date. The fair value of a liability reflects its non-performance risk.

A number of the Group’s accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities (see note 4).

When one is available, the Group measures the fair value of an instrument using the quoted price in an active market for that instrument. A market is regarded as ‘active’ if transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

If there is no quoted price in an active market, then the Group uses valuation techniques that maximize the use of relevant observable inputs and minimize the use of unobservable inputs. The chosen valuation technique incorporates all of the factors that market participants would take into account in pricing a transaction.

If an asset or a liability measured at fair value has a bid price and an ask price, then the Group measures assets and long positions at a bid price and liabilities and short positions at an ask price.

The best evidence of the fair value of a financial instrument on initial recognition is normally the transaction price - i.e. the fair value of the consideration given or received. If the Group determines that the fair value on initial recognition differs from the transaction price and the fair value is evidenced neither by a quoted price in an active market for an identical asset or liability nor based on a valuation technique for which any unobservable inputs are judged to be insignificant in relation to the measurement, then the financial instrument is initially measured at fair value, adjusted to defer the difference between the fair value on initial recognition and the transaction price. Subsequently, that difference is recognized in profit or loss on an appropriate basis over the life of the instrument but no later than when the valuation is wholly supported by observable market data or the transaction is closed out.

O Discontinued operation

A discontinued operation is a component of the Group’s business, the operations and cash flows of which can be clearly distinguished from the rest of the Group and which:

–represents a separate major line of business or geographic area of operations;

–is a part of a single co-ordinated plan to dispose of a separate major line of business or geographic area of operations; or

–is a subsidiary acquired exclusively with a view to resale.

Classification as a discontinued operation occurs at the earlier of disposal or when the operation meets the criteria to be classified as held-for-sale.

When an operation is classified as a discontinued operation, the comparative statement of profit or loss and other comprehensive income is re-presented as if the operation had been discontinued from the start of the comparative year.

Interests in equity-accounted investees (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of associates [abstract]

Summary of detailed information about interest in associates


	2023		2022
Interest in a joint venture	$	97,858,820	$	—
Interests in associates	606,055		788,472
	$	98,464,875	$	788,472

Summary of interests in equity accounted investees

Particulars of equity-accounted investees of the Group are as follows:


Name of an equity-accounted investee	Place of incorporation/ operation	Particular of issued and paid-up capital	Proportion of nominal value of issue capital held by the Company				Principal activity
			2023		2022
			Directly	Indirectly	Directly	Indirectly
			%	%	%	%
Insighta	Cayman Islands	2,000,000 ordinary shares	50	—	—	—	Multi-cancer genetic testing services
アクトメッド株式会社 (“ACTmed Co., Ltd.”)	Japan	1,347 ordinary shares	—	24.85	—	24.85	Precise cancer genetic testing services
CERBACT Asia Holdings Pte. Ltd. (“CERBACT”)	Singapore	100 ordinary shares	—	26.04	—	26.04	Investment holdings

Summary of detailed information of joint venture

in accounting policies. The table also reconciles the summarized financial information to the carrying amount of the Group's interest in Insighta.


	2023
Non-current assets	$	132,725,811
Current assets (including cash and cash equivalents $79,108,498)	79,310,442
Non-current liabilities	(15,192,930)
Other payables, accruals and contract liabilities	(200,052)
Amount due to a related company	(925,631)
Net assets (100%)	195,717,640
Group's share of net assets (50%)	97,858,820
Other income	580,440
Interest income	927,019
Depreciation and amortization	(2,141,759)
Other expenses	(1,054,858)
Income tax expense	349,018
Loss and total comprehensive income (100%)	$	(1,340,140)
Group's share of loss and total comprehensive income (50%)	$	(670,070)
Dividends received by the Group	$	—

Summary of detailed information about financial information of associates

Aggregate information of associates that are not individually material:


	2023		2022
Carrying amount of interests in associates	$	606,055	$	788,472
Group's share of total comprehensive income	(188,830)		—

Financial assets at fair value through profit or loss (Details) - Financial assets measured at fair value through profit or loss (“FVTPL”) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of financial assets [line items]
Financial assets	$ 20,405,264	$ 17,537,608	$ 9,906,000
- Unlisted securities
Disclosure of financial assets [line items]
Financial assets	$ 20,405,264	$ 17,537,608

- Definition

+ References + Details

Warrant liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Warrant Liabilities [Abstract]

Summary of movement in warrant liabilities

Movement of the balance during the years ended December 31, 2022 and 2023 is as follow:


	2023		2022
Balance at January 1	$	3,574,885	$	—
Assumption of warrant upon the Reverse Recapitalization	—		6,186,423
Issuance of warrant	—		585,000
Change in fair value recognized in profit or loss	(3,351,035)		(3,196,538)
Balance at December 31	$	223,850	$	3,574,885

Operating segments - Results of each reportable segment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of operating segments [line items]
Revenue	$ 21,742,675	$ 13,163,841	$ 12,532,744
Gross profit	8,829,887	3,618,295	3,602,597
Unallocated amounts
Disclosure of operating segments [line items]
Revenue	0	0	0
Gross profit	(1,942,117)	(773,697)	(789,497)
Prevention \| Operating segments
Disclosure of operating segments [line items]
Revenue	6,155,140	13,163,841	12,532,744
Gross profit	3,115,480	4,391,992	4,392,094
Diagnostics \| Operating segments
Disclosure of operating segments [line items]
Revenue	15,587,535	0	0
Gross profit	7,656,524	0	0
Hong Kong
Disclosure of operating segments [line items]
Revenue	13,461,964	262,597,457	263,320,009
Gross profit	6,105,445	127,936,591	102,528,614
Hong Kong \| Operating segments
Disclosure of operating segments [line items]
Revenue	13,461,964	262,597,457	263,320,009
Gross profit	6,105,445	127,936,591	102,528,614
Aggregate continuing and discontinued operations
Disclosure of operating segments [line items]
Revenue	35,204,639	275,761,298	275,852,753
Gross profit	$ 14,935,332	$ 131,554,886	$ 106,131,211

- Definition

+ References

+ Details

Property, plant and equipment - Right-of-use assets (Details) - Right-of-use Assets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	$ 2,055,745	$ 5,751,118
Properties leased for own use, carried at depreciated cost
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	2,023,753	5,739,426
Office equipment, carried at depreciated cost
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	$ 31,992	$ 11,692

Financial instruments - Fair values and risk management

12 Months Ended

Dec. 31, 2023

Financial Risk Management And Fair Value Of Financial Instruments [Abstract]

Financial instruments - Fair values and risk management

A.Accounting classification and fair values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.


		Carrying amount								Fair value
	Note	Mandatorily at FVTPL - others		Financial assets at amortized cost		Other financial liabilities		Total		Level 1		Level 2		Level 3		Total
Balance at December 31, 2023
Financial asset measured at fair value
Financial assets at FVTPL	20	$	20,405,264	$	—	$	—	$	20,405,264	$	—	$	—	$	20,405,264	$	20,405,264
Financial assets at amortized cost
Trade receivables	19	$	—	$	4,058,007	$	—	$	4,058,007	n/a		n/a		n/a		n/a
Deposits and other receivables	17,19	—		6,028,021		—		6,028,021		n/a		n/a		n/a		n/a
Amount due from a related company		—		5,123		—		5,123		n/a		n/a		n/a		n/a
Amounts due from equity-accounted investees		—		132,114		—		132,114		n/a		n/a		n/a		n/a
Short-term deposits		—		16,000,000		—		16,000,000		n/a		n/a		n/a		n/a
Cash and cash equivalents	21(b)	—		45,706,448		—		45,706,448		n/a		n/a		n/a		n/a
		$	—	$	71,929,713	$	—	$	71,929,713
Financial liabilities measured at fair value
Warrant liabilities	27	$	223,850	$	—	$	—	$	223,850	223,850		—		—		223,850
Financial liabilities at amortized cost
Trade payables		$	—	$	—	$	1,671,019	$	1,671,019	n/a		n/a		n/a		n/a
Accrued expenses and other liabilities	22	—		—		8,174,815		8,174,815		n/a		n/a		n/a		n/a
Liabilities for puttable financial instrument	28	—		—		14,622,529		14,622,529		n/a		n/a		n/a		n/a
		$	—	$	—	$	24,468,363	$	24,468,363


		Carrying amount								Fair value
	Note	Mandatorily at FVTPL - others		Financial assets at amortized cost		Other financial liabilities		Total		Level 1		Level 2		Level 3		Total
Balance at December 31, 2022
Financial asset measured at fair value
Financial assets at FVTPL	20	$	17,537,608	$	—	$	—	$	17,537,608	$	—	$	—	$	17,537,608	$	17,537,608
Financial assets at amortized cost
Trade receivables	19	$	—	$	41,691,913	$	—	$	41,691,913	n/a		n/a		n/a		n/a
Deposits and other receivables	17,19	—		8,181,576		—		8,181,576		n/a		n/a		n/a		n/a
Short-term deposits		—		19,920,160		—		19,920,160		n/a		n/a		n/a		n/a
Cash and cash equivalents	21(b)	—		146,660,195		—		146,660,195		n/a		n/a		n/a		n/a
		$	—	$	216,453,844	$	—	$	216,453,844
Financial liabilities measured at fair value
Warrant liabilities	27	$	3,574,885	$	—	$	—	$	3,574,885	3,574,885		—		—		3,574,885
Financial liabilities at amortized cost
Trade payables		$	—	$	—	$	7,291,133	$	7,291,133	n/a		n/a		n/a		n/a
Accrued expenses and other liabilities	22	—		—		15,668,734		15,668,734		n/a		n/a		n/a		n/a
Liabilities for puttable financial instrument	28	—		—		17,138,905		17,138,905		n/a		n/a		n/a		n/a
		$	—	$	—	$	40,098,772	$	40,098,772

The Group’s finance team is responsible for overseeing the valuation of the financial instruments of the unlisted securities which are categorized into Level 3 of the fair value hierarchy. The team reports directly to the chief financial officer. Valuation results with analysis of changes in fair value measurement are prepared by the team with the assistance from external valuers where necessary and reviewed by the chief financial officer at each quarter end and annual reporting date. The valuation process is documented and updated where appropriate by the team and reviewed by the chief financial officer quarterly that coincides with the reporting dates.

B.Measurement of fair values

(i)Valuation techniques and significant unobservable inputs

The following tables show the valuation techniques used in measuring Level 3 fair values for financial instruments in the statement of financial position, as well as the significant unobservable inputs used.

Financial instruments measured at fair value

Type

Valuation technique

Significant
unobservable inputs

Inter-relationship between significant unobservable inputs and fair value measurement

Financial assets at FVTPL

Adjusted net asset value

Underlying assets’ value

The estimated fair value would increase if the underlying assets’ value is higher.

Discounted cash flow method

Risk-adjusted discount rate: 17.5%

Discount for lack of marketability: 32.5%

The estimated fair value would increase if:

–the risk-adjusted discount rate was lower; or

–the discount for lack of marketability was lower.

(ii)Transfers between Levels 1 and 2

There were no transfers from Level 2 to Level 1 in 2023 and no transfers in either direction in 2022.

(iii)Level 3 recurring fair values

Reconciliation of Level 3 fair values

The following table shows a reconciliation of financial assets at FVTPL from the opening balances to the closing balances for Level 3 fair values.


	2023		2022
Balance at January 1	$	17,537,608	$	9,906,000
Additions	10,002,442		20,000,000
Redemption	—		(3,004,897)
Changes in fair value recognized in profit or loss	(7,134,786)		(9,363,495)
Balance at December 31	$	20,405,264	$	17,537,608

C.Financial risk management

The Group has exposure to the following risks arising from financial instruments:

-credit risk (see (C)(ii));

-liquidity risk (see (C)(iii)); and

-currency risk (see (C)(iv)).

(i)Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the Group's risk management framework. The management of the Group establishes policies and procedures around risk identification, measurement and management; and setting and monitoring risk limits and controls, in accordance with the objectives and underlying principles in the risk management framework approved by the board of directors. Risk management policies and procedures are reviewed regularly to reflect changes in market conditions and the Group's activities.

(ii)Credit risk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Group's receivables from customers.

The carrying amounts of financial assets represent the maximum credit exposure.

Trade receivables

The Group’s exposure to credit risk is influenced mainly by the individual characteristics of each customer. At December 31, 2023 and 2022, 11% and 56% of the total trade receivables were due from the Group’s largest customer, and 26% and 73% of the total trade receivables were due from the Group’s five largest customers, respectively.

Individual credit evaluations are performed on all customers requiring credit over a certain amount. These take into account the customer’s past payment history, financial position and other factors. Trade receivables are due within 30 to 90 days from the billing date. The Group does not obtain collateral in respect of trade and other receivables. The Group does not have trade receivable for which no loss allowance is recognized because of collateral.

Expected credit loss assessment for individual customers

The Group has applied the simplified approach in IFRS 9 Financial Instruments to measure the loss allowance at lifetime ECL. The Group determines the expected credit losses on trade receivables by using a provision matrix, estimated based on historical credit loss experience based on the past due status of the debtors, adjusted as appropriate to reflect current conditions and estimates of future economic conditions at the reporting date.

At December 31, 2023 and 2022, the overall expected loss rate was 37.40% and 3.68%, respectively, which reflected the settlement experience on the trade receivables.

Movement in the allowance for impairment in respect of trade receivables

Movement in the loss allowance account in respect of trade receivable during the years ended December 31, 2023 and 2022 is as follows:


	2023		2022
Balance at January 1	$	1,592,119	$	518,968
Additions from acquisition (note 34(C))	—		1,263,570
Net remeasurement of loss allowance	782,488		(136,493)
Amounts written off	(41,776)		(33,808)
Exchange differences	91,278		(20,118)
Balance at December 31	$	2,424,109	$	1,592,119

Cash and cash equivalents

The Group held cash and cash equivalents and short-term deposits of $45,706,448 and $16,000,000 at December 31, 2023, respectively (2022: $146,660,195 and $19,920,160, respectively). The cash and cash equivalents and short-term deposits are held with bank and financial institution counterparties with high credit-ratings assigned by international credit-rating agencies.

Impairment on cash and cash equivalents and short-term deposits has been measured on a 12-month expected loss basis and reflects the short maturities of the exposures. The Group considers that its cash and cash equivalents and short-term deposits have low credit risk based on the external credit ratings of the counterparties.

(iii)Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group's objective when managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation.

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include contractual interest payments.


			Contractual undiscounted cash flows
	Carrying amount		Total		Within 1 year or on demand		1 - 2 years		More than 2 years
Balance at December 31, 2023
Trade payables	$	1,671,019	$	1,671,019	$	1,671,019	$	—	$	—
Accrued expenses and other liabilities	8,174,815		8,174,815		8,174,815		—		—
Lease liabilities	2,369,388		2,440,587		1,549,027		787,708		103,852
Liabilities for puttable financial instrument	14,622,529		14,622,529		14,622,529		—		—
	$	26,837,751	$	26,908,950	$	26,017,390	$	787,708	$	103,852
Balance at December 31, 2022
Trade payables	$	7,291,133	$	7,291,133	$	7,291,133	$	—	$	—
Accrued expenses and other liabilities	15,668,734		15,668,734		15,611,421		57,313		—
Lease liabilities	6,646,163		7,308,540		3,022,367		1,678,615		2,607,558
Liabilities for puttable financial instrument	17,138,905		17,138,905		17,138,905		—		—
	$	46,744,935	$	47,407,312	$	43,063,826	$	1,735,928	$	2,607,558

(iv)Market risk

Market risk is the risk that changes in market prices – e.g. foreign exchange rates – will affect the Group’s income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return.

Currency risk

The Group is exposed to transactional foreign currency risk to the extent that there is a mismatch between the currencies in which sales, purchases and receivables are denominated and the respective functional currencies of Group companies. The functional currencies of Group companies are primarily USD, Hong Kong dollar ("HKD"), British Pound ("GBP") and New Taiwan dollar ("TWD"). The currencies in which theses transactions are primarily denominated are USD, HKD, GBP, TWD and Renminbi ("RMB").

As the HKD is pegged to the USD, the Group considers the risk of movements in exchange rates between the HKD and the USD to be insignificant.

Exposure to currency risk

The summary quantitative data about the Group’s exposure to currency risk as reported to the management of the Group is as follows.


	December 31, 2023				December 31, 2022
	USD		RMB		USD		RMB
Trade receivables	$	50,696	$	—	$	79,220	$	—
Deposits, prepayments and other receivables	76,586		—		2,972,471		872,455
Cash and cash equivalents	41,388,803		253,839		12,225,385		14
Trade payables	(45,754)		(167,889)		(3,984,494)		(2,029,309)
Accrued expenses and other liabilities	—		(2,608)		(3,741,359)		—
Net exposure	$	41,470,331	$	83,342	$	7,551,223	$	(1,156,840)

The following significant exchange rates have been applied.


	Average rate				Year-end spot rate
	2023		2022		2023		2022
USD 1	$	7.82	$	7.83	$	7.81	$	7.78
RMB 1	1.10		1.17		1.10		1.11

Sensitivity analysis

The following table indicates the instantaneous change in the Group’s loss after tax (and accumulated losses) that would arise if foreign exchange rates to which the Group has significant exposure at the end of the reporting period had changed at that date, assuming all other risk variables remained constant.


	2023			2022
	Increase/(decrease) in foreign exchange rates	Decrease/(increase) on loss after tax and accumulated losses		Increase/(decrease) in foreign exchange rates	Decrease/(increase) on loss after tax and accumulated losses
	%			%
USD	1	$	(346,058)	1	$	(63,061)
	(1)	346,058		(1)	63,061
RMB	5	(3,478)		5	48,298
	(5)	3,478		(5)	(48,298)

Material accounting policies (Policies)

12 Months Ended

Dec. 31, 2023

Disclosure Of Summary Of Material Accounting Policies [Abstract]

Basis of consolidation

A Basis of consolidation

(i)Business combinations

(ii)Subsidiaries

(iii)Non-controlling interests

Non-controlling interests are measured initially at their proportionate share of the acquiree’s identifiable net assets at the date of acquisition.

Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

(iv)Transactions eliminated on consolidation

(v)Interests in equity-accounted investees

The Group’s interests in equity-accounted investees comprise interests in associates.

Foreign currency

B Foreign currency

(i)Foreign currency transactions

Transactions in foreign currencies are translated into the respective functional currencies of Group companies at the exchange rates at the dates of the transactions.

(ii)Foreign operations

Revenue and other income

C Revenue and other income

Income is classified by the Group as revenue when it arises from the sale of goods or the provision of services in the ordinary course of the Group’s business.

The Group transfers control of a good or service at a point in time unless one of the following overtime criteria is met:

(a)the customer simultaneously receives and consumes the benefits provided as the Group performs;

(b)the Group’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or

(c)the Group’s performance does not create an asset with an alternative use and the Group has an enforceable right to payment for performance completed to date.

(i)Performance obligations

(ii)Revenue breakage

(iii)Interest income

Interest income is recognized as it accrues using the effective interest method.

(iv)Government subsidies

Employee benefits

D Employee benefits

(i)Short-term employee benefits

(ii)Share-based payment arrangements

(iii)Defined contribution plans

Obligations for contributions to defined contribution plans are expensed as the related service is provided.

Other finance costs

E Other finance costs

The Group’s other finance costs include:

-interest expense;

-interest expenses on lease liabilities;

-imputed interest on deferred consideration; and

-changes in the carrying amount of preference shares liabilities.

Interest expense is recognized using the effective interest method.

Income tax

F Income tax

Income tax expense comprises current and deferred tax. It is are recognized in profit or loss.

(i)Current tax

(ii)Deferred tax

-temporary differences on the initial recognition of assets or liabilities in a transaction that

◦is not a business combination; and

◦at the time of the transaction (i) affects neither accounting nor taxable profit or loss and (ii) does not give rise to equal taxable and deductible temporary differences.

-taxable temporary differences arising on the initial recognition of goodwill.

Deferred tax assets and liabilities are offset only if certain criteria are met.

Inventories

G Inventories

Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on the first-in,first-out allocation method.

Property, plant and equipment

H Property, plant and equipment

(i)Recognition and measurement

Items of property, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognized in profit or loss.

(ii)Subsequent expenditure

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Group.

(iii)Depreciation

The estimated useful lives of property, plant and equipment for current and comparative periods are as follows:


– Properties leased for own use			Over the unexpired lease period

– Office equipment leased for own use			Over the unexpired lease period

– Leasehold improvements			Shorter period of the lease term or the useful life

– Fixtures and furniture			3 - 5 years

– Office and lab equipment			3 - 5 years

– Computer equipment			3 years

– Motor vehicles			3 - 5 years

– Manufacturing equipment			3 - 5 years

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

Intangible assets and goodwill

I Intangible assets and goodwill

(i)Recognition and measurement

Goodwill

Goodwill arising on the acquisition of subsidiaries is measured at cost less accumulated impairment losses.

Research and development

Expenditure on research activities is recognized in profit or loss as incurred.

Other intangible assets

(ii)Subsequent expenditure

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates.

(iii)Amortization

The estimated useful lives for current and comparative periods are as follows:


– Website and mobile apps			2 years
– Trademark and technology			10 - 20 years
– Products development cost			3 years
– Computer software			3 years
– Customer relationship			10 years

Amortization methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

Financial instruments

J Financial instruments

(i)Recognition and initial measurement

(ii)Classification and subsequent measurement

Financial assets - classification

On initial recognition, a financial asset is classified as subsequently measured at amortized cost or FVTPL.

A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:

-it is held within a business model whose objective is to hold assets to collect contractual cash flows; and

-its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest ("SPPI") on the principal amount outstanding.

All financial assets not classified as measured at amortized cost as described above are measured at FVTPL. This includes all derivative financial assets.

Financial assets – Business model assessment

The business models of the Group are as follows.

Held to collect

Held to collect and sell

The Group holds a portfolio of corporate debt securities for liquidity management purposes.

Financial assets – Assessment whether contractual cash flows are solely payments of principal and interest

-contingent events that would change the amount or timing of cash flows;

-terms that may adjust the contractual coupon rate, including variable-rate features;

-prepayment and extension features; and

-terms that limit the Group’s claim to cash flows from specified assets (e.g. non-recourse features).

A prepayment feature is consistent with the SPPI criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding.

Financial assets – Subsequent measurement and gains and losses

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss.

Financial assets at amortized cost

Financial liabilities – Classification, subsequent measurement and gains and losses

Liabilities for puttable financial instrument – Classification, subsequent measurement and gains and losses

Share capital

K Share capital

(i)Ordinary shares

Incremental costs directly attributable to the issue of ordinary shares are recognized as a deduction from equity.

(ii)Preference shares

(iii)Repurchase and reissue of ordinary shares (treasury shares)

Impairment

L Impairment

(i)Non-derivative financial assets

Financial instruments

The Group recognizes loss allowances for ECLs on financial assets measured at amortized cost.

Loss allowances for trade receivables are always measured at an amount equal to lifetime ECLs.

The Group assumes that the credit risk on a financial asset has increased significantly if it is more than 30 days past due.

The Group considers a financial asset to be in default when:

-the debtor is unlikely to pay its credit obligations to the Group in full, without recourse by the Group to actions such as realizing security (if any is held); or

-the financial asset is more than 90 days past due.

Lifetime ECLs are the ECLs that result from all possible default events over the expected life of a financial instrument.

The maximum period considered when estimating ECLs is the maximum contractual period over which the Group is exposed to credit risk.

Measurement of ECLs

ECLs are discounted at the effective interest rate of the financial asset.

Credit-impaired financial assets

Evidence that a financial asset is credit-impaired includes the following observable data:

-significant financial difficulty of the debtor;

-a breach of contract such as a default or being more than 90 days past due;

-the restructuring of a loan or advance by the Group on terms that the Group would not consider otherwise;

-it is probable that the debtor will enter bankruptcy or other financial reorganization; or

-the disappearance of an active market for a security because of financial difficulties.

Presentation of allowance for ECL in the statement of financial position

Loss allowances for financial assets measured at amortized cost are deducted from the gross carrying amount of the assets

Write-off

(ii)Non-financial assets

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its recoverable amount.

Leases

M Leases

As a lessee

Lease payments included in the measurement of the lease liability comprise fixed payments, including in-substance fixed payments.

Short-term leases and leases of low-value assets

Fair value measurement

N Fair value measurement

A number of the Group’s accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities (see note 4).

Discontinued operation

See accounting policy in note 38(O).

In 2023, the Group discontinued its 2019 novel coronavirus (“COVID-19”) related diagnostic services globally and other DNA testing operations in the EMEA region. This strategic decision was influenced by the World Health Organization's latest pronouncements and the diminishing demand for COVID-19 diagnostic services. This reduced demand was primarily attributable to the relaxation of testing mandates for international travelers and local citizens worldwide. Consequently, this shift in circumstances led to a noticeable decline in the number of testing centers operating in Hong Kong and the United Kingdom. The decision to discontinue operations in the EMEA region is a strategic move to streamline operations and consolidate resources to better address the evolving needs of the market.

The comparative information in the consolidated statement of profit or loss and other comprehensive income has been restated to show the discontinued operations separately from continuing operations.

a.Results of discontinued operation


	2023		2022		2021
Revenue	$	13,461,964	$	262,597,457	$	263,320,009
Direct costs	(7,356,519)		(134,660,866)		(160,791,395)
Gross profit	6,105,445		127,936,591		102,528,614
Other income and other net gains/(losses)	289,614		(25,214)		341,124
Selling and distribution expenses	(631,812)		(8,563,337)		(16,193,640)
Research and development expenses	(1,188,677)		(9,530,323)		(4,172,461)
Restructuring costs	—		(30,378,741)		—
Administrative and other operating expenses	(12,946,412)		(36,721,676)		(36,059,318)
(Loss)/profit from operating activities	(8,371,842)		42,717,300		46,444,319
Other finance costs	(122,300)		(203,429)		(185,954)
Write-off on amount due from a shareholder	—		—		(106,179)
Gain on bargain purchase	—		—		117,238
(Loss)/profit from discontinued operation before taxation	(8,494,142)		42,513,871		46,269,424
Income tax credit/(expense)	116,482		(7,391,920)		(1,164,222)
(Loss)/profit from discontinued operation, net of tax	$	(8,377,660)	$	35,121,951	$	45,105,202

(Loss)/earnings per share
Basic	(0.74)		6.93		3.09
Diluted	(0.74)		6.93		3.09

The loss from discontinued operation of $8,377,660 (2022: profit from discontinued operation of $35,121,951; 2021: profit from discontinued operation of $45,105,202) was attributable entirely to the owners of the Company. Of the loss from continuing operations of $56,399,672 (2022: $225,575,338; 2021: $219,122,044), an amount of $54,346,211 was attributable to the owners of the Company (2022: $225,575,284; 2021: $219,114,475).

(i)Other income and other net gains/(losses)


	2023		2022		2021
Bank interest income	$	19,297	$	311	$	3,779
Net foreign exchange (losses)/gains	(25,049)		(25,721)		336,285
Sundry income	295,366		196		1,060
	$	289,614	$	(25,214)	$	341,124

(ii)Other finance costs


	2023		2022		2021
Interest expenses on lease liabilities (notes 13(a) and 25(b))	$	122,300	$	203,429	$	163,719
Imputed interest on deferred consideration	—		—		22,235
	$	122,300	$	203,429	$	185,954

(iii)Staff costs


	2023		2022		2021
Salaries, wages and other benefits	$	9,121,633	$	88,585,752	$	63,375,740
Contributions to defined contribution retirement plan	—		492,761		217,501
Equity-settled share-based payment expenses	—		5,425,468		1,715,588
	$	9,121,633	$	94,503,981	$	65,308,829
Represented by:
Direct costs	$	2,057,344	$	63,364,134	$	48,069,439
Selling and distribution expenses	—		188,414		154,606
Research and development expenses	—		7,767,201		795,494
Administrative and other operating expenses	7,064,289		23,184,232		16,289,290
Total staff costs	$	9,121,633	$	94,503,981	$	65,308,829

(iv)Restructuring costs


	2023		2022		2021
Impairment of intangible assets (note 14)	$	—	$	19,109,580	$	—
Impairment of goodwill (note 15)	—		3,272,253		—
Impairment losses on property, plant and equipment (note 13)	—		4,447,610		—
Write-off of prepayment	—		3,549,298		—
	$	—	$	30,378,741	$	—

(v)Other items


	2023		2022		2021
Cost of inventories (note 18)	$	2,760,713	$	50,312,357	$	43,752,723
Depreciation of (note 13)
- property, plant and equipment#	98,290		2,831,186		1,807,544
- right-of-use assets#	1,025,062		1,136,690		917,282
Amortization of intangible assets# (note 14)	—		1,498,245		2,991,094
Write-off on property, plant and equipment	—		268,226		476,431
Auditor’s remuneration	76,985		120,570		168,529
# Represented by:
Direct costs	$	—	$	1,390,250	$	751,775
Research and development expenses	405,100		208,534		90,357
Administrative and other operating expenses	718,252		3,867,337		4,873,788
Total depreciation and amortization charges	$	1,123,352	$	5,466,121	$	5,715,920

b.Cash flows (used in)/from discontinued operation


	2023		2022		2021
Net cash (used in)/from operating activities	$	(901,176)	$	88,324,872	$	49,430,661
Net cash from/(used in) investing activities	118,645		(4,676,216)		(8,798,532)
Net cash used in financing activities	(1,183,878)		(343,407)		(502,543)
Net cash flows for the year	$	(1,966,409)	$	83,305,249	$	40,129,586

O Discontinued operation

A discontinued operation is a component of the Group’s business, the operations and cash flows of which can be clearly distinguished from the rest of the Group and which:

–represents a separate major line of business or geographic area of operations;

–is a part of a single co-ordinated plan to dispose of a separate major line of business or geographic area of operations; or

–is a subsidiary acquired exclusively with a view to resale.

Classification as a discontinued operation occurs at the earlier of disposal or when the operation meets the criteria to be classified as held-for-sale.

Measurement of fair value

Measurement of fair values

Certain Group’s accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.

The Group assigned its finance team to oversee all significant fair value measurements, including Level 3 fair values, and reports directly to the chief financial officer.

The finance team regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as broker quotes or pricing services, is used to measure fair values, then the finance team assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of the IFRS Accounting Standards, including the level in the fair value hierarchy in which the valuations should be classified.

Significant valuation issues are reported to the Group’s audit committee.

When measuring the fair value of an asset or a liability, the Group uses observable market data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

•Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

•Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

•Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Group recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

Further information about the assumptions made in measuring fair values is included in the following notes:

•Note 15: acquisition of ACT Genomics;

•Note 30: equity-settled share-based transactions; and

•Note 32(B): financial instruments

Contract liabilities

12 Months Ended

Dec. 31, 2023

Contract liabilities [abstract]

Contract liabilities

See accounting policy in note 38(C).

Contract liabilities represents non-refundable consideration received from customers before the Group recognizes the related revenue. Such consideration is recognized as contract liabilities until the performance obligation is fulfilled or the likelihood of having to fulfil the performance obligation is remote and it is highly probable that a significant reversal of revenue will not occur.


	2023		2022
Contract liabilities	$	6,111,017	$	5,674,290

Movement in contract liabilities is as follows:


	2023		2022
Balance at January 1	$	5,674,290	$	9,587,245
Revenue recognized	(1,937,086)		(5,904,877)
Additions from acquisition (note 34(C))	—		416,307
Receipt from customers upon entering sales contracts	2,373,813		1,575,615
Balance at December 31	$	6,111,017	$	5,674,290

At December 31, 2023 and 2022, except for the amount of $2,508,663 and $2,500,370, respectively, which is expected to be recognized as revenue within one year, the remaining amount will be recognized as revenue when the performance obligations are fulfilled, which may be after one year from the end of the reporting period.

Other income and other net gains/(losses) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Continuing operations
Government subsidies (note)	$ 108,248	$ 534,678	$ 7,932
Bank interest income	3,923,279	471,878	201
Dividend income	0	9,862	0
Net foreign exchange gains/(losses)	330,193	(663,004)	(51,260)
Impairment loss on amount due from an equity-accounted investee	0	0	(176,227)
Sundry income	145,383	76,443	17,178
Other income and other net gain/(losses)	$ 4,507,103	$ 429,857	$ (202,176)

Inventories

12 Months Ended

Dec. 31, 2023

Classes of current inventories [abstract]

Inventories

See accounting policy in note 38(G).


	2023		2022
Consumables and reagent	$	2,471,318	$	3,662,303
Work in progress	104,165		137,106
Finished goods	551,293		734,663
	$	3,126,776	$	4,534,072

In 2023, 2022 and 2021, inventories of $9,081,519, $57,442,036 and $52,701,330, respectively, were recognized as an expense during the year and included in ‘direct costs’.

In addition, inventories have been reduced by $3,136,551 (2022: $2,055,859) as a result of the write-down to net realizable value. This write-down was recognized as an expense during 2023.

The write-downs are included in ‘direct costs’.

All inventories are expected to be recovered within one year.

Goodwill

12 Months Ended

Dec. 31, 2023

Disclosure of reconciliation of changes in goodwill [abstract]

Goodwill

See accounting policies in notes 38(I) and (L)(ii).


At January 1, 2022	$	3,978,065
Additions from acquisition (note 34(D))	33,800,276
Impairment loss (note 7(a)(iv))	(3,272,253)
Exchange differences	(705,812)
At December 31, 2022 and January 1, 2023	33,800,276
Adjustment of non-controlling interests	(729,885)
Impairment loss	(3,900,268)
At December 31, 2023	$	29,170,123

Impairment tests for cash-generating units (“CGU”) containing goodwill

The Group tests goodwill annually for impairment, or more frequently if there are indications that goodwill might be impaired.

Prevention and Diagnostics services of Prenetics EMEA

The goodwill balance arose from the acquisition of Prenetics EMEA in 2018 representing the excess of the purchase consideration over the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed, which had been fully impaired at December 31, 2022.

Cancer genetic testing services within the Diagnostics segment

The goodwill associated with cancer genetic testing services within the Diagnostics segment arose when that business was acquired by the Group at December 30, 2022. It comprises of a CGU responsible for the related operations based in Hong Kong, Taiwan and Thailand.

Sales of medical diagnostics products within the Diagnostics segment

The goodwill associated with sales of medical diagnostics products within the Diagnostics segment arose when that business was acquired by the Group at December 30, 2022. It represents a CGU responsible for the related operations based in the United Kingdom.

Below is the summary of ACT Genomics goodwill balance allocated to the Group’s CGUs:


	2023		2022
Cancer genetic testing services within the Diagnostics segment	$	28,319,438	$	30,639,976
Sales of medical diagnostics products within the Diagnostics segment	850,685		3,160,300
	$	29,170,123	$	33,800,276

CGUs of cancer genetic testing services and sales of medical diagnostics products

The recoverable amounts of the CGU of cancer genetic testing services and the CGU of sales of medical diagnostics products were determined based on value-in-use calculations. These calculations use cash flow projections based on financial budgets approved by management covering six years period and a terminal growth rate thereafter. This projections for a period of greater than five years have been used on the basis that a longer projection period facilitates a comprehensive evaluation of the future prospects and stability of both CGUs, allowing for a thorough consideration of potential technological advancements that could impact the long-term performance. Cash flows beyond the six years period are extrapolated using the estimated average growth rates stated below. The key assumptions used in the estimation of the recoverable amounts of the two CGUs are set out below. The values assigned to the key assumptions represent management’s assessment of future trends in the relevant industries and are based on historical data from external and internal sources.


	2023		2022
CGU of cancer genetic testing services
Pre-tax discount rate	21.9	%	19.5	%
Terminal value growth rate	3.0	%	3.0	%
Average revenue growth rate	24.7	%	31.1	%
CGU of sales of medical diagnostics products
Pre-tax discount rate	21.7	%	19.6	%
Terminal value growth rate	3.0	%	3.0	%
Average revenue growth rate	12.0	%	18.3	%

Pre-tax discount rate represents the current market assessment of the risks specific to the relevant CGU, regarding the time value of money and individual risks of the underlying assets which have not been incorporated in the cash flow estimates. The pre-tax discount rate calculation is based on the specific circumstances of the Group and its operating segments and derived from its weighted average cost of capital (“WACC”). The WACC is calculated based on the weighted value of the cost of equity which is derived from the expected return on investment by the Group’s investors, and the cost of debt which is derived from the market lending rate for peer companies.

The cash flow projections included specific estimates for six years and a terminal growth rate thereafter. The terminal growth rate was determined based on management’s estimate of the long-term compound annual EBITDA growth rate, consistent with the assumptions that a market participant would make.

Average revenue growth rate was estimated taking into account past experience and anticipated market share gains on existing products.

At December 31, 2022, the recoverable amounts of the CGU of cancer genetic testing services and the CGU of sales of medical diagnostics products based on the estimated value-in-use calculations were higher than the carrying amounts of the respective CGUs. Accordingly, no impairment for goodwill is considered necessary.

Any reasonably possible changes in the key assumptions used in the value-in-use assessment model would not affect management’s view on impairment at December 31, 2022.

At December 31, 2023, the CGU cancer genetic testing services and the CGU sales of medical diagnostics products were determined to be impaired and the related amount of goodwill of $1,658,897 and $2,241,371, were impaired. The impairment loss has been included in profit or loss.

CGUs Prevention EMEA and Diagnostics EMEA

The recoverable amounts of the CGU Prevention EMEA and CGU Diagnostics EMEA were determined based on value-in-use calculations.

In September 2022, the Group implemented a restructuring plan for its UK business so as to streamline the resources on new business opportunity and to allow capacity to pursue other more sustainable business opportunities in the UK. The management considered this development represented indicators of impairment for the CGU Prevention EMEA and CGU Diagnostics EMEA and has performed the impairment assessments. The calculation of recoverable amounts of the CGU Prevention EMEA use cash flow projections based on financial budgets approved by management covering six years period and a terminal growth rate thereafter. Cash flows beyond six years period are extrapolated using the estimated average growth rates stated below. The calculation of recoverable amounts of the CGU Diagnostics EMEA use cash flow projections based on financial budgets approved by management covering the expected remaining period of the business.

The key assumptions used in the estimation of the recoverable amounts of the two CGUs are set out below. The values assigned to the key assumptions represent management’s assessment of future trends in the relevant industries and are based on historical data from external and internal sources.


	2022
CGU Prevention EMEA
Pre-tax discount rate	16.8	%
Terminal value growth rate	3.2	%
Average revenue growth rate	25.1	%
CGU Diagnostics EMEA
Pre-tax discount rate	16.8	%
Terminal value growth rate	N/A
Average revenue growth rate	N/A

Pre-tax discount rate represents the current market assessment of the risks specific to the relevant CGU, regarding the time value of money and individual risks of the underlying assets which have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Group and its operating segments and derived from its WACC. The WACC is calculated based on the weighted value of the cost of equity which is derived from the expected return on investment by the Group’s investors, and the cost of debt which is derived from the market lending rate for peer companies.

At September 30, 2022, the CGU Prevention EMEA and CGU Diagnostics EMEA were determined to be impaired and the related full amount of goodwill of $703,534 and $2,568,719, were impaired, respectively. The impairment loss has been included in profit or loss under restructuring costs in relation to diagnostic business (see note 10(a)(iv)).

Equity-settled share-based transactions - Prenetics 2022 Plan, Narrative (Details) - Restricted share units								12 Months Ended
	Dec. 31, 2023 shares $ / shares	Jun. 30, 2023 shares	Jun. 23, 2023 shares	Feb. 01, 2023 shares	Dec. 31, 2022 shares $ / shares	Jun. 30, 2022 shares	May 18, 2022 shares	Dec. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares	Dec. 31, 2021 $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted (in shares) \| shares	7,928	2,403,529	16,486,108	66,666	946,330	2,446,557	144,522
Weighted average exercise price (in $ per share)	$ 0.01				$ 0.01			$ 0.01	$ 0.01	$ 0.01
Weighted average remaining contractual life								1 year 4 months 24 days	4 years 8 months 12 days
Prenetics 2022 Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price (in $ per share)					$ 0.001				$ 0.001
Weighted average remaining contractual life								3 years	3 years
Bottom \| Prenetics 2022 Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price (in $ per share)	0.001							$ 0.001
Top of range \| Prenetics 2022 Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price (in $ per share)	$ 2.96							$ 2.96

Contract liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Contract liabilities [abstract]

Schedule of contract liabilities


	2023		2022
Contract liabilities	$	6,111,017	$	5,674,290

Movement in contract liabilities is as follows:


	2023		2022
Balance at January 1	$	5,674,290	$	9,587,245
Revenue recognized	(1,937,086)		(5,904,877)
Additions from acquisition (note 34(C))	—		416,307
Receipt from customers upon entering sales contracts	2,373,813		1,575,615
Balance at December 31	$	6,111,017	$	5,674,290

Discontinued operations

12 Months Ended

Dec. 31, 2023

Non-Current Assets Held For Sale And Discontinued Operations [Abstract]

Discontinued operation

See accounting policy in note 38(O).

The comparative information in the consolidated statement of profit or loss and other comprehensive income has been restated to show the discontinued operations separately from continuing operations.

a.Results of discontinued operation


	2023		2022		2021
Revenue	$	13,461,964	$	262,597,457	$	263,320,009
Direct costs	(7,356,519)		(134,660,866)		(160,791,395)
Gross profit	6,105,445		127,936,591		102,528,614
Other income and other net gains/(losses)	289,614		(25,214)		341,124
Selling and distribution expenses	(631,812)		(8,563,337)		(16,193,640)
Research and development expenses	(1,188,677)		(9,530,323)		(4,172,461)
Restructuring costs	—		(30,378,741)		—
Administrative and other operating expenses	(12,946,412)		(36,721,676)		(36,059,318)
(Loss)/profit from operating activities	(8,371,842)		42,717,300		46,444,319
Other finance costs	(122,300)		(203,429)		(185,954)
Write-off on amount due from a shareholder	—		—		(106,179)
Gain on bargain purchase	—		—		117,238
(Loss)/profit from discontinued operation before taxation	(8,494,142)		42,513,871		46,269,424
Income tax credit/(expense)	116,482		(7,391,920)		(1,164,222)
(Loss)/profit from discontinued operation, net of tax	$	(8,377,660)	$	35,121,951	$	45,105,202

(Loss)/earnings per share
Basic	(0.74)		6.93		3.09
Diluted	(0.74)		6.93		3.09

(i)Other income and other net gains/(losses)


	2023		2022		2021
Bank interest income	$	19,297	$	311	$	3,779
Net foreign exchange (losses)/gains	(25,049)		(25,721)		336,285
Sundry income	295,366		196		1,060
	$	289,614	$	(25,214)	$	341,124

(ii)Other finance costs


	2023		2022		2021
Interest expenses on lease liabilities (notes 13(a) and 25(b))	$	122,300	$	203,429	$	163,719
Imputed interest on deferred consideration	—		—		22,235
	$	122,300	$	203,429	$	185,954

(iii)Staff costs


	2023		2022		2021
Salaries, wages and other benefits	$	9,121,633	$	88,585,752	$	63,375,740
Contributions to defined contribution retirement plan	—		492,761		217,501
Equity-settled share-based payment expenses	—		5,425,468		1,715,588
	$	9,121,633	$	94,503,981	$	65,308,829
Represented by:
Direct costs	$	2,057,344	$	63,364,134	$	48,069,439
Selling and distribution expenses	—		188,414		154,606
Research and development expenses	—		7,767,201		795,494
Administrative and other operating expenses	7,064,289		23,184,232		16,289,290
Total staff costs	$	9,121,633	$	94,503,981	$	65,308,829

(iv)Restructuring costs


	2023		2022		2021
Impairment of intangible assets (note 14)	$	—	$	19,109,580	$	—
Impairment of goodwill (note 15)	—		3,272,253		—
Impairment losses on property, plant and equipment (note 13)	—		4,447,610		—
Write-off of prepayment	—		3,549,298		—
	$	—	$	30,378,741	$	—

(v)Other items


	2023		2022		2021
Cost of inventories (note 18)	$	2,760,713	$	50,312,357	$	43,752,723
Depreciation of (note 13)
- property, plant and equipment#	98,290		2,831,186		1,807,544
- right-of-use assets#	1,025,062		1,136,690		917,282
Amortization of intangible assets# (note 14)	—		1,498,245		2,991,094
Write-off on property, plant and equipment	—		268,226		476,431
Auditor’s remuneration	76,985		120,570		168,529
# Represented by:
Direct costs	$	—	$	1,390,250	$	751,775
Research and development expenses	405,100		208,534		90,357
Administrative and other operating expenses	718,252		3,867,337		4,873,788
Total depreciation and amortization charges	$	1,123,352	$	5,466,121	$	5,715,920

b.Cash flows (used in)/from discontinued operation


	2023		2022		2021
Net cash (used in)/from operating activities	$	(901,176)	$	88,324,872	$	49,430,661
Net cash from/(used in) investing activities	118,645		(4,676,216)		(8,798,532)
Net cash used in financing activities	(1,183,878)		(343,407)		(502,543)
Net cash flows for the year	$	(1,966,409)	$	83,305,249	$	40,129,586

O Discontinued operation

A discontinued operation is a component of the Group’s business, the operations and cash flows of which can be clearly distinguished from the rest of the Group and which:

–represents a separate major line of business or geographic area of operations;

–is a part of a single co-ordinated plan to dispose of a separate major line of business or geographic area of operations; or

–is a subsidiary acquired exclusively with a view to resale.

Classification as a discontinued operation occurs at the earlier of disposal or when the operation meets the criteria to be classified as held-for-sale.

Acquisition of ACT Genomics (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about business combination [abstract]

Summary of acquisition date fair value of each major class of consideration transferred

The following table summarizes the acquisition date fair value of each major class of consideration transferred.


Cash	$	9,041,776
Deferred consideration (note 22)	958,224
Equity instruments (1,326,127 ordinary shares)	39,783,820
Total consideration transferred	$	49,783,820
Net cash outflow arising on acquisition:
Cash consideration	$	9,041,776
Less: cash and cash equivalent balances acquired (note 34(C))	5,623,061
Total net cash outflow arising on acquisition	$	3,418,715

Summarises the recognised amounts of assets acquired and liabilities assumed at the date of acquisition

The following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition.


Property, plant and equipment (note 13)	$	5,649,182
Intangible assets (note 14)	13,826,389
Interests in equity-accounted investees (note 16)	788,472
Deferred tax assets	235,879
Inventories	1,294,959
Trade receivables (including loss allowance $1,263,570)	2,594,976
Deposits, prepayments and other receivables	2,013,985
Cash and cash equivalents (note 34(A))	5,623,061
Trade payables	(857,537)
Accrued expenses and other current liabilities	(2,763,480)
Contract liabilities (note 23)	(416,307)
Lease liabilities	(2,379,687)
Tax liabilities	(5,713)
Deferred tax liabilities	(2,913,666)
Other non-current liabilities	(223,207)
Total identifiable net assets acquired	$	22,467,306

Disclosure of valuation techniques

The valuation technique used for measuring the fair value of material assets acquired was as follow.


Assets acquired			Valuation technique
Property, plant and equipment			Cost technique: The valuation model considers market prices for depreciated replacement cost when appropriate. Depreciated replacement cost reflects functional and economic obsolescence.
Intangible assets			Multi-period excess earnings method: The multi-period excess earnings method considers the present value of net cash flows expected to be generated by the technology and customer relationships, by excluding any cash flows related to contributory assets.

Summary of changes in goodwill explanatory

Goodwill arising from the acquisition has been recognized as follows.


	2022
Consideration transferred (note 34(A))	$	49,783,820
Non-controlling interests, based on their proportionate interest in the recognized amounts of the assets and liabilities of ACT Genomics	6,483,762
Fair value of identifiable net assets (note 34(C))	(22,467,306)
Goodwill (note 15)	$	33,800,276

Liabilities for puttable financial instrument (Tables)

12 Months Ended

Dec. 31, 2023

Liabilities For Puttable Financial Instrument [Abstract]

Schedule of liabilities for puttable financial instrument

The movement of the liabilities for puttable financial instrument during years ended December 31, 2023 and 2022 are analyzed as follows:


	2023		2022
Balance at January 1	$	17,138,905	$	—
Issuance of puttable financial instrument	—		17,138,905
Change in fair value recognized in equity	(2,516,376)		—
Balance at December 31	$	14,622,529	$	17,138,905

Reverse Recapitalization (Tables)

12 Months Ended

Dec. 31, 2023

Reverse Recapitalization [Abstract]

Summary of fair value of Artisan's identifiable net assets acquired

The stock exchange listing service has been recorded in profit or loss and measured as the excess of fair value of the Company’s Class A ordinary shares issued to acquire Artisan over the fair value of Artisan’s identifiable net assets acquired, with the amount expensed as incurred:


Fair value of Artisan’s identifiable net assets acquired comprising			$	23,599,605
Prepayments	$	538,315
Cash and cash equivalent	30,363,822
Accrued expenses	(231,109)
Warrants liabilities (note (i))	(6,186,423)
Derivative liabilities (note (ii))	(885,000)
Less: Fair value of consideration comprising:
14,523,244 Company’s Class A ordinary shares			(113,146,206)
Share-based payment expense on listing			$	(89,546,601)

Notes:

Related parties

12 Months Ended

Dec. 31, 2023

Disclosure Of Material Related Party Transactions [Abstract]

Related parties

Apart from balances and transactions disclosed elsewhere in these consolidated financial statements, the Group has also entered into the following related party transactions under the normal course of the Group’s business:

(a)Transactions with other related parties


	2023		2022		2021
Sales to an equity-accounted investee	$	701,807	$	—	$	—
Services recharge received from an equity-accounted investee	12,857		—		—
Purchase from an equity-accounted investee	—		—		(53,981)
Services provided by a company with control from a director of the Company	—		(30,630)		(90,353)
Legal and professional fee paid on behalf of related companies	—		—		(9,060)

(b)Key management personnel compensation

Key management personnel compensation comprised as following.


	2023		2022		2021
Directors’ fees	$	420,000	$	261,110	$	—
Salaries, wages and other benefits	4,239,821		24,549,012		2,281,701
Contributions to defined contribution retirement plan	14,779		17,538		15,643
Equity-settled share-based payment expenses (note)	10,297,075		30,284,686		21,500,167
	$	14,971,675	$	55,112,346	$	23,797,511

Note: The balances are non-cash transactions for the reporting period. Details of the recognition and the fair value determination are included in note 30.

Equity-settled share-based transactions - Narrative (Details)	Dec. 31, 2023 plan
Share options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share option scheme	2
Restricted share units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share option scheme	1

Trade and other receivables and deferred expenses - Additional Information (Details)	12 Months Ended
	Dec. 31, 2023
Bottom
Disclosure of financial assets [line items]
Trade receivables period	30 days
Top of range
Disclosure of financial assets [line items]
Trade receivables period	90 days

Goodwill - Summary of the estimation of recoverable amounts of two CGU's (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of reconciliation of changes in goodwill [line items]
Impairment loss recognised in profit or loss, goodwill	$ 3,900,268	$ 3,272,253
Cancer genetic testing services within the Diagnostics segment
Disclosure of reconciliation of changes in goodwill [line items]
Pre-tax discount rate (%)	21.90%	19.50%
Terminal value growth rate (%)	3.00%	3.00%
Average revenue growth rate (%)	24.70%	31.10%
Impairment loss recognised in profit or loss, goodwill	$ 1,658,897
Sales of medical diagnostics products within the Diagnostics segment
Disclosure of reconciliation of changes in goodwill [line items]
Pre-tax discount rate (%)	21.70%	19.60%
Terminal value growth rate (%)	3.00%	3.00%
Average revenue growth rate (%)	12.00%	18.30%
Impairment loss recognised in profit or loss, goodwill	$ 2,241,371

Short-term deposits and cash and cash equivalents - Additional Information (Details)	Dec. 31, 2023	Dec. 31, 2022
Cash and cash equivalents [abstract]
Short term deposits weighted average interest rate point in time	6.00%	5.21%

Income tax (credit)/expense - Expiry dates of the cumulative tax losses (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Line Items]
Tax losses utilized	$ 97,793,602	$ 62,586,553
Within 1 year
Income Tax Disclosure [Line Items]
Tax losses utilized	32,048,645	893,511
Over 1 year but within 5 years
Income Tax Disclosure [Line Items]
Tax losses utilized	14,113,958	14,362,136
Over 5 years but within 10 years
Income Tax Disclosure [Line Items]
Tax losses utilized	28,452,567	25,085,050
Do not expire under the relevant tax legislation
Income Tax Disclosure [Line Items]
Tax losses utilized	$ 23,178,432	$ 22,245,856

Material accounting policies - Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Material Accounting Policies Table [Line Items]
Revenue recognized	$ (1,937,086)	$ (5,904,877)
Breakage revenue from unreturned kits	$ 502,707	230,107	$ 347,894
Bottom
Material Accounting Policies Table [Line Items]
Sample return period	1 year
Top of range
Material Accounting Policies Table [Line Items]
Consideration refundable period from the date of delivery, services upfront	30 days
Revenue from service
Material Accounting Policies Table [Line Items]
Revenue recognized	$ 0	$ 0	$ 0

Warrant liabilities

12 Months Ended

Dec. 31, 2023

Warrant Liabilities [Abstract]

Warrant liabilities

See accounting policies in note 38(J).

The Reverse Recapitalization (see note 31) has included the issuance of 1,492,306 warrants. Each warrant entitles the holder to purchase one Class A ordinary share of the Company at an exercise price of $8.91 per whole share (equivalent to $133.65 per whole share after reverse stock split). The warrants are exercisable from May 18, 2022 and will expire on May 18, 2027.

The warrants are listed on NASDAQ under the trading symbol “PRENW” and are measured based on the market price.

Movement of the balance during the years ended December 31, 2022 and 2023 is as follow:


	2023		2022
Balance at January 1	$	3,574,885	$	—
Assumption of warrant upon the Reverse Recapitalization	—		6,186,423
Issuance of warrant	—		585,000
Change in fair value recognized in profit or loss	(3,351,035)		(3,196,538)
Balance at December 31	$	223,850	$	3,574,885

Material accounting policies (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure Of Summary Of Material Accounting Policies [Abstract]

Schedule of estimated useful lives of property and equipment

The estimated useful lives of property, plant and equipment for current and comparative periods are as follows:


– Properties leased for own use			Over the unexpired lease period

– Office equipment leased for own use			Over the unexpired lease period

– Leasehold improvements			Shorter period of the lease term or the useful life

– Fixtures and furniture			3 - 5 years

– Office and lab equipment			3 - 5 years

– Computer equipment			3 years

– Motor vehicles			3 - 5 years

– Manufacturing equipment			3 - 5 years

Schedule of estimated useful lives of intangible assets

The estimated useful lives for current and comparative periods are as follows:


– Website and mobile apps			2 years
– Trademark and technology			10 - 20 years
– Products development cost			3 years
– Computer software			3 years
– Customer relationship			10 years

Basis of accounting	12 Months Ended
Basis of accounting	Dec. 31, 2023
Basis Of Accounting [Abstract]
Basis of accounting	Basis of accounting These consolidated financial statements have been prepared in accordance with IFRS Accounting Standards. They were authorized for issue by the Company’s board of directors on April 30, 2024. On November 1, 2023, the Company's shareholders approved a 1-for-15 reverse stock split of the Company's issued and unissued Class A ordinary shares and Class B ordinary shares, which was effected on November 14, 2023. The effect of the reverse stock split was to consolidate each 15 existing issued and outstanding share of $0.0001 pa value each in the Company, into one share of $0.0015 par value each in the Company, with no change in authorized shares. The number of issued and outstanding ordinary shares, including shares reserved for issuance, was reduced from approximately 181.8 million ordinary shares to approximately 12.2 million ordinary shares. 35,755 ordinary shares were issued in connection with the reverse stock split as no fractional shares were issued in connection, and a shareholder who would otherwise be entitled to receive a fractional share received a whole share. All issued and unissued ordinary shares contained in the consolidated financial statements have been retroactively adjusted to reflect the reverse split for all periods presented. Details of the Group’s accounting policies are included in note 38.

Changes in material accounting policies

12 Months Ended

Dec. 31, 2023

Changes in material accounting policies [Abstract]

Changes in material accounting policies

Material accounting policy information

Material accounting policies

The Group has consistently applied the following accounting policies to all periods presented in these consolidated financial statements.

Certain comparative amounts in the statement of profit or loss and other comprehensive income have been re-presented, as a result of operations discontinued during the current year (see note 7).

A Basis of consolidation

(i)Business combinations

(ii)Subsidiaries

(iii)Non-controlling interests

Non-controlling interests are measured initially at their proportionate share of the acquiree’s identifiable net assets at the date of acquisition.

Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

(iv)Transactions eliminated on consolidation

(v)Interests in equity-accounted investees

The Group’s interests in equity-accounted investees comprise interests in associates.

B Foreign currency

(i)Foreign currency transactions

Transactions in foreign currencies are translated into the respective functional currencies of Group companies at the exchange rates at the dates of the transactions.

(ii)Foreign operations

C Revenue and other income

Income is classified by the Group as revenue when it arises from the sale of goods or the provision of services in the ordinary course of the Group’s business.

The Group transfers control of a good or service at a point in time unless one of the following overtime criteria is met:

(a)the customer simultaneously receives and consumes the benefits provided as the Group performs;

(b)the Group’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or

(c)the Group’s performance does not create an asset with an alternative use and the Group has an enforceable right to payment for performance completed to date.

(i)Performance obligations

(ii)Revenue breakage

(iii)Interest income

Interest income is recognized as it accrues using the effective interest method.

(iv)Government subsidies

D Employee benefits

(i)Short-term employee benefits

(ii)Share-based payment arrangements

(iii)Defined contribution plans

Obligations for contributions to defined contribution plans are expensed as the related service is provided.

E Other finance costs

The Group’s other finance costs include:

-interest expense;

-interest expenses on lease liabilities;

-imputed interest on deferred consideration; and

-changes in the carrying amount of preference shares liabilities.

Interest expense is recognized using the effective interest method.

F Income tax

Income tax expense comprises current and deferred tax. It is are recognized in profit or loss.

(i)Current tax

(ii)Deferred tax

-temporary differences on the initial recognition of assets or liabilities in a transaction that

◦is not a business combination; and

◦at the time of the transaction (i) affects neither accounting nor taxable profit or loss and (ii) does not give rise to equal taxable and deductible temporary differences.

-taxable temporary differences arising on the initial recognition of goodwill.

Deferred tax assets and liabilities are offset only if certain criteria are met.

G Inventories

Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on the first-in,first-out allocation method.

H Property, plant and equipment

(i)Recognition and measurement

Items of property, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognized in profit or loss.

(ii)Subsequent expenditure

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Group.

(iii)Depreciation

The estimated useful lives of property, plant and equipment for current and comparative periods are as follows:


– Properties leased for own use			Over the unexpired lease period

– Office equipment leased for own use			Over the unexpired lease period

– Leasehold improvements			Shorter period of the lease term or the useful life

– Fixtures and furniture			3 - 5 years

– Office and lab equipment			3 - 5 years

– Computer equipment			3 years

– Motor vehicles			3 - 5 years

– Manufacturing equipment			3 - 5 years

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

I Intangible assets and goodwill

(i)Recognition and measurement

Goodwill

Goodwill arising on the acquisition of subsidiaries is measured at cost less accumulated impairment losses.

Research and development

Expenditure on research activities is recognized in profit or loss as incurred.

Other intangible assets

(ii)Subsequent expenditure

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates.

(iii)Amortization

The estimated useful lives for current and comparative periods are as follows:


– Website and mobile apps			2 years
– Trademark and technology			10 - 20 years
– Products development cost			3 years
– Computer software			3 years
– Customer relationship			10 years

Amortization methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

J Financial instruments

(i)Recognition and initial measurement

(ii)Classification and subsequent measurement

Financial assets - classification

On initial recognition, a financial asset is classified as subsequently measured at amortized cost or FVTPL.

A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:

-it is held within a business model whose objective is to hold assets to collect contractual cash flows; and

-its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest ("SPPI") on the principal amount outstanding.

All financial assets not classified as measured at amortized cost as described above are measured at FVTPL. This includes all derivative financial assets.

Financial assets – Business model assessment

The business models of the Group are as follows.

Held to collect

Held to collect and sell

The Group holds a portfolio of corporate debt securities for liquidity management purposes.

Financial assets – Assessment whether contractual cash flows are solely payments of principal and interest

-contingent events that would change the amount or timing of cash flows;

-terms that may adjust the contractual coupon rate, including variable-rate features;

-prepayment and extension features; and

-terms that limit the Group’s claim to cash flows from specified assets (e.g. non-recourse features).

A prepayment feature is consistent with the SPPI criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding.

Financial assets – Subsequent measurement and gains and losses

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss.

Financial assets at amortized cost

Financial liabilities – Classification, subsequent measurement and gains and losses

Liabilities for puttable financial instrument – Classification, subsequent measurement and gains and losses

K Share capital

(i)Ordinary shares

Incremental costs directly attributable to the issue of ordinary shares are recognized as a deduction from equity.

(ii)Preference shares

(iii)Repurchase and reissue of ordinary shares (treasury shares)

L Impairment

(i)Non-derivative financial assets

Financial instruments

The Group recognizes loss allowances for ECLs on financial assets measured at amortized cost.

Loss allowances for trade receivables are always measured at an amount equal to lifetime ECLs.

The Group assumes that the credit risk on a financial asset has increased significantly if it is more than 30 days past due.

The Group considers a financial asset to be in default when:

-the debtor is unlikely to pay its credit obligations to the Group in full, without recourse by the Group to actions such as realizing security (if any is held); or

-the financial asset is more than 90 days past due.

Lifetime ECLs are the ECLs that result from all possible default events over the expected life of a financial instrument.

The maximum period considered when estimating ECLs is the maximum contractual period over which the Group is exposed to credit risk.

Measurement of ECLs

ECLs are discounted at the effective interest rate of the financial asset.

Credit-impaired financial assets

Evidence that a financial asset is credit-impaired includes the following observable data:

-significant financial difficulty of the debtor;

-a breach of contract such as a default or being more than 90 days past due;

-the restructuring of a loan or advance by the Group on terms that the Group would not consider otherwise;

-it is probable that the debtor will enter bankruptcy or other financial reorganization; or

-the disappearance of an active market for a security because of financial difficulties.

Presentation of allowance for ECL in the statement of financial position

Loss allowances for financial assets measured at amortized cost are deducted from the gross carrying amount of the assets

Write-off

(ii)Non-financial assets

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its recoverable amount.

M Leases

As a lessee

Lease payments included in the measurement of the lease liability comprise fixed payments, including in-substance fixed payments.

Short-term leases and leases of low-value assets

N Fair value measurement

A number of the Group’s accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities (see note 4).

O Discontinued operation

A discontinued operation is a component of the Group’s business, the operations and cash flows of which can be clearly distinguished from the rest of the Group and which:

–represents a separate major line of business or geographic area of operations;

–is a part of a single co-ordinated plan to dispose of a separate major line of business or geographic area of operations; or

–is a subsidiary acquired exclusively with a view to resale.

Classification as a discontinued operation occurs at the earlier of disposal or when the operation meets the criteria to be classified as held-for-sale.

Consolidated statements of cash flows - USD ($)	12 Months Ended
Consolidated statements of cash flows - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of cash flows [abstract]
Loss for the year	$ (64,777,332)	$ (190,453,387)	$ (174,016,842)
Adjustments for:
Bank interest income	(3,942,576)	(472,189)	(3,980)
Dividend income	0	(9,862)	0
Depreciation	5,879,813	5,986,888	4,288,115
Amortization of intangible assets	1,914,561	1,556,091	3,058,527
Other finance costs	241,962	4,198,184	5,238,030
Fair value loss on convertible securities	0	0	29,054,669
Fair value loss on preference shares liabilities	0	60,091,353	125,398,798
Fair value loss on financial assets at fair value through profit or loss	7,134,786	9,363,495	94,000
Fair value gain on warrant liabilities	(3,351,035)	(3,196,538)	0
Restructuring costs	0	30,378,741	0
Net foreign exchange losses/(gains)	819,653	223,927	(285,025)
Write-off on amount due from a shareholder	0	0	106,179
Gain on bargain purchase	0	0	(117,238)
Loss on disposal of a subsidiary	0	0	292,132
Impairment loss on amount due form a joint venture	0	0	176,227
Impairment loss of goodwill	3,900,268	0	0
Loss/(gain) on disposal of property, plant and equipment	818,356	72,976	(39)
Write-off on property, plant and equipment	331,121	268,226	476,431
Write-off on inventories	3,136,551	2,055,859	0
Share of loss of equity-accounted investees	858,900	0	0
Share-based payment on listing	0	89,546,601	0
Equity-settled share-based payment expenses	10,588,944	31,580,383	22,494,918
Income tax (credit)/expense	(385,841)	7,147,104	3,732,744
Total adjustments to reconcile profit (loss)	(36,831,869)	48,337,852	19,987,646
Changes in:
Increase in deferred expenses	(958,557)	(10,885,089)	0
(Increase)/decrease in inventories	(1,729,255)	1,256,133	(2,331,649)
Decrease/(increase) in trade receivables	37,633,287	6,966,189	(24,050,811)
Decrease/(increase) in deposits, prepayments and other receivables	1,589,190	(1,213,944)	(6,126,194)
(Increase)/decrease in amounts due from related companies	(5,123)	9,060	(9,060)
Increase in amounts due from equity-accounted investees	(132,114)	0	0
Decrease/(increase) in other non-current assets	535,283	430,534	(499,966)
Decrease in trade payables	(5,617,891)	(2,627,637)	(3,457,215)
(Decrease)/increase in accrued expenses and other current liabilities	(7,416,560)	(24,390,581)	27,350,803
Increase/(decrease) in contract liabilities	436,727	(4,034,911)	2,532,659
(Decrease)/increase in other non-current liabilities	(123,944)	726,494	0
Cash (used in)/generated from operating activities	(12,620,826)	14,574,100	13,396,213
Income taxes (paid)/refund	(1,144,101)	(59,504)	20,284
Net cash (used in)/from operating activities	(13,764,927)	14,514,596	13,416,497
Cash flows from investing activities
Payment for purchase of property, plant and equipment	(345,290)	(4,948,151)	(8,546,945)
Proceeds from disposal of property, plant and equipment	99,348	49,938	713,523
Payment for purchase of intangible assets	(566,523)	(1,394,553)	(2,865,315)
Proceeds from redemption of short-term deposits	(16,000,000)	(19,920,160)	0
Payment for purchase of financial assets at fair value through profit or loss	(10,002,442)	(20,000,000)	(10,000,000)
Proceeds from redemption of short-term deposits	19,920,160	0	0
Proceeds from redemption of financial assets at fair value through profit or loss	0	3,004,897	0
Payment for acquisition, net of cash acquired	0	(3,418,715)	0
Investment in an equity-accounted investee	(80,000,000)	0	0
Settlement of deferred consideration	0	0	(1,326,823)
Dividend received	0	9,862	0
Interest received	3,942,576	472,189	3,980
Net cash used in investing activities	(82,952,171)	(46,144,693)	(22,021,580)
Cash flows from financing activities
Capital element of lease rentals paid	(3,234,883)	(1,877,896)	(1,299,031)
Interest element of lease rentals paid	(241,497)	(244,085)	(205,915)
Proceeds from new trade financing	0	21,677,075	0
Interest paid	0	(172,978)	(33)
Repayment of trade financing	0	(21,677,075)	0
Proceeds from issuance of shares	2,170	116,864	0
Proceeds from issuance of preference shares	0	0	25,970,000
Proceeds from Reverse Recapitalization	0	146,158,422	0
Proceeds from issuance of convertible securities	0	0	4,980,718
Payment for purchase of treasury shares	(1,230,373)	(661,519)	0
Decrease in amounts due to shareholders	0	0	(128,797)
Net cash (used in)/from financing activities	(4,704,583)	143,318,808	29,316,942
Net cash outflow	(101,421,681)	111,688,711	20,711,859
Cash and cash equivalents at the beginning of the year	146,660,195	35,288,952	14,489,880
Effect of foreign exchange rate changes	467,934	(317,468)	87,213
Cash and cash equivalents at the end of the year	$ 45,706,448	$ 146,660,195	$ 35,288,952

Reverse Recapitalization - Additional Information (Details) - USD ($)		12 Months Ended
	Mar. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	May 18, 2022	Sep. 15, 2021
Disclosure Of Reverse Recapitalization [Line Items]
Issuance of bonus shares		$ 2,170	$ 0
Administrative and other operating expenses		41,438,301	59,341,636	$ 47,932,095
NASDAQ Stock Market
Disclosure Of Reverse Recapitalization [Line Items]
Professional services expenditure		$ 18,231,775
Administrative and other operating expenses			$ 3,529,904	$ 14,701,871
Class A ordinary shares \| PIPE Investors
Disclosure Of Reverse Recapitalization [Line Items]
Number of shares issued (in share)					372,000
Issuance of bonus shares	$ 55,800,000
Sale of stock price per share ($ per shares)						$ 10
Shares issued upon conversion (in shares)						516,000
Class A ordinary shares \| Artisan
Disclosure Of Reverse Recapitalization [Line Items]
Number of shares issued (in share)		6,000,000
Sale of stock price per share ($ per shares)		$ 10
Class A ordinary shares after reverse stock split \| PIPE Investors
Disclosure Of Reverse Recapitalization [Line Items]
Sale of stock price per share ($ per shares)						$ 150
Warrants
Disclosure Of Reverse Recapitalization [Line Items]
Number of warrants issued (in shares)		100,000

Material accounting policies - Property - plant and equipment (Details)	12 Months Ended
	Dec. 31, 2023
Fixtures and furniture \| Bottom
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	3 years
Fixtures and furniture \| Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	5 years
Office equipment, carried at depreciated cost \| Bottom
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	3 years
Office equipment, carried at depreciated cost \| Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	5 years
Computer equipment
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	3 years
Motor vehicles \| Bottom
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	3 years
Motor vehicles \| Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	5 years
Manufacturing equipment \| Bottom
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	3 years
Manufacturing equipment \| Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	5 years

Warrant liabilities - Summary of Movement in Warrant Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of warranty liabilities [line items]
Balance at January 1	$ 68,668,371
Balance at December 31	44,013,247	$ 68,668,371
Level 3 \| Warrant liabilities
Disclosure of warranty liabilities [line items]
Balance at January 1	3,574,885	0
Assumption of warrant upon the Reverse Recapitalization	0	6,186,423
Issuance of warrant	0	585,000
Change in fair value recognized in profit or loss	(3,351,035)	(3,196,538)
Balance at December 31	$ 223,850	$ 3,574,885

Income tax (credit)/expense - Deferred tax assets and liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Deferred tax arising from:
At the beginning of the period	$ 2,941,991	$ 579,796	$ (1,951,154)
Charged to profit or loss	(315,796)	(279,633)	2,530,047
Exchange differences	(39,052)	(35,959)	903
Additions from acquisition (note 34(C))		2,677,787
At the end of the year	2,587,143	2,941,991	579,796
Depreciation allowances in excess of the related depreciation
Deferred tax arising from:
At the beginning of the period	335,440	1,267,681	364,745
Charged to profit or loss	(41,796)	(957,459)	906,775
Exchange differences	10,012	(38,448)	(3,839)
Additions from acquisition (note 34(C))		63,666
At the end of the year	303,656	335,440	1,267,681
Tax losses recognized
Deferred tax arising from:
At the beginning of the period	(243,449)	(1,809,162)	(3,347,753)
Charged to profit or loss	0	1,799,103	1,528,881
Exchange differences	(49,064)	2,489	9,710
Additions from acquisition (note 34(C))		(235,879)
At the end of the year	(292,513)	(243,449)	(1,809,162)
Intangible assets arising from business combination
Deferred tax arising from:
At the beginning of the period	2,850,000	1,121,277	1,031,854
Charged to profit or loss	(274,000)	(1,121,277)	94,391
Exchange differences	0	0	(4,968)
Additions from acquisition (note 34(C))		2,850,000
At the end of the year	$ 2,576,000	$ 2,850,000	$ 1,121,277

Loss before taxation - Other finance costs and staff costs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Continuing operations
Interest expenses on lease liabilities (notes 13(a) and 25(b))	$ 241,497	$ 244,085	$ 205,915
Changes in the carrying amount of preference shares liabilities (note 26)		(3,752,758)
Continuing operations
Salaries, wages and other benefits	27,745,031	21,058,447	13,246,763
Contributions to defined contribution retirement plan	718,933	369,102	344,926
Equity-settled share-based payment expenses	10,495,706	25,913,717	20,426,026
Total staff costs	38,959,670	47,341,266	34,017,715
Other finance cost
Continuing operations
Interest expenses on lease liabilities (notes 13(a) and 25(b))	119,197	40,656	42,196
Interest expenses on trade financing (note 25(b))	0	172,978	0
Changes in the carrying amount of preference shares liabilities (note 26)	0	3,752,758	5,009,847
Other interest expenses	465	28,363	33
Finance costs	119,662	3,994,755	5,052,076
Direct costs
Continuing operations
Total staff costs	1,997,360	282,918	345,183
Selling and distribution expenses
Continuing operations
Total staff costs	3,891,109	1,593,735	1,144,714
Research and development expenses
Continuing operations
Total staff costs	10,226,280	5,637,295	6,147,814
Administrative and other operating expenses
Continuing operations
Total staff costs	$ 22,844,921	$ 39,827,318	$ 26,380,004

Financial assets at fair value through profit or loss

12 Months Ended

Dec. 31, 2023

Financial assets designated as measured at fair value through profit or loss [abstract]

Financial assets at fair value through profit or loss

See accounting policy in note 38(J).


	2023		2022
Financial assets measured at fair value through profit or loss (“FVTPL”)
- Unlisted securities	$	20,405,264	$	17,537,608

Movement of the balance during the years ended December 31, 2023 and 2022 is as follow:


	2023		2022
Balance at January 1	$	17,537,608	$	9,906,000
Additions	10,002,442		20,000,000
Redemption	—		(3,004,897)
Changes in fair value recognized in profit or loss	(7,134,786)		(9,363,495)
Balance at December 31	$	20,405,264	$	17,537,608

Acquisition of ACT Genomics - Summary of Acquisition Date Fair Value of Each Major Class of Consideration Transferred (Details) - ACT Genomics Holdings Company Limited	Dec. 31, 2022 USD ($) shares
Acquisition-date fair value of total consideration transferred [abstract]
Cash consideration	$ 9,041,776
Deferred consideration (note 22)	958,224
Equity instruments ($1,326,127 ordinary shares)	39,783,820
Total consideration transferred	49,783,820
Less: cash and cash equivalent balances acquired (note 34(C))	5,623,061
Total net cash outflow arising on acquisition	$ 3,418,715
Ordinary shares
Acquisition-date fair value of total consideration transferred [abstract]
Number of instruments or interests issued or issuable (in shares) \| shares	1,326,127

Income tax (credit)/expense - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Line Items]
Provision for income tax	$ (269,359)	$ (244,816)	$ 2,568,522
Hong Kong
Income Tax Disclosure [Line Items]
Applicable tax rate (%)	16.50%	16.50%
Provision for income tax			$ 0

- Definition

The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]

+ References + Details

Short-term deposits and cash and cash equivalents

12 Months Ended

Dec. 31, 2023

Cash and cash equivalents [abstract]

Short-term deposits and cash and cash equivalents

See accounting policies in notes 38(J)(i)-(ii) and (L)(i).

(a)Short-term deposits

At December 31, 2023, the short-term deposits of the Group carried weighted average interest rates of 6.00% per annum (2022: 5.21%).

(b)Cash and cash equivalents


	2023		2022
Bank balances	$	45,701,633	$	146,656,326
Cash on hand	4,815		3,869
Cash and cash equivalents	$	45,706,448	$	146,660,195

Other income and other net gains/(losses) - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Analysis of income and expense [abstract]
Revenue from funding support of employee support scheme	$ 71,657	$ 234,470
Revenue from funding support of jobs Support scheme			$ 7,932
Revenue from funding support of job creation scheme	$ 36,591	$ 300,208

Non-controlling interests (Details) - USD ($)	12 Months Ended
Non-controlling interests (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about business combination [line items]
Non-controlling interests percentage	25.61%
Non-current assets	$ 160,510,113	$ 70,320,914
Current assets	93,660,406	241,810,317
Non-current liabilities	(4,529,233)	(11,473,256)
Amount due to a related company	(39,484,014)	(57,195,115)
Equity attributable to equity shareholder of the parent Company	206,357,798	237,064,127
Non-controlling interests	3,799,474	6,398,733
Revenue	21,742,675	13,163,841	$ 12,532,744
Loss for the year	(64,777,332)	(190,453,387)	(174,016,842)
Equity shareholders of the Company	(62,723,871)	(190,453,333)	(174,009,273)
Non-controlling interests	(2,053,461)	(54)	(7,569)
Other comprehensive income for the year	1,795,623	(4,842,932)	260,112
Equity shareholders of the Company	(61,112,335)	(195,296,265)	(173,749,161)
Non-controlling interests	(1,869,374)	(54)	(7,569)
Total comprehensive income for the year	(62,981,709)	(195,296,319)	(173,756,730)
Net cash (used in)/from operating activities	(13,764,927)	14,514,596	13,416,497
Net cash used in investing activities	(82,952,171)	(46,144,693)	(22,021,580)
Net cash (used in)/from financing activities	(4,704,583)	143,318,808	29,316,942
Net cash outflow	(101,421,681)	$ 111,688,711	$ 20,711,859
Subsidiaries with material non-controlling interests
Disclosure of detailed information about business combination [line items]
Non-current assets	28,072,665
Current assets	18,267,042
Non-current liabilities	(3,666,563)
Amount due to a related company	(7,752,718)
Equity attributable to equity shareholder of the parent Company	25,977,305
Non-controlling interests	8,943,121
Revenue	17,085,906
Expenses	(25,054,425)
Loss for the year	(7,968,519)
Equity shareholders of the Company	(5,927,781)
Non-controlling interests	(2,040,738)
Other comprehensive income attributable to equity shareholder of the parent Company	534,723
Other comprehensive income attributable to non-controlling interests	184,087
Other comprehensive income for the year	718,810
Equity shareholders of the Company	(5,393,058)
Non-controlling interests	(1,856,651)
Total comprehensive income for the year	(7,249,709)
Net cash (used in)/from operating activities	(10,519,097)
Net cash used in investing activities	(522,742)
Net cash (used in)/from financing activities	(1,469,418)
Net cash outflow	(12,511,257)
Dividends paid to non-controlling interests	$ 0

Interests in equity-accounted investees - Additional information (Details) $ / shares in Units, $ in Millions		12 Months Ended
	Jul. 20, 2023 USD ($) shares $ / shares	Dec. 31, 2023	Dec. 31, 2022 $ / shares
Class A ordinary shares
Disclosure of associates [line items]
Number of instruments (in shares) \| shares	1,481,481
Share price (in $ per share)	$ 0.83
Class A ordinary shares after reverse stock split
Disclosure of associates [line items]
Share price (in $ per share)	$ 12.51
Insighta
Disclosure of associates [line items]
Percentage of shareholding of an equity accounted investee (%)	50.00%	50.00%
Interests in equity-accounted investees \| $	$ 80
ACT Genomics Holdings Company Limited
Disclosure of associates [line items]
Share price (in $ per share)			$ 2

Discontinued operations - Additional information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Non-Current Assets Held For Sale And Discontinued Operations [Abstract]
Income from discontinued operations attributable to owners of parent	$ (8,377,660)	$ 35,121,951	$ 45,105,202
Loss from continuing operations	(56,399,672)	(225,575,338)	(219,122,044)
Loss from discontinued operation	$ (54,346,211)	$ (225,575,284)	$ (219,114,475)

Financial instruments - Fair values and risk management - Credit risk narrative (Details) - customer	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of major customers [line items]
Percentage of total trade receivables (%)	11.00%	56.00%
Overall expected loss rate	37.40%	3.68%
Largest customer
Disclosure of major customers [line items]
Percentage of total trade receivables (%)	26.00%	73.00%
Five largest customers
Disclosure of major customers [line items]
Number of largest customers	5

Equity-settled share-based transactions

12 Months Ended

Dec. 31, 2023

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Equity-settled share-based transactions

See accounting policy in note 38(D)(ii).

Prenetics HK terminated two share option schemes which were approved in 2014 and 2016 (collectively as the “Option Schemes”) and one restricted share scheme which was approved in 2017 (the “Restricted Share Scheme”) on June 16, 2021, and were rolled up to a new ESOP scheme of PHCL (the “PHCL 2021 Plan”).

Following the consummation of the Reverse Recapitalization, no further awards would be granted under the PHCL 2021 Plan and all restricted shares units (“RSU”) with respect to PHCL ordinary shares that were outstanding under the PHCL 2021 Plan have been replaced by Prenetics 2022 Share Incentive Plan (the “Prenetics 2022 Plan”). There was no incremental fair value in addition to the original grant-date fair value of those cancels under PHCL 2021 Plan as a result of the replacement with Prenetics 2022 Plan.

(a)Prenetics 2022 Plan

The number of RSUs and aggregate fair value of RSUs granted to certain employees, directors and third parties under Prenetics 2022 Plan were as follows,


Grant date	Number of RSUs	Closing price per ordinary share less subscription price per ordinary share		Aggregate fair value of the RSUs
On May 18, 2022	144,522	$	7.64	$	1,104,148
On June 30, 2022	2,446,557	4.04		9,884,090
On December 31, 2022	946,330	2.00		1,892,660
On February 1, 2023	66,666	1.49		99,332
On June 23, 2023	16,486,108	0.90		14,874,763
On June 30, 2023	2,403,529	0.79		1,903,341
On December 31, 2023	7,928	3.39		26,855

The RSUs granted were measured at the closing price per ordinary share less subscription price per ordinary share on grant date. The Company recognized employee share-based compensation benefits according to the restriction conditions.

The RSUs outstanding at December 31, 2023 had an exercise price ranged from $0.001 to $2.96 per ordinary share (2022: $0.001 per ordinary share), and a range of vesting period up to 3 years (2022: up to 3 years).

The number and weighted average exercise prices of the RSUs are as follows:


	2023			2022
	Weighted average exercise price		Number of RSUs	Weighted average exercise price		Number of RSUs
Balance at January 1	$	0.01	2,360,267	$	—	—
Granted	$	0.03	18,964,231	0.01		3,537,409
Cancelled	$	0.001	(9,364,807)	0.01		(75,031)
Exercised	$	0.004	(878,332)	0.01		(1,102,111)
Outstanding balance at December 31	$	0.06	11,081,359	$	0.01	2,360,267
Exercisable balance at December 31	$	0.001	180,194	$	0.01	16,775

During the year ended December 31, 2023, equity-settled share-based payment expenses in respect of the Prenetics 2022 Plan of $4,841,444 (2022: $7,732,961) was recognized in profit or loss, respectively. The remaining balance is recognized in profit or loss over the remaining vesting period.

(b)PHCL 2021 Plan

Details of the RSUs outstanding at December 31, 2023 and 2022 are as follows:


	Number of instruments
	2023	2022
RSUs granted to directors	821,111	1,636,011
RSUs granted to employees	2,126	43,045
RSUs granted to third parties	11,710	11,710
	834,947	1,690,766

Under the PHCL 2021 Plan, PHCL granted 3,933,063 RSUs to certain employees, directors and third parties on June 16, 2021 and 63,934 RSUs in December 2021 to certain directors, employees and third parties, respectively.

The fair value of services received in return for the RSUs granted is measured by reference to the fair value of share options granted. The estimate of the fair value of the share options granted is measured based on Black-Scholes Model. The contractual life of RSUs is used as an input into this model.


	2021
Fair value of RSUs and key assumptions
Fair value at measurement date	$13.89 - $18.91
Share price	$13.89 - $18.91
Exercise price	$	0.01
Expected volatility	41.03% - 44.26%
Expected option life	1 year
Expected dividends	0		%
Risk-free interest rate	1% - 1.13%
Likelihood of achieving a redemption event	5		%
Likelihood of achieving a liquidity event	5		%

The number and weighted average exercise prices of the RSUs are as follows:


	2023			2022
	Weighted average exercise price		Number of RSUs	Weighted average exercise price		Number of RSUs
Balance at January 1	$	0.01	1,690,766	$	0.01	14,748,217
Exercised	0.01		(829,459)	0.01		(12,821,445)
Forfeited	0.01		(26,360)	0.01		(168,894)
Cancelled	—		—	0.01		(67,112)
Outstanding balance at December 31	$	0.01	834,947	$	0.01	1,690,766
Exercisable balance at December 31	$	0.01	283,338	$	0.01	14,571

The RSUs outstanding at December 31, 2023 had a weighted average exercise price of $0.01 per ordinary share (2022: $0.01 per ordinary share), and a weighted average remaining contractual life of 1.4 years (2022: 4.7 years).

The aggregate fair value of the restricted shares united granted to the selected employees on the dates of grants on June 30, 2021 and December 31, 2021 was $54,645,652 ($13.89 per share) and $1,209,111 ($18.91 per share) respectively. The Company recognized employee share-based compensation benefits according to the restriction conditions.

During the year ended December 31, 2023, equity-settled share-based payment expenses in respect of the PHCL 2021 Plan of $5,623,551 (2022: $23,847,422) was recognized in profit or loss, respectively. The remaining balance is recognized in profit or loss over the remaining vesting period.

Related parties - Transactions with key management personnel (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Material Related Party Transactions [Abstract]
Sales to an equity-accounted investee	$ 701,807	$ 0	$ 0
Services recharge received from an equity-accounted investee	12,857	0	0
Purchase from an equity-accounted investee	0	0	(53,981)
Services provided by a company with control from a director of the Company	0	(30,630)	(90,353)
Legal and professional fee paid on behalf of related companies	$ 0	$ 0	$ (9,060)

Financial instruments- Fair values and risk management - Liquidity Risk (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of maturity analysis for financial assets held for managing liquidity risk [line items]
Trade payables	$ 1,671,019	$ 7,291,133
Trade payables	1,671,019	7,291,133
Accrued expenses and other liabilities	8,174,815	15,668,734
Accrued expenses and other liabilities	8,174,815	15,668,734
Lease liabilities	2,369,388	6,646,163
Lease liabilities	2,440,587	7,308,540
Liabilities for puttable financial instrument	14,622,529	17,138,905	$ 0
Liabilities for puttable financial instrument	14,622,529	17,138,905
Financial liabilities	26,837,751	46,744,935
Liabilities, Undiscounted Cash Flows	26,908,950	47,407,312
Within 1 year
Disclosure of maturity analysis for financial assets held for managing liquidity risk [line items]
Trade payables	1,671,019	7,291,133
Accrued expenses and other liabilities	8,174,815	15,611,421
Lease liabilities	1,549,027	3,022,367
Liabilities for puttable financial instrument	14,622,529	17,138,905
Liabilities, Undiscounted Cash Flows	26,017,390	43,063,826
After 1 year but within 2 years
Disclosure of maturity analysis for financial assets held for managing liquidity risk [line items]
Trade payables	0	0
Accrued expenses and other liabilities	0	57,313
Lease liabilities	787,708	1,678,615
Liabilities for puttable financial instrument	0	0
Liabilities, Undiscounted Cash Flows	787,708	1,735,928
After 2 years but within 5 years
Disclosure of maturity analysis for financial assets held for managing liquidity risk [line items]
Trade payables	0	0
Accrued expenses and other liabilities	0	0
Lease liabilities	103,852	2,607,558
Liabilities for puttable financial instrument	0	0
Liabilities, Undiscounted Cash Flows	$ 103,852	$ 2,607,558

List of subsidiaries

12 Months Ended

Dec. 31, 2023

Disclosure of subsidiaries [abstract]

List of subsidiaries

See accounting policy in note 38(A)(ii).

The following list contains the material subsidiaries of the Group at December 31, 2023 and 2022 are as follows:


Name of subsidiaries	Place of incorporation/ operation	Issued and fully paid share capital	Proportion of nominal value of issue capital held by the Company				Principal activities
			2023		2022
			Directly	Indirectly	Directly	Indirectly
			%	%	%	%
Prenetics Limited	Hong Kong	HK$415,276,716	—	100	—	100	Genetic and diagnostic health testing
Prenetics EMEA Limited*	United Kingdom	GBP76,765.81	—	100	—	100	Genetic and diagnostic health testing
ACT Genomics Holdings Company Limited (note 34)	Cayman Islands	$16,713	74.39	—	74.39	—	Precise cancer genetic testing services
ACT Genomics Co., Ltd.	Taiwan	TWD455,080,000	—	74.33	—	74.33	Precise cancer genetic testing - services
ACT Genomics (Hong Kong) Limited	Hong Kong	HK$775,000	—	74.39	—	74.39	Precise cancer genetic testing - services
Sanomics Limited	Hong Kong	HK$500,000	—	74.39	—	74.39	Precise cancer genetic testing - services
MC Diagnostics Limited	United Kingdom	GBP1,164	—	74.39	—	74.39	Sales of medical diagnostics products

* The entity is classified under discontinued operation during the year.

Contract liabilities - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Contract liabilities [abstract]
Revenue to be recognized in within one year	$ 2,508,663	$ 2,500,370
Period of revenue to be recognized	1 year

Consolidated statements of changes in equity - USD ($)	Total	Sub-total	Share capital	Share premium	Treasury stock	Translation reserve	Other reserve	Capital reserve	Accumulated losses	Non- controlling interests
Beginning balance at Dec. 31, 2020	$ 31,007,007	$ 31,084,413	$ 53,240,604	$ 0	$ 0	$ 767,623	$ 5,321,465	$ 15,335,892	$ (43,581,171)	$ (77,406)
Total comprehensive income for the year
Loss for the year	(174,016,842)	(174,009,273)							(174,009,273)	(7,569)
Other comprehensive income for the year	260,112	260,112				260,112
Total comprehensive income for the year	(173,756,730)	(173,749,161)				260,112			(174,009,273)	(7,569)
Equity-settled share-based transactions	22,494,918	22,494,918						22,494,918
Vesting of shares under the restricted share scheme	4,517	4,517						4,517
Reclassification from preference shares liabilities	(279,832,806)	(279,832,806)	(37,890,771)				(241,942,035)
Shares issued upon conversion of exchange loan notes	0		39	1,777,990			(1,778,029)
Reclassification to share premium arising from the restructuring	0		(15,348,379)	15,348,379
Fair value loss of convertible securities	(811,819)	(811,819)					(811,819)
Ending balance at Dec. 31, 2021	(400,894,913)	(400,809,938)	1,493	17,126,369	0	1,027,735	(239,210,418)	37,835,327	(217,590,444)	(84,975)
Total comprehensive income for the year
Loss for the year	(190,453,387)	(190,453,333)							(190,453,333)	(54)
Other comprehensive income for the year	(4,842,932)	(4,842,932)				(4,842,932)
Total comprehensive income for the year	(195,296,319)	(195,296,265)				(4,842,932)			(190,453,333)	(54)
Equity-settled share-based transactions	31,580,383	31,580,383						31,580,383
Vesting of shares under the restricted share scheme	116,864	116,864	785	116,079
Reclassification from preference shares liabilities	550,248,881	550,248,881	5,116	550,243,765
Modification of agreement with PIPE investors	(17,400,000)	(17,400,000)					(17,400,000)
Settlement of agreement with PIPE investors upon listing	17,400,000	17,400,000					17,400,000
Capital contribution	116,094,600	116,094,600	1,494	116,093,106
Shares issued on Reverse Recapitalization	113,146,206	113,146,206	1,452	113,144,754
Shares issued upon conversion of exchange loan notes	0		79	(79)
Issuance of bonus shares	0		1,543	(1,543)
Issuance of shares for acquisition	39,783,820	39,783,820	1,736	34,720,780			5,061,304
Issuance of liabilities for puttable financial instrument for acquisition	(17,138,905)	(17,138,905)					(17,138,905)
Repurchase of shares	(661,519)	(661,519)			(661,519)
Acquisition of non-controlling interests	6,483,762									6,483,762
Ending balance at Dec. 31, 2022	243,462,860	237,064,127	13,698	831,443,231	(661,519)	(3,815,197)	(251,288,019)	69,415,710	(408,043,777)	6,398,733
Total comprehensive income for the year
Loss for the year	(64,777,332)	(62,723,871)							(62,723,871)	(2,053,461)
Other comprehensive income for the year	1,795,623	1,611,536				1,611,536				184,087
Total comprehensive income for the year	(62,981,709)	(61,112,335)				1,611,536			(62,723,871)	(1,869,374)
Equity-settled share-based transactions	10,588,944	10,588,944						10,588,944
Adjustments of non-controlling interests	(729,885)									(729,885)
Shares issued on Reverse Recapitalization	18,528,889	18,528,889	2,222	18,526,667
Shares issued upon conversion of exchange loan notes	0		79	(79)
Issuance of bonus shares	2,170	2,170	2,170
Issuance of shares for acquisition	0		253	5,061,051			(5,061,304)
Issuance of shares for reverse stock split	0		54	(54)
Issuance of liabilities for puttable financial instrument for acquisition	2,516,376	2,516,376					2,516,376
Repurchase of shares	(1,230,373)	(1,230,373)			(1,230,373)
Cancellation and retirement of repurchased shares	0		(168)	(1,828,430)	1,828,598
Ending balance at Dec. 31, 2023	$ 210,157,272	$ 206,357,798	$ 18,308	$ 853,202,386	$ (63,294)	$ (2,203,661)	$ (253,832,947)	$ 80,004,654	$ (470,767,648)	$ 3,799,474

Loans and borrowings

12 Months Ended

Dec. 31, 2023

Borrowings [abstract]

Loans and borrowings

See accounting policies in notes 38(B), (J)(i), (J)(iii) and (L)(ii).

(a)Trade financing

During the year ended December 31, 2022, the Group has entered into certain bank facilities amounted to $14,500,000, which were secured by trade receivables. The balance of trade financing was interest bearing at Hong Kong Interbank Offered Rate (“HIBOR”) plus 1.2% per annum or at United States Dollar reference rate (“USD Reference Rate”) plus 1.2% per annum and repayable within one year.

The Group has also entered into certain reverse factoring arrangements with banks, under which the Group obtained extended credit in respect of the invoice amounts owed to certain suppliers. Under these arrangements, the banks pay suppliers the amounts owed by the Group on the original due dates, and then the Group settles the banks between 120 - 180 days later than the original due dates with the suppliers, with interest at HIBOR plus 1% per annum or at USD Reference Rate plus 1% per annum.

In the consolidated statement of financial position, the Group has presented payables to the banks under these arrangements as “trade financing”, having compared the nature and function of such liabilities with trade payables to suppliers.

Proceeds from trade financing of $21,677,075 were received during the year ended December 31, 2022 and the balances were fully repaid as at December 31, 2022.

(b)Reconciliation of movements of liabilities to cash flows arising from financing activities


	Lease liabilities		Trade financing		Preference shares liabilities		Total
	(note 24)		(note 25(a))		(note 26)
Balance at January 1, 2022	$	5,267,210	$	—	$	486,404,770	$	491,671,980
Changes from financing cash flows:
Capital element of lease rentals paid	(1,834,272)		—		—		(1,834,272)
Interest element of lease rentals paid	(244,085)		—		—		(244,085)
Interest paid	—		(172,978)		—		(172,978)
Proceeds from trade financing	—		21,677,075		—		21,677,075
Repayment of trade financing	—		(21,677,075)		—		(21,677,075)
Total changes from financing cash flows	(2,078,357)		(172,978)		—		(2,251,335)
Other changes:
Increase in lease liabilities from entering into new leases	833,538		—		—		833,538
Interest expenses (notes 7(a)(ii) and 10(a))	244,085		172,978		—		417,063
Changes in the carrying amount of preference shares liabilities (note 26)	—		—		3,752,758		3,752,758
Additions from acquisition (note 34(C))	2,379,687		—		—		2,379,687
Fair value loss on preference shares liabilities (note 26)	—		—		60,091,353		60,091,353
Reclassification to share premium (note 26)	—		—		(550,248,881)		(550,248,881)
Total other changes	3,457,310		172,978		(486,404,770)		(482,774,482)
Balance at December 31, 2022 and January 1, 2023	6,646,163		—		—		6,646,163
Changes from financing cash flows:
Capital element of lease rentals paid	(3,234,883)		—		—		(3,234,883)
Interest element of lease rentals paid	(241,497)		—		—		(241,497)
Total changes from financing cash flows	(3,476,380)		—		—		(3,476,380)
Other changes:
Increase in lease liabilities from entering into new leases	196,626		—		—		196,626
Lease modification	(1,238,518)		—		—		(1,238,518)
Interest expenses (notes 7(a)(ii) and 10(a))	241,497		—		—		241,497
Total other changes	(800,395)		—		—		(800,395)
Balance at December 31, 2023	$	2,369,388	$	—	$	—	$	2,369,388

Income tax (credit)/expense

12 Months Ended

Dec. 31, 2023

Major components of tax expense (income) [abstract]

Income tax (expense)/credit

Income tax (credit)/expense

See accounting policy in note 38(F).

(a)Taxation in the consolidated statements of profit or loss represents:


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Current tax - Hong Kong Profits Tax
Changes in estimates related to prior years	$	(23,323)	$	—	$	—
Current tax - Overseas
Current year	69,760		34,817		38,475
Deferred tax
Origination and reversal of temporary differences	(315,796)		(279,633)		2,530,047
Tax (credit)/expense	$	(269,359)	$	(244,816)	$	2,568,522

Notes:

(i)The provision for Hong Kong Profits Tax is calculated by applying the estimated annual effective tax rate of 16.5% for years ended December 31, 2023 and 2022, except for one subsidiary of the Group which is a qualifying corporation under the two-tiered Profits Tax rate regime. No provision has been made for Hong Kong Profits Tax for the year ended December 31, 2021 as the subsidiary in Hong Kong had unutilized tax loss to set-off against taxable income.

(ii)Taxation for other overseas subsidiaries and branch is charged at the appropriate current rates of taxation ruling in the relevant countries.

(b)Reconciliation of effective tax rate:


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Loss before taxation	$	(56,669,031)	$	(225,820,154)	$	(216,553,522)
Notional tax on loss before taxation, calculated at the applicable rate	$	(8,935,753)	$	(24,306,622)	$	(13,864,746)
Tax effect of non-deductible expenses	3,917,601		24,387,021		17,502,323
Tax effect of non-taxable income	(1,136,909)		(163,797)		(846,573)
Tax effect on utilization of previously unrecognized tax losses	(70,806)		—		(579,657)
Tax effect of tax losses not recognized	6,186,067		101,854		—
Tax effect of previously unrecognized temporary differences recognized in current year	(272,720)		(263,272)		360,922
Others	43,161		—		(3,747)
	$	(269,359)	$	(244,816)	$	2,568,522

(c)Movement in deferred tax balances:

The components of deferred tax (assets)/liabilities recognized in the consolidated statement of financial position and the movements during the years ended December 31, 2021, 2022 and 2023 are as follows:


	Depreciation allowances in excess of the related depreciation		Tax losses recognized		Intangible assets arising from business combination		Total
Deferred tax arising from:
At January 1, 2021	$	364,745	$	(3,347,753)	$	1,031,854	$	(1,951,154)
Charged to profit or loss	906,775		1,528,881		94,391		2,530,047
Exchange differences	(3,839)		9,710		(4,968)		903
At December 31, 2021 and January 1, 2022	1,267,681		(1,809,162)		1,121,277		579,796
(Credited)/charged to profit or loss	(957,459)		1,799,103		(1,121,277)		(279,633)
Additions from acquisition (note 34(C))	63,666		(235,879)		2,850,000		2,677,787
Exchange differences	(38,448)		2,489		—		(35,959)
At December 31, 2022 and January 1, 2023	335,440		(243,449)		2,850,000		2,941,991
Credited to profit or loss	(41,796)		—		(274,000)		(315,796)
Exchange differences	10,012		(49,064)		—		(39,052)
At December 31, 2023	$	303,656	$	(292,513)	$	2,576,000	$	2,587,143


	2023		2022
Represented by:
Deferred tax assets	$	(27,680)	$	(243,449)
Deferred tax liabilities	2,614,823		3,185,440
	$	2,587,143	$	2,941,991

(d)Unrecognized deferred tax assets

The Group has not recognized deferred tax assets in respect of cumulative tax losses of $97,793,602 (2022: $62,586,553) as it is not probable that future taxable profits against which the losses can be utilized will be available in the relevant tax jurisdictions and entities.

The expiry dates of the cumulative tax losses are as follows:


	2023		2022
Within 1 year	$	32,048,645	$	893,511
Over 1 year but within 5 years	14,113,958		14,362,136
Over 5 years but within 10 years	28,452,567		25,085,050
Do not expire under the relevant tax legislation	23,178,432		22,245,856
	$	97,793,602	$	62,586,553

Loss per share - Additional Information (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restricted share units
Earnings per share [line items]
Anti-dilutive excluded from the diluted weighted-average number of ordinary shares (in shares)	859,331	1,674,285	826,695
Warrants
Earnings per share [line items]
Anti-dilutive excluded from the diluted weighted-average number of ordinary shares (in shares)	1,492,307	1,492,306
Exchange Notes
Earnings per share [line items]
Anti-dilutive excluded from the diluted weighted-average number of ordinary shares (in shares)		52,619	51,762

Short-term deposits and cash and cash equivalents (Tables)

12 Months Ended

Dec. 31, 2023

Cash and cash equivalents [abstract]

Schedule of cash and cash equivalents


	2023		2022
Bank balances	$	45,701,633	$	146,656,326
Cash on hand	4,815		3,869
Cash and cash equivalents	$	45,706,448	$	146,660,195

Financial assets at fair value through profit or loss (Tables)

12 Months Ended

Dec. 31, 2023

Financial assets designated as measured at fair value through profit or loss [abstract]

Schedule of financial assets at fair value through profit or loss


	2023		2022
Financial assets measured at fair value through profit or loss (“FVTPL”)
- Unlisted securities	$	20,405,264	$	17,537,608

Schedule of movements in balance

Movement of the balance during the years ended December 31, 2023 and 2022 is as follow:


	2023		2022
Balance at January 1	$	17,537,608	$	9,906,000
Additions	10,002,442		20,000,000
Redemption	—		(3,004,897)
Changes in fair value recognized in profit or loss	(7,134,786)		(9,363,495)
Balance at December 31	$	20,405,264	$	17,537,608


	2023		2022
Represented by:
Non-current	$	9,371,064	$	—
Current	11,034,200		17,537,608
	$	20,405,264	$	17,537,608

Loans and borrowings - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure In Entirety Of Trade Financing [Line Items]
Proceeds from trade financing		$ 21,677,075
Repayments Of Trade Financing Liabilities Arising From Financing Activities		(21,677,075)
Floating interest rate \| Trade financing
Disclosure In Entirety Of Trade Financing [Line Items]
Proceeds from trade financing		21,677,075
Repayments Of Trade Financing Liabilities Arising From Financing Activities		21,677,075
Floating interest rate \| Trade financing \| Trade receivables pledged
Disclosure In Entirety Of Trade Financing [Line Items]
Borrowings notional amount		$ 14,500,000
Floating interest rate \| Bottom \| Trade financing \| Reverse factoring arrangement
Disclosure In Entirety Of Trade Financing [Line Items]
Period within which the amount is to be settled to the bank	120 days
Floating interest rate \| Top of range \| Trade financing \| Reverse factoring arrangement
Disclosure In Entirety Of Trade Financing [Line Items]
Period within which the amount is to be settled to the bank	180 days
Floating interest rate \| Hongking Interbank Offer Rate (%) \| Trade financing \| Reverse factoring arrangement
Disclosure In Entirety Of Trade Financing [Line Items]
Borrowings adjustment to interest rate basis	1.00%
Floating interest rate \| Hongking Interbank Offer Rate (%) \| Remaining Portion (%) \| Trade financing \| Trade receivables pledged
Disclosure In Entirety Of Trade Financing [Line Items]
Borrowings adjustment to interest rate basis	1.20%
Floating interest rate \| USD reference rate (%) \| Remaining Portion (%) \| Trade financing \| Trade receivables pledged
Disclosure In Entirety Of Trade Financing [Line Items]
Borrowings adjustment to interest rate basis	1.20%

Equity-settled share-based transactions - Schedule of fair value of RSUs and assumptions (Details) - Restricted share units	12 Months Ended
	Dec. 31, 2021 $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in $ per share)	$ 0.01
Expected option life	1 year
Expected dividends	0.00%
Likelihood of achieving a redemption event	5
Likelihood of achieving a liquidity event	5
Bottom
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value at measurement date (in $ per share)	$ 13.89
Share price (in $ per share)	$ 13.89
Expected volatility	41.03%
Risk-free interest rate	1.00%
Top of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value at measurement date (in $ per share)	$ 18.91
Share price (in $ per share)	$ 18.91
Expected volatility	44.26%
Risk-free interest rate	1.13%

Non-controlling interests (Tables)

12 Months Ended

Dec. 31, 2023

Non-controlling interests [Abstract]

Summary of the group's material non-controlling interests

The following list contains the material subsidiaries of the Group at December 31, 2023 and 2022 are as follows:


Name of subsidiaries	Place of incorporation/ operation	Issued and fully paid share capital	Proportion of nominal value of issue capital held by the Company				Principal activities
			2023		2022
			Directly	Indirectly	Directly	Indirectly
			%	%	%	%
Prenetics Limited	Hong Kong	HK$415,276,716	—	100	—	100	Genetic and diagnostic health testing
Prenetics EMEA Limited*	United Kingdom	GBP76,765.81	—	100	—	100	Genetic and diagnostic health testing
ACT Genomics Holdings Company Limited (note 34)	Cayman Islands	$16,713	74.39	—	74.39	—	Precise cancer genetic testing services
ACT Genomics Co., Ltd.	Taiwan	TWD455,080,000	—	74.33	—	74.33	Precise cancer genetic testing - services
ACT Genomics (Hong Kong) Limited	Hong Kong	HK$775,000	—	74.39	—	74.39	Precise cancer genetic testing - services
Sanomics Limited	Hong Kong	HK$500,000	—	74.39	—	74.39	Precise cancer genetic testing - services
MC Diagnostics Limited	United Kingdom	GBP1,164	—	74.39	—	74.39	Sales of medical diagnostics products

* The entity is classified under discontinued operation during the year.

The following table summaries the information relating each of the Group's subsidiaries that has material non-controlling interests, before any intra-group eliminations.


	2023
ACT Genomics
Non-controlling interests percentage	25.61	%


	2023
Non-current assets	$	28,072,665
Current assets	18,267,042
Non-current liabilities	(3,666,563)
Current liabilities	(7,752,718)

Equity attributable to equity shareholder of the parent Company	25,977,305
Equity attributable to non-controlling interests	8,943,121


	2023
Revenue	$	17,085,906
Expenses	(25,054,425)
Loss for the year	$	(7,968,519)
Loss attributable to equity shareholder of the parent Company	$	(5,927,781)
Loss attributable to non-controlling interests	(2,040,738)
Loss for the year	$	(7,968,519)
Other comprehensive income attributable to equity shareholder of the parent Company	$	534,723
Other comprehensive income attributable to non-controlling interests	184,087
Other comprehensive income for the year	$	718,810
Total comprehensive income attributable to equity shareholder of the parent Company	$	(5,393,058)
Total comprehensive income attributable to non-controlling interests	(1,856,651)
Total comprehensive income for the year	$	(7,249,709)
Net cash outflow from operating activities	$	(10,519,097)
Net cash outflow from investment activities	(522,742)
Net cash outflow from financing activities	(1,469,418)
Net cash outflow	$	(12,511,257)
Dividends paid to non-controlling interests	$	—

List of subsidiaries (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of subsidiaries [abstract]

Disclosure of the principal subsidiaries of the Company

The following list contains the material subsidiaries of the Group at December 31, 2023 and 2022 are as follows:


Name of subsidiaries	Place of incorporation/ operation	Issued and fully paid share capital	Proportion of nominal value of issue capital held by the Company				Principal activities
			2023		2022
			Directly	Indirectly	Directly	Indirectly
			%	%	%	%
Prenetics Limited	Hong Kong	HK$415,276,716	—	100	—	100	Genetic and diagnostic health testing
Prenetics EMEA Limited*	United Kingdom	GBP76,765.81	—	100	—	100	Genetic and diagnostic health testing
ACT Genomics Holdings Company Limited (note 34)	Cayman Islands	$16,713	74.39	—	74.39	—	Precise cancer genetic testing services
ACT Genomics Co., Ltd.	Taiwan	TWD455,080,000	—	74.33	—	74.33	Precise cancer genetic testing - services
ACT Genomics (Hong Kong) Limited	Hong Kong	HK$775,000	—	74.39	—	74.39	Precise cancer genetic testing - services
Sanomics Limited	Hong Kong	HK$500,000	—	74.39	—	74.39	Precise cancer genetic testing - services
MC Diagnostics Limited	United Kingdom	GBP1,164	—	74.39	—	74.39	Sales of medical diagnostics products

* The entity is classified under discontinued operation during the year.

The following table summaries the information relating each of the Group's subsidiaries that has material non-controlling interests, before any intra-group eliminations.


	2023
ACT Genomics
Non-controlling interests percentage	25.61	%


	2023
Non-current assets	$	28,072,665
Current assets	18,267,042
Non-current liabilities	(3,666,563)
Current liabilities	(7,752,718)

Equity attributable to equity shareholder of the parent Company	25,977,305
Equity attributable to non-controlling interests	8,943,121


	2023
Revenue	$	17,085,906
Expenses	(25,054,425)
Loss for the year	$	(7,968,519)
Loss attributable to equity shareholder of the parent Company	$	(5,927,781)
Loss attributable to non-controlling interests	(2,040,738)
Loss for the year	$	(7,968,519)
Other comprehensive income attributable to equity shareholder of the parent Company	$	534,723
Other comprehensive income attributable to non-controlling interests	184,087
Other comprehensive income for the year	$	718,810
Total comprehensive income attributable to equity shareholder of the parent Company	$	(5,393,058)
Total comprehensive income attributable to non-controlling interests	(1,856,651)
Total comprehensive income for the year	$	(7,249,709)
Net cash outflow from operating activities	$	(10,519,097)
Net cash outflow from investment activities	(522,742)
Net cash outflow from financing activities	(1,469,418)
Net cash outflow	$	(12,511,257)
Dividends paid to non-controlling interests	$	—

Basis of measurement	12 Months Ended
Basis of measurement	Dec. 31, 2023
Basis Of Measurement [Abstract]
Basis of measurement	Basis of measurement The consolidation financial statements have been prepared on the historical cost basis except for financial assets measured at FVTPL, which are measured on an alternative basis on each reporting date. -preference share liabilities – conversion feature (see note 38(K)(ii)); -financial assets at FVTPL (see note 38(J)); and -warrant liabilities (see note 38(J)).

Use of estimates	12 Months Ended
Use of estimates	Dec. 31, 2023
Use Of Estimates [Abstract]
Use of estimates	Use of estimates In preparing these consolidated financial statements, management has made estimates about the future that affect the application of the Group’s accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognized prospectively. Assumptions and estimation uncertainties Information about assumptions and estimation uncertainties at the reporting date that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial year is included in the following notes: •Notes 14 and 15: impairment test of the cash generating units, ACT Genomics, which contains goodwill and intangible assets: key assumptions underlying recoverable amounts. Measurement of fair values Certain Group’s accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities. The Group assigned its finance team to oversee all significant fair value measurements, including Level 3 fair values, and reports directly to the chief financial officer. The finance team regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as broker quotes or pricing services, is used to measure fair values, then the finance team assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of the IFRS Accounting Standards, including the level in the fair value hierarchy in which the valuations should be classified. Significant valuation issues are reported to the Group’s audit committee. When measuring the fair value of an asset or a liability, the Group uses observable market data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows. •Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities. •Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices). •Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs). If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Group recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. Further information about the assumptions made in measuring fair values is included in the following notes: •Note 15: acquisition of ACT Genomics; •Note 30: equity-settled share-based transactions; and •Note 32(B): financial instruments

Property, plant and equipment - Right-of -use assets recognized in Profit & loss (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation charge of right-of-use assets by class of underlying asset:	$ 1,761,394	$ 950,477	$ 625,284
Interest on lease liabilities (notes 7(a)(ii) and 10(a))	241,497	244,085	205,915
Expense relating to short-term leases or leases of low-value assets	136,940	831,631	1,019,937
Aggregate continuing and discontinued operations
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation charge of right-of-use assets by class of underlying asset:	2,786,456	2,087,167	1,542,566
Aggregate continuing and discontinued operations \| - Properties leased for own use
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation charge of right-of-use assets by class of underlying asset:	2,772,649	2,039,815	1,535,333
Aggregate continuing and discontinued operations \| - Office equipment
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation charge of right-of-use assets by class of underlying asset:	$ 13,807	$ 47,352	$ 7,233

Trade and other receivables and deferred expenses

12 Months Ended

Dec. 31, 2023

Trade and other receivables [abstract]

Trade and other receivables and deferred expenses

See accounting policies in notes 38(J)(i)-(ii) and (L)(i).


	2023		2022
Current
Trade receivables, net of loss allowance	$	4,058,007	$	41,691,913
Deposits, prepayments and other receivables
- deposits	887,262		1,119,968
- prepayments	3,298,558		4,965,101
- other receivables	1,099,028		804,045
	5,284,848		6,889,114
Deferred expenses (note)	8,312,890		4,577,255
	17,655,745		53,158,282
Non-current
Deferred expenses (note)	3,530,756		6,307,834
	$	21,186,501	$	59,466,116

All trade receivables, deposits, prepayments and other receivables are expected to be recovered or recognized as expense within one year. Trade receivables are due within 30 to 90 days from the date of billing.

Information about the Group’s exposure to credit and market risks, and impairment losses for trade receivables is included in note 32(C).

Acquisition of ACT Genomics - Summary of Recognized Amounts of Assets Acquired and Liabilities Assumed at the Date of Acquisition (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about business combination [line items]
Contract liabilities (note 23)	$ 0	$ (416,307)
ACT Genomics Holdings Company Limited
Disclosure of detailed information about business combination [line items]
Property, plant and equipment (note 13)		5,649,182
Intangible assets (note 14)		13,826,389
Interests in equity-accounted investees (note 16)		788,472
Deferred tax assets		235,879
Inventories		1,294,959
Trade receivables (including loss allowance $1,263,570)		2,594,976
Allowance account for credit losses of financial assets		1,263,570
Deposits, prepayments and other receivables		2,013,985
Cash and cash equivalents (note 34(A))		5,623,061
Trade payables		(857,537)
Accrued expenses and other current liabilities		(2,763,480)
Contract liabilities (note 23)		(416,307)
Lease liabilities		(2,379,687)
Tax liabilities		(5,713)
Deferred tax liabilities		(2,913,666)
Other non-current liabilities		(223,207)
Total identifiable net assets acquired		$ 22,467,306

Cover Page	12 Months Ended
Cover Page	Dec. 31, 2023 shares
Document Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-41401
Entity Registrant Name	Prenetics Global Limited
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	Unit 703-706, K11 Atelier King’s Road
Entity Address, Address Line Two	728 King’s Road
Entity Address, City or Town	Quarry Bay
Entity Address, Country	HK
Title of 12(b) Security	Class A ordinary shares, par value $0.0015 per share
Trading Symbol	PRE
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding (in shares)	12,205,200
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Central Index Key	0001876431
Entity Address, Postal Zip Code	000000
Warrants
Document Information [Line Items]
Title of 12(b) Security	Warrants
Trading Symbol	PRENW
Security Exchange Name	NASDAQ
Business Contact
Document Information [Line Items]
Entity Address, Address Line One	Unit 703-706, K11 Atelier King’s Road
Entity Address, Address Line Two	728 King’s Road
Entity Address, City or Town	Quarry Bay
Entity Address, Country	HK
Contact Personnel Name	Stephen Lo, Chief Financial Officer
City Area Code	852
Local Phone Number	2210-9588
Entity Address, Postal Zip Code	000000

Other income and other net gains/(losses) (Tables)

12 Months Ended

Dec. 31, 2023

Analysis of income and expense [abstract]

Disclosure of other operating income expense


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Government subsidies (note)	$	108,248	$	534,678	$	7,932
Bank interest income	3,923,279		471,878		201
Dividend income	—		9,862		—
Net foreign exchange gains/(losses)	330,193		(663,004)		(51,260)
Impairment loss on amount due from an equity-accounted investee	—		—		(176,227)
Sundry income	145,383		76,443		17,178
	$	4,507,103	$	429,857	$	(202,176)

Note: The Group has recognized various subsidies granted by the governments in different jurisdictions, including:

Equity-settled share-based transactions - Schedule of number and weighted average exercise prices of RSU (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares
Restricted share units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding at the beginning of the year (in dollars per share)	$ 0.01	$ 0.01
Exercised (in dollars per share)	0.01	0.01
Forfeited (in dollars per share)	0.01	0.01
Cancelled (in dollars per share)	0	0.01
Outstanding at the end of the year (in dollars per share)	0.01	0.01
Exercisable (in dollars per share)	$ 0.01	$ 0.01
Outstanding at the beginning of the year (in shares)	1,690,766	14,748,217
Exercised (in shares)	(829,459)	(12,821,445)
Forfeited (in shares)	(26,360)	(168,894)
Cancelled (in shares)	0	(67,112)
Outstanding at the end of the year (in shares)	834,947	1,690,766
Exercisable (in shares)	283,338	14,571
Restricted shares \| Prenetics 2022 Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense from equity-settled share-based payment transactions \| $	$ 4,841,444	$ 7,732,961

Discontinued operations - Cash flows (used in)/from discontinued operation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Non-Current Assets Held For Sale And Discontinued Operations [Abstract]
Net cash (used in)/from operating activities	$ (901,176)	$ 88,324,872	$ 49,430,661
Net cash from/(used in) investing activities	118,645	(4,676,216)	(8,798,532)
Net cash used in financing activities	(1,183,878)	(343,407)	(502,543)
Net cash flows for the year	$ (1,966,409)	$ 83,305,249	$ 40,129,586

Operating segments - Additional information (Details)	12 Months Ended
Operating segments - Additional information (Details)	Dec. 31, 2023 segment
Disclosure of credit risk exposure [line items]
Number of reportable segments	2

Financial instruments - Fair values and risk management - Schedule of Carrying Amounts and Fair Values of Financial Assets and Financial Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Financial assets at amortized cost
Financial assets at amortized cost	$ 71,929,713	$ 216,453,844
Financial liabilities measured at fair value
Financial liabilities at fair value through profit or loss	223,850
Financial liabilities at amortized cost
Financial liabilities at amortized cost	24,468,363	40,098,772
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	71,929,713	216,453,844
Level 1
Financial liabilities measured at fair value
Financial liabilities at fair value through profit or loss	223,850
Level 2
Financial liabilities measured at fair value
Financial liabilities at fair value through profit or loss	0
Level 3
Financial liabilities measured at fair value
Financial liabilities at fair value through profit or loss	0
Financial liabilities at amortized cost
Financial liabilities at amortized cost
Financial liabilities at amortized cost	24,468,363	40,098,772
Warrant liabilities
Financial liabilities measured at fair value
Financial liabilities at fair value through profit or loss	223,850	3,574,885
Financial liabilities at amortized cost
Financial liabilities at amortized cost		7,291,133
Warrant liabilities \| Level 1
Financial liabilities measured at fair value
Financial liabilities at fair value through profit or loss		3,574,885
Warrant liabilities \| Level 2
Financial liabilities measured at fair value
Financial liabilities at fair value through profit or loss		0
Warrant liabilities \| Level 3
Financial liabilities measured at fair value
Financial liabilities at fair value through profit or loss		0
Warrant liabilities \| Financial liabilities measured at fair value
Financial liabilities measured at fair value
Financial liabilities at fair value through profit or loss	223,850	3,574,885
Warrant liabilities \| Financial liabilities at amortized cost
Financial liabilities at amortized cost
Financial liabilities at amortized cost		7,291,133
Trade payables
Financial liabilities at amortized cost
Financial liabilities at amortized cost	1,671,019
Trade payables \| Financial liabilities at amortized cost
Financial liabilities at amortized cost
Financial liabilities at amortized cost	1,671,019
Accrued expenses and other liabilities
Financial liabilities at amortized cost
Financial liabilities at amortized cost	8,174,815	15,668,734
Accrued expenses and other liabilities \| Financial liabilities at amortized cost
Financial liabilities at amortized cost
Financial liabilities at amortized cost	8,174,815	15,668,734
Liabilities for puttable financial instrument
Financial liabilities at amortized cost
Financial liabilities at amortized cost	14,622,529	17,138,905
Liabilities for puttable financial instrument \| Financial liabilities at amortized cost
Financial liabilities at amortized cost
Financial liabilities at amortized cost	14,622,529	17,138,905
Financial assets at amortized cost
Financial assets at amortized cost
Financial assets at amortized cost	71,929,713	216,453,844
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	71,929,713	216,453,844
Financial assets at FVTPL
Financial asset measured at fair value
Financial assets at fair value through profit or loss	20,405,264	17,537,608
Financial assets at FVTPL \| Level 1
Financial asset measured at fair value
Financial assets at fair value through profit or loss	0	0
Financial assets at FVTPL \| Level 2
Financial asset measured at fair value
Financial assets at fair value through profit or loss	0	0
Financial assets at FVTPL \| Level 3
Financial asset measured at fair value
Financial assets at fair value through profit or loss	20,405,264	17,537,608
Financial assets at FVTPL \| Financial assets at FVTPL
Financial asset measured at fair value
Financial assets at fair value through profit or loss	20,405,264	17,537,608
Trade receivables
Financial assets at amortized cost
Financial assets at amortized cost	4,058,007	41,691,913
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	4,058,007	41,691,913
Trade receivables \| Financial assets at amortized cost
Financial assets at amortized cost
Financial assets at amortized cost	4,058,007	41,691,913
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	4,058,007	41,691,913
Deposits and other receivables
Financial assets at amortized cost
Financial assets at amortized cost	6,028,021	8,181,576
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	6,028,021	8,181,576
Deposits and other receivables \| Financial assets at amortized cost
Financial assets at amortized cost
Financial assets at amortized cost	6,028,021	8,181,576
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	6,028,021	8,181,576
Amount due from a related company
Financial assets at amortized cost
Financial assets at amortized cost	5,123
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	5,123
Amount due from a related company \| Financial assets at amortized cost
Financial assets at amortized cost
Financial assets at amortized cost	5,123
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	5,123
Amounts due from equity-accounted investees
Financial assets at amortized cost
Financial assets at amortized cost	132,114
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	132,114
Amounts due from equity-accounted investees \| Financial assets at amortized cost
Financial assets at amortized cost
Financial assets at amortized cost	132,114
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	132,114
Short-term deposits
Financial assets at amortized cost
Financial assets at amortized cost	16,000,000	19,920,160
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	16,000,000	19,920,160
Short-term deposits \| Financial assets at amortized cost
Financial assets at amortized cost
Financial assets at amortized cost	16,000,000	19,920,160
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	16,000,000	19,920,160
Cash and cash equivalents
Financial assets at amortized cost
Financial assets at amortized cost	45,706,448	146,660,195
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	45,706,448	146,660,195
Cash and cash equivalents \| Financial assets at amortized cost
Financial assets at amortized cost
Financial assets at amortized cost	45,706,448	146,660,195
ScheduleOfCarryingAmountsAndFairValuesOfFinancialAssetsAndFinancialLiabilitiesTable [Line Items]
Financial assets at amortized cost	$ 45,706,448	$ 146,660,195

Financial instruments - Fair values and risk management (Tables)

12 Months Ended

Dec. 31, 2023

Financial Risk Management And Fair Value Of Financial Instruments [Abstract]

Schedule of carrying amounts and fair values of financial assets and financial liabilities


		Carrying amount								Fair value
	Note	Mandatorily at FVTPL - others		Financial assets at amortized cost		Other financial liabilities		Total		Level 1		Level 2		Level 3		Total
Balance at December 31, 2023
Financial asset measured at fair value
Financial assets at FVTPL	20	$	20,405,264	$	—	$	—	$	20,405,264	$	—	$	—	$	20,405,264	$	20,405,264
Financial assets at amortized cost
Trade receivables	19	$	—	$	4,058,007	$	—	$	4,058,007	n/a		n/a		n/a		n/a
Deposits and other receivables	17,19	—		6,028,021		—		6,028,021		n/a		n/a		n/a		n/a
Amount due from a related company		—		5,123		—		5,123		n/a		n/a		n/a		n/a
Amounts due from equity-accounted investees		—		132,114		—		132,114		n/a		n/a		n/a		n/a
Short-term deposits		—		16,000,000		—		16,000,000		n/a		n/a		n/a		n/a
Cash and cash equivalents	21(b)	—		45,706,448		—		45,706,448		n/a		n/a		n/a		n/a
		$	—	$	71,929,713	$	—	$	71,929,713
Financial liabilities measured at fair value
Warrant liabilities	27	$	223,850	$	—	$	—	$	223,850	223,850		—		—		223,850
Financial liabilities at amortized cost
Trade payables		$	—	$	—	$	1,671,019	$	1,671,019	n/a		n/a		n/a		n/a
Accrued expenses and other liabilities	22	—		—		8,174,815		8,174,815		n/a		n/a		n/a		n/a
Liabilities for puttable financial instrument	28	—		—		14,622,529		14,622,529		n/a		n/a		n/a		n/a
		$	—	$	—	$	24,468,363	$	24,468,363


		Carrying amount								Fair value
	Note	Mandatorily at FVTPL - others		Financial assets at amortized cost		Other financial liabilities		Total		Level 1		Level 2		Level 3		Total
Balance at December 31, 2022
Financial asset measured at fair value
Financial assets at FVTPL	20	$	17,537,608	$	—	$	—	$	17,537,608	$	—	$	—	$	17,537,608	$	17,537,608
Financial assets at amortized cost
Trade receivables	19	$	—	$	41,691,913	$	—	$	41,691,913	n/a		n/a		n/a		n/a
Deposits and other receivables	17,19	—		8,181,576		—		8,181,576		n/a		n/a		n/a		n/a
Short-term deposits		—		19,920,160		—		19,920,160		n/a		n/a		n/a		n/a
Cash and cash equivalents	21(b)	—		146,660,195		—		146,660,195		n/a		n/a		n/a		n/a
		$	—	$	216,453,844	$	—	$	216,453,844
Financial liabilities measured at fair value
Warrant liabilities	27	$	3,574,885	$	—	$	—	$	3,574,885	3,574,885		—		—		3,574,885
Financial liabilities at amortized cost
Trade payables		$	—	$	—	$	7,291,133	$	7,291,133	n/a		n/a		n/a		n/a
Accrued expenses and other liabilities	22	—		—		15,668,734		15,668,734		n/a		n/a		n/a		n/a
Liabilities for puttable financial instrument	28	—		—		17,138,905		17,138,905		n/a		n/a		n/a		n/a
		$	—	$	—	$	40,098,772	$	40,098,772

Schedule of fair value measurements

Financial instruments measured at fair value

Type

Valuation technique

Significant
unobservable inputs

Inter-relationship between significant unobservable inputs and fair value measurement

Financial assets at FVTPL

Adjusted net asset value

Underlying assets’ value

The estimated fair value would increase if the underlying assets’ value is higher.

Discounted cash flow method

Risk-adjusted discount rate: 17.5%

Discount for lack of marketability: 32.5%

The estimated fair value would increase if:

–the risk-adjusted discount rate was lower; or

–the discount for lack of marketability was lower.

Schedule of information about Level 3 fair value measurements

The following table shows a reconciliation of financial assets at FVTPL from the opening balances to the closing balances for Level 3 fair values.


	2023		2022
Balance at January 1	$	17,537,608	$	9,906,000
Additions	10,002,442		20,000,000
Redemption	—		(3,004,897)
Changes in fair value recognized in profit or loss	(7,134,786)		(9,363,495)
Balance at December 31	$	20,405,264	$	17,537,608

Schedule of movement in the loss allowance account in respect of trade receivable

Movement in the loss allowance account in respect of trade receivable during the years ended December 31, 2023 and 2022 is as follows:


	2023		2022
Balance at January 1	$	1,592,119	$	518,968
Additions from acquisition (note 34(C))	—		1,263,570
Net remeasurement of loss allowance	782,488		(136,493)
Amounts written off	(41,776)		(33,808)
Exchange differences	91,278		(20,118)
Balance at December 31	$	2,424,109	$	1,592,119

Schedule of remaining contractual maturities at the end of the reporting period of the non-derivative financial liabilities and derivative financial liabilities, which are based on contractual undiscounted cash flows

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include contractual interest payments.


			Contractual undiscounted cash flows
	Carrying amount		Total		Within 1 year or on demand		1 - 2 years		More than 2 years
Balance at December 31, 2023
Trade payables	$	1,671,019	$	1,671,019	$	1,671,019	$	—	$	—
Accrued expenses and other liabilities	8,174,815		8,174,815		8,174,815		—		—
Lease liabilities	2,369,388		2,440,587		1,549,027		787,708		103,852
Liabilities for puttable financial instrument	14,622,529		14,622,529		14,622,529		—		—
	$	26,837,751	$	26,908,950	$	26,017,390	$	787,708	$	103,852
Balance at December 31, 2022
Trade payables	$	7,291,133	$	7,291,133	$	7,291,133	$	—	$	—
Accrued expenses and other liabilities	15,668,734		15,668,734		15,611,421		57,313		—
Lease liabilities	6,646,163		7,308,540		3,022,367		1,678,615		2,607,558
Liabilities for puttable financial instrument	17,138,905		17,138,905		17,138,905		—		—
	$	46,744,935	$	47,407,312	$	43,063,826	$	1,735,928	$	2,607,558

Schedule of amounts for the exposure to currency risk

The summary quantitative data about the Group’s exposure to currency risk as reported to the management of the Group is as follows.


	December 31, 2023				December 31, 2022
	USD		RMB		USD		RMB
Trade receivables	$	50,696	$	—	$	79,220	$	—
Deposits, prepayments and other receivables	76,586		—		2,972,471		872,455
Cash and cash equivalents	41,388,803		253,839		12,225,385		14
Trade payables	(45,754)		(167,889)		(3,984,494)		(2,029,309)
Accrued expenses and other liabilities	—		(2,608)		(3,741,359)		—
Net exposure	$	41,470,331	$	83,342	$	7,551,223	$	(1,156,840)

The following significant exchange rates have been applied.


	Average rate				Year-end spot rate
	2023		2022		2023		2022
USD 1	$	7.82	$	7.83	$	7.81	$	7.78
RMB 1	1.10		1.17		1.10		1.11

Schedule of sensitivity analysis


	2023			2022
	Increase/(decrease) in foreign exchange rates	Decrease/(increase) on loss after tax and accumulated losses		Increase/(decrease) in foreign exchange rates	Decrease/(increase) on loss after tax and accumulated losses
	%			%
USD	1	$	(346,058)	1	$	(63,061)
	(1)	346,058		(1)	63,061
RMB	5	(3,478)		5	48,298
	(5)	3,478		(5)	(48,298)

Reporting entity (Details) - pillar		12 Months Ended
Reporting entity (Details) - pillar	Jul. 20, 2023	Dec. 31, 2023	Dec. 30, 2022
General Information About Reporting Entity [line items]
Number pillars		3
Insighta
General Information About Reporting Entity [line items]
Percentage of shareholding of an equity accounted investee (%)	50.00%	50.00%
ACT Genomics Holdings Company Limited
General Information About Reporting Entity [line items]
Percentage of voting equity interests acquired (%)			74.39%

Loss before taxation (Tables)

12 Months Ended

Dec. 31, 2023

Profit Or Loss Before Tax [Abstract]

Schedule of expenses by nature

See accounting policies in notes 38(E) and (J).


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Interest expenses on lease liabilities (notes 13(a) and 25(b))	$	119,197	$	40,656	$	42,196
Interest expenses on trade financing (note 25(b))	—		172,978		—
Changes in the carrying amount of preference shares liabilities (note 26)	—		3,752,758		5,009,847
Other interest expenses	465		28,363		33
	$	119,662	$	3,994,755	$	5,052,076

(b)Staff costs


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Salaries, wages and other benefits	$	27,745,031	$	21,058,447	$	13,246,763
Contributions to defined contribution retirement plan	718,933		369,102		344,926
Equity-settled share-based payment expenses	10,495,706		25,913,717		20,426,026
	$	38,959,670	$	47,341,266	$	34,017,715
Represented by:
Direct costs	$	1,997,360	$	282,918	$	345,183
Selling and distribution expenses	3,891,109		1,593,735		1,144,714
Research and development expenses	10,226,280		5,637,295		6,147,814
Administrative and other operating expenses	22,844,921		39,827,318		26,380,004
Total staff costs	$	38,959,670	$	47,341,266	$	34,017,715

(c)Other items


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Cost of inventories (note 18)	$	6,320,806	$	7,129,679	$	8,948,607
Depreciation of (note 13)
- property, plant and equipment#	2,995,067		1,068,535		938,005
- right-of-use assets#	1,761,394		950,477		625,284
Amortization of intangible assets# (note 14)	1,914,561		57,846		67,433
Write-off on property, plant and equipment	331,121		—		—
Auditor’s remuneration	1,244,315		1,319,047		1,052,910
Miscellaneous laboratory charges	2,200		268		13,953
# Represented by:
Direct costs	$	1,435,709	$	501,786	$	430,359
Research and development expenses	584,545		132,156		55,519
Administrative and other operating expenses	4,650,768		1,442,916		1,144,844
Total depreciation and amortization charges	$	6,671,022	$	2,076,858	$	1,630,722

Basis of Accounting (Details)		12 Months Ended
Basis of Accounting (Details)	Nov. 01, 2023 shares	Dec. 31, 2023 $ / shares	Oct. 31, 2023 shares
Stockholders equity note, stock split, shares converted	15
Stockholders equity note, new share	1
Number of shares outstanding (in shares)	12,200,000		181,800,000
Increase (decrease) in number of ordinary shares issued	35,755
Stockholders equity note stock split conversion ratio	0.0667	0.0667
Par value per share ($ per share) \| $ / shares		$ 1

Accrued expenses and other liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current
Accrued staff costs	$ 612,036	$ 1,405,316
Accrued expenses	5,336,981	2,949,038
Accrued professional fee	88,211	4,432,425
Value added tax payable	35,480	58,093
Deposit liabilities	868,517	328,559
Consideration payable in relation to the ACT Acquisition (note)	0	958,224
Other payables and accruals	1,233,590	5,479,766
Accrued expenses and other current liabilities	8,174,815	15,611,421
Non-current
Other non-current liabilities	823,345	949,701
Non accrued expenses and other non current liabilities	$ 8,998,160	$ 16,561,122

Equity-settled share-based transactions - Number and weighted average exercise prices RSUs, Narrative (Details) - USD ($)		12 Months Ended
	Jun. 30, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
2021 Share Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Equity-settled share-based payment expenses		$ 5,623,551	$ 23,847,422
Restricted share units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price (in $ per share)		$ 0.01	$ 0.01	$ 0.01
Weighted average remaining contractual life		1 year 4 months 24 days	4 years 8 months 12 days
Restricted share units \| Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Aggregate fair value of the RSUs united granted	$ 54,645,652			$ 1,209,111
Fair value of the RSUs united granted (in dollar per share)	$ 13.89			$ 18.91

Discontinued operations - Results of discontinued expenses by nature (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of analysis of single amount of discontinued operations [line items]
Interest on lease liabilities (notes 7(a)(ii) and 10(a))	$ 241,497	$ 244,085	$ 205,915
Salaries, wages and other benefits	27,745,031	21,058,447	13,246,763
Contributions to defined contribution retirement plan	718,933	369,102	344,926
Equity-settled share-based payment expenses	10,495,706	25,913,717	20,426,026
Total staff costs	38,959,670	47,341,266	34,017,715
Cost of inventories (note 18)	6,320,806	7,129,679	8,948,607
Depreciation of (note 13)
- property, plant and equipment#	2,995,067	1,068,535	938,005
- right-of-use assets#	1,761,394	950,477	625,284
Amortization of intangible assets# (note 14)	1,914,561	57,846	67,433
Write-off on inventories	3,136,551	2,055,859	0
Auditor’s remuneration	1,244,315	1,319,047	1,052,910
Direct costs
Disclosure of analysis of single amount of discontinued operations [line items]
Total staff costs	1,997,360	282,918	345,183
Cost of inventories (note 18)	9,081,519	57,442,036	52,701,330
Depreciation of (note 13)
Total depreciation and amortization charges	1,435,709	501,786	430,359
Selling and distribution expenses
Disclosure of analysis of single amount of discontinued operations [line items]
Total staff costs	3,891,109	1,593,735	1,144,714
Research and development expenses
Depreciation of (note 13)
Total depreciation and amortization charges	584,545	132,156	55,519
Administrative and other operating expenses
Disclosure of analysis of single amount of discontinued operations [line items]
Total staff costs	22,844,921	39,827,318	26,380,004
Depreciation of (note 13)
Total depreciation and amortization charges	4,650,768	1,442,916	1,144,844
Total depreciation and amortization charges
Depreciation of (note 13)
Total depreciation and amortization charges	6,671,022	2,076,858	1,630,722
Hong Kong
Disclosure of analysis of single amount of discontinued operations [line items]
Interest on lease liabilities (notes 7(a)(ii) and 10(a))	122,300	203,429	163,719
Imputed interest on deferred consideration	0	0	22,235
Finance costs	122,300	203,429	185,954
Salaries, wages and other benefits	9,121,633	88,585,752	63,375,740
Contributions to defined contribution retirement plan	0	492,761	217,501
Equity-settled share-based payment expenses	0	5,425,468	1,715,588
Total staff costs	9,121,633	94,503,981	65,308,829
Restructuring costs	0	30,378,741	0
Cost of inventories (note 18)	2,760,713	50,312,357	43,752,723
Depreciation of (note 13)
- property, plant and equipment#	98,290	2,831,186	1,807,544
- right-of-use assets#	1,025,062	1,136,690	917,282
Amortization of intangible assets# (note 14)	0	1,498,245	2,991,094
Write-off on inventories	0	268,226	476,431
Auditor’s remuneration	76,985	120,570	168,529
Hong Kong \| Direct costs
Disclosure of analysis of single amount of discontinued operations [line items]
Total staff costs	2,057,344	63,364,134	48,069,439
Depreciation of (note 13)
Total depreciation and amortization charges	0	1,390,250	751,775
Hong Kong \| Selling and distribution expenses
Disclosure of analysis of single amount of discontinued operations [line items]
Total staff costs	0	188,414	154,606
Hong Kong \| Research and development expenses
Disclosure of analysis of single amount of discontinued operations [line items]
Total staff costs	0	7,767,201	795,494
Depreciation of (note 13)
Total depreciation and amortization charges	405,100	208,534	90,357
Hong Kong \| Administrative and other operating expenses
Disclosure of analysis of single amount of discontinued operations [line items]
Total staff costs	7,064,289	23,184,232	16,289,290
Depreciation of (note 13)
Total depreciation and amortization charges	718,252	3,867,337	4,873,788
Hong Kong \| Total depreciation and amortization charges
Depreciation of (note 13)
Total depreciation and amortization charges	1,123,352	5,466,121	5,715,920
Hong Kong \| Impairment of intangible assets (note 14)
Disclosure of analysis of single amount of discontinued operations [line items]
Restructuring costs	0	19,109,580	0
Hong Kong \| Impairment of goodwill (note 15)
Disclosure of analysis of single amount of discontinued operations [line items]
Restructuring costs	0	3,272,253	0
Hong Kong \| Impairment losses on property, plant and equipment (note 13)
Disclosure of analysis of single amount of discontinued operations [line items]
Restructuring costs	0	4,447,610	0
Hong Kong \| Write-off of prepayment
Disclosure of analysis of single amount of discontinued operations [line items]
Restructuring costs	$ 0	$ 3,549,298	$ 0

Property, plant and equipment (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about property, plant and equipment [abstract]

Schedule of property, plant and equipment


	Right-of-use assets (note (a))		Leasehold improvements		Fixtures and furniture		Office and lab equipment		Computer equipment		Motor vehicles		Manufacturing equipment		Total
Cost:
At January 1, 2022	$	8,833,201	$	3,898,422	$	39,974	$	5,582,338	$	439,543	$	453,182	$	1,162,681	$	20,409,341
Additions	833,538		598,672		569		4,160,369		188,541		—		—		5,781,689
Additions from acquisition (note 34(C))	4,623,601		3,102,189		—		6,898,517		—		8,261		—		14,632,568
Disposals	—		(30,492)		—		(357,127)		(65,993)		(55,847)		—		(509,459)
Written off	(40,080)		—		—		(438,530)		(6,320)		—		(1,158,041)		(1,642,971)
Exchange differences	(180,180)		(92,424)		(3,669)		(158,913)		(37,044)		(40,483)		(4,640)		(517,353)
At December 31, 2022 and January 1, 2023	14,070,080		7,476,367		36,874		15,686,654		518,727		365,113		—		38,153,815
Additions	196,626		53,521		5,809		285,615		345		—		—		541,916
Disposals	(2,060,684)		(1,158,623)		(27,548)		(4,926,398)		(81,844)		(57,451)		—		(8,312,548)
Written off	(1,938,394)		(850,863)		(4,443)		(1,863,592)		(221,395)		(312,048)		—		(5,190,735)
Exchange differences	847,132		356,124		34,363		(313,508)		2,667		12,504		—		939,282
At December 31, 2023	$	11,114,760	$	5,876,526	$	45,055	$	8,868,771	$	218,500	$	8,118	$	—	$	26,131,730
Accumulated depreciation and impairment loss:
At January 1, 2022	$	3,518,776	$	1,459,157	$	17,926	$	1,930,922	$	152,484	$	123,644	$	169,240	$	7,372,149
Charge for the year	2,087,167		1,088,119		10,582		2,287,110		127,052		136,524		250,334		5,986,888
Additions from acquisition (note 34(C))	2,720,997		2,199,166		—		4,058,977		—		4,246		—		8,983,386
Written back on disposal	—		(24,776)		—		(285,044)		(41,151)		(35,574)		—		(386,545)
Written off	(34,068)		—		—		(176,672)		(5,964)		—		(1,158,041)		(1,374,745)
Impairment loss (note 7(a)(iv))	—		297,061		—		3,308,559		102,776		—		739,214		4,447,610
Exchange differences	26,090		(21,879)		(6,128)		51,607		(13,907)		(12,510)		(747)		22,526
At December 31, 2022 and January 1, 2023	8,318,962		4,996,848		22,380		11,175,459		321,290		216,330		—		25,051,269
Charge for the year	2,786,456		1,282,641		7,981		1,681,221		70,432		51,082		—		5,879,813
Written back on disposal	(370,606)		(1,122,738)		(26,351)		(4,539,440)		(49,500)		(47,692)		—		(6,156,327)
Written off	(1,938,394)		(575,599)		(4,443)		(1,915,113)		(204,433)		(221,632)		—		(4,859,614)
Exchange differences	262,597		242,762		15,160		(90,724)		1,562		7,438		—		438,795
At December 31, 2023	$	9,059,015	$	4,823,914	$	14,727	$	6,311,403	$	139,351	$	5,526	$	—	$	20,353,936
Carrying amounts:
At January 1, 2022	$	5,314,425	$	2,439,265	$	22,048	$	3,651,416	$	287,059	$	329,538	$	993,441	$	13,037,192
At December 31, 2022	$	5,751,118	$	2,479,519	$	14,494	$	4,511,195	$	197,437	$	148,783	$	—	$	13,102,546
At December 31, 2023	$	2,055,745	$	1,052,612	$	30,328	$	2,557,368	$	79,149	$	2,592	$	—	$	5,777,794

Schedule of net book value of right-of-use assets

The analysis of the carrying amount of right-of-use assets by class of underlying asset is as follows:


	Note	2023		2022
Properties leased for own use, carried at depreciated cost	(i)	$	2,023,753	$	5,739,426
Office equipment, carried at depreciated cost	(ii)	31,992		11,692
		$	2,055,745	$	5,751,118

Schedule of analysis of expense items in relation to leases

The analysis of expense items in relation to leases recognized in profit or loss is as follows:


	2023		2022		2021
Depreciation charge of right-of-use assets by class of underlying asset:
- Properties leased for own use	$	2,772,649	$	2,039,815	$	1,535,333
- Office equipment	13,807		47,352		7,233
	$	2,786,456	$	2,087,167	$	1,542,566
Interest on lease liabilities (notes 7(a)(ii) and 10(a))	$	241,497	$	244,085	$	205,915
Expense relating to short-term leases or leases of low-value assets	136,940		831,631		1,019,937

Schedule of amounts included in the consolidated statement of cash flows

Amounts included in the consolidated statement of cash flows for leases comprise the following:


	2023		2022		2021
Within operating cash flows	$	(136,940)	$	(831,631)	$	(1,019,937)
Within financing cash flows	(3,476,380)		(2,121,981)		(1,504,946)
	$	(3,613,320)	$	(2,953,612)	$	(2,524,883)

Financial assets at fair value through profit or loss - Movements (Details) - Financial assets measured at fair value through profit or loss (“FVTPL”) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of financial assets [line items]
Balance at January 1	$ 17,537,608	$ 9,906,000
Additions	10,002,442	20,000,000
Redemption	0	(3,004,897)
Changes in fair value recognized in profit or loss	(7,134,786)	(9,363,495)
Balance at December 31	20,405,264	17,537,608
Represented by:
Non-current	9,371,064	0
Current	$ 11,034,200	$ 17,537,608

- Definition

+ References + Details

Discontinued operations (Tables)

12 Months Ended

Dec. 31, 2023

Non-Current Assets Held For Sale And Discontinued Operations [Abstract]

Disclosure of analysis of single amount of discontinued operations

Results of discontinued operation


	2023		2022		2021
Revenue	$	13,461,964	$	262,597,457	$	263,320,009
Direct costs	(7,356,519)		(134,660,866)		(160,791,395)
Gross profit	6,105,445		127,936,591		102,528,614
Other income and other net gains/(losses)	289,614		(25,214)		341,124
Selling and distribution expenses	(631,812)		(8,563,337)		(16,193,640)
Research and development expenses	(1,188,677)		(9,530,323)		(4,172,461)
Restructuring costs	—		(30,378,741)		—
Administrative and other operating expenses	(12,946,412)		(36,721,676)		(36,059,318)
(Loss)/profit from operating activities	(8,371,842)		42,717,300		46,444,319
Other finance costs	(122,300)		(203,429)		(185,954)
Write-off on amount due from a shareholder	—		—		(106,179)
Gain on bargain purchase	—		—		117,238
(Loss)/profit from discontinued operation before taxation	(8,494,142)		42,513,871		46,269,424
Income tax credit/(expense)	116,482		(7,391,920)		(1,164,222)
(Loss)/profit from discontinued operation, net of tax	$	(8,377,660)	$	35,121,951	$	45,105,202

(Loss)/earnings per share
Basic	(0.74)		6.93		3.09
Diluted	(0.74)		6.93		3.09

Other income and other net gains/(losses)


	2023		2022		2021
Bank interest income	$	19,297	$	311	$	3,779
Net foreign exchange (losses)/gains	(25,049)		(25,721)		336,285
Sundry income	295,366		196		1,060
	$	289,614	$	(25,214)	$	341,124

Other finance costs


	2023		2022		2021
Interest expenses on lease liabilities (notes 13(a) and 25(b))	$	122,300	$	203,429	$	163,719
Imputed interest on deferred consideration	—		—		22,235
	$	122,300	$	203,429	$	185,954

(iii)Staff costs


	2023		2022		2021
Salaries, wages and other benefits	$	9,121,633	$	88,585,752	$	63,375,740
Contributions to defined contribution retirement plan	—		492,761		217,501
Equity-settled share-based payment expenses	—		5,425,468		1,715,588
	$	9,121,633	$	94,503,981	$	65,308,829
Represented by:
Direct costs	$	2,057,344	$	63,364,134	$	48,069,439
Selling and distribution expenses	—		188,414		154,606
Research and development expenses	—		7,767,201		795,494
Administrative and other operating expenses	7,064,289		23,184,232		16,289,290
Total staff costs	$	9,121,633	$	94,503,981	$	65,308,829

(iv)Restructuring costs


	2023		2022		2021
Impairment of intangible assets (note 14)	$	—	$	19,109,580	$	—
Impairment of goodwill (note 15)	—		3,272,253		—
Impairment losses on property, plant and equipment (note 13)	—		4,447,610		—
Write-off of prepayment	—		3,549,298		—
	$	—	$	30,378,741	$	—

(v)Other items


	2023		2022		2021
Cost of inventories (note 18)	$	2,760,713	$	50,312,357	$	43,752,723
Depreciation of (note 13)
- property, plant and equipment#	98,290		2,831,186		1,807,544
- right-of-use assets#	1,025,062		1,136,690		917,282
Amortization of intangible assets# (note 14)	—		1,498,245		2,991,094
Write-off on property, plant and equipment	—		268,226		476,431
Auditor’s remuneration	76,985		120,570		168,529
# Represented by:
Direct costs	$	—	$	1,390,250	$	751,775
Research and development expenses	405,100		208,534		90,357
Administrative and other operating expenses	718,252		3,867,337		4,873,788
Total depreciation and amortization charges	$	1,123,352	$	5,466,121	$	5,715,920

Cash flows (used in)/from discontinued operation


	2023		2022		2021
Net cash (used in)/from operating activities	$	(901,176)	$	88,324,872	$	49,430,661
Net cash from/(used in) investing activities	118,645		(4,676,216)		(8,798,532)
Net cash used in financing activities	(1,183,878)		(343,407)		(502,543)
Net cash flows for the year	$	(1,966,409)	$	83,305,249	$	40,129,586

Related parties - Summary of key management personnel compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Material Related Party Transactions [Abstract]
Directors’ fees	$ 420,000	$ 261,110	$ 0
Salaries, wages and other benefits	4,239,821	24,549,012	2,281,701
Contributions to defined contribution retirement plan	14,779	17,538	15,643
Equity-settled share-based payment expenses (note)	10,297,075	30,284,686	21,500,167
Total	$ 14,971,675	$ 55,112,346	$ 23,797,511

Revenue (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue [abstract]
Contract liabilities	$ 6,111,017	$ 5,674,290	$ 9,587,245

Financial instruments - Fair values and risk management - Reconciliation of Level 3 fair values (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Changes in fair value recognized in profit or loss	$ 0	$ 0	$ (29,054,669)
Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Balance at January 1	17,537,608	9,906,000
Additions	10,002,442	20,000,000
Redemption	0	(3,004,897)
Changes in fair value recognized in profit or loss	(7,134,786)	(9,363,495)
Balance at December 31	$ 20,405,264	$ 17,537,608	$ 9,906,000

- Definition

+ References + Details

Financial instruments - Fair values and risk management - Cash and Cash Equivalents (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial Risk Management And Fair Value Of Financial Instruments [Abstract]
Cash and cash equivalents	$ 45,706,448	$ 146,660,195	$ 35,288,952	$ 14,489,880

Equity-settled share-based transactions - Schedule of number and weighted average exercise prices of RSU (Details) - Restricted share units								12 Months Ended
	Dec. 31, 2023 shares $ / shares	Jun. 30, 2023 shares	Jun. 23, 2023 shares	Feb. 01, 2023 shares	Dec. 31, 2022 shares $ / shares	Jun. 30, 2022 shares	May 18, 2022 shares	Dec. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding at the beginning of the year (in dollars per share)								$ 0.01	$ 0.01
Cancelled (in dollars per share)								0	0.01
Exercised (in dollars per share)								0.01	0.01
Outstanding at the end of the year (in dollars per share)	$ 0.01				$ 0.01			0.01	0.01
Exercisable (in dollars per share)	$ 0.01				$ 0.01			$ 0.01	$ 0.01
Outstanding at the beginning of the year (in shares)								1,690,766	14,748,217
Granted (in shares) \| shares	7,928	2,403,529	16,486,108	66,666	946,330	2,446,557	144,522
Cancelled (in shares)								0	(67,112)
Exercised (in shares)								(829,459)	(12,821,445)
Outstanding at the end of the year (in shares)	834,947				1,690,766			834,947	1,690,766
Exercisable (in shares)	283,338				14,571			283,338	14,571
PRE Prenetics 2022 Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding at the beginning of the year (in dollars per share)								$ 0.01	$ 0
Granted (in dollars per share)								0.03	0.01
Cancelled (in dollars per share)								0.001	0.01
Exercised (in dollars per share)								0.004	0.01
Outstanding at the end of the year (in dollars per share)	$ 0.06				$ 0.01			0.06	0.01
Exercisable (in dollars per share)	$ 0.001				$ 0.01			$ 0.001	$ 0.01
Outstanding at the beginning of the year (in shares)								2,360,267	0
Granted (in shares)								18,964,231	3,537,409
Cancelled (in shares)								(9,364,807)	(75,031)
Exercised (in shares)								(878,332)	(1,102,111)
Outstanding at the end of the year (in shares)	11,081,359				2,360,267			11,081,359	2,360,267
Exercisable (in shares)	180,194				16,775			180,194	16,775

Financial instruments - Financial instruments measured at fair value (Details) - Discounted cash flow	Dec. 31, 2023
Measurement input, discount rate
Disclosure of fair value measurement of assets [abstract]
Significant unobservable input, assets (%)	0.175
Lack of marketability, measurement input
Disclosure of fair value measurement of assets [abstract]
Significant unobservable input, assets (%)	0.325

List of subsidiaries - Disclosure of the principal subsidiaries of the Company (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2023 GBP (£)	Dec. 31, 2023 HKD ($)	Dec. 31, 2023 TWD ($)
Disclosure of subsidiaries [line items]
Share capital	$ 18,308	$ 13,698
Prenetics Limited
Disclosure of subsidiaries [line items]
Share capital				$ 415,276,716
Directly	0.00%	0.00%
Indirectly	100.00%	100.00%
Prenetics EMEA Limited*
Disclosure of subsidiaries [line items]
Share capital \| £			£ 76,765.81
Directly	0.00%	0.00%
Indirectly	100.00%	100.00%
ACT Genomics Holdings Company Limited (note 34)
Disclosure of subsidiaries [line items]
Share capital	$ 16,713
Directly	74.39%	74.39%
Indirectly	0.00%	0.00%
ACT Genomics Co., Ltd.
Disclosure of subsidiaries [line items]
Share capital					$ 455,080,000
Directly	0.00%	0.00%
Indirectly	74.33%	74.33%
ACT Genomics (Hong Kong) Limited
Disclosure of subsidiaries [line items]
Share capital				775,000
Directly	0.00%	0.00%
Indirectly	74.39%	74.39%
Sanomics Limited
Disclosure of subsidiaries [line items]
Share capital				$ 500,000
Directly	0.00%	0.00%
Indirectly	74.39%	74.39%
MC Diagnostics Limited
Disclosure of subsidiaries [line items]
Share capital \| £			£ 1,164
Directly	0.00%	0.00%
Indirectly	74.39%	74.39%

Equity-settled share-based transactions (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Schedule of number and aggregate fair value of RSU

The number of RSUs and aggregate fair value of RSUs granted to certain employees, directors and third parties under Prenetics 2022 Plan were as follows,


Grant date	Number of RSUs	Closing price per ordinary share less subscription price per ordinary share		Aggregate fair value of the RSUs
On May 18, 2022	144,522	$	7.64	$	1,104,148
On June 30, 2022	2,446,557	4.04		9,884,090
On December 31, 2022	946,330	2.00		1,892,660
On February 1, 2023	66,666	1.49		99,332
On June 23, 2023	16,486,108	0.90		14,874,763
On June 30, 2023	2,403,529	0.79		1,903,341
On December 31, 2023	7,928	3.39		26,855

Schedule of number and weighted average exercise prices of RSU and share options

The number and weighted average exercise prices of the RSUs are as follows:


	2023			2022
	Weighted average exercise price		Number of RSUs	Weighted average exercise price		Number of RSUs
Balance at January 1	$	0.01	2,360,267	$	—	—
Granted	$	0.03	18,964,231	0.01		3,537,409
Cancelled	$	0.001	(9,364,807)	0.01		(75,031)
Exercised	$	0.004	(878,332)	0.01		(1,102,111)
Outstanding balance at December 31	$	0.06	11,081,359	$	0.01	2,360,267
Exercisable balance at December 31	$	0.001	180,194	$	0.01	16,775

The number and weighted average exercise prices of the RSUs are as follows:


	2023			2022
	Weighted average exercise price		Number of RSUs	Weighted average exercise price		Number of RSUs
Balance at January 1	$	0.01	1,690,766	$	0.01	14,748,217
Exercised	0.01		(829,459)	0.01		(12,821,445)
Forfeited	0.01		(26,360)	0.01		(168,894)
Cancelled	—		—	0.01		(67,112)
Outstanding balance at December 31	$	0.01	834,947	$	0.01	1,690,766
Exercisable balance at December 31	$	0.01	283,338	$	0.01	14,571

Schedule of details of the restricted share units outstanding

Details of the RSUs outstanding at December 31, 2023 and 2022 are as follows:


	Number of instruments
	2023	2022
RSUs granted to directors	821,111	1,636,011
RSUs granted to employees	2,126	43,045
RSUs granted to third parties	11,710	11,710
	834,947	1,690,766

Schedule of fair value of RSUs and assumptions


	2021
Fair value of RSUs and key assumptions
Fair value at measurement date	$13.89 - $18.91
Share price	$13.89 - $18.91
Exercise price	$	0.01
Expected volatility	41.03% - 44.26%
Expected option life	1 year
Expected dividends	0		%
Risk-free interest rate	1% - 1.13%
Likelihood of achieving a redemption event	5		%
Likelihood of achieving a liquidity event	5		%

Interests in equity-accounted investees - Summary of details information of joint venture (Details) - USD ($)		12 Months Ended
	Jul. 20, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of associates [line items]
Non-current assets		$ 160,510,113	$ 70,320,914
Cash and cash equivalents		45,706,448	146,660,195	$ 35,288,952	$ 14,489,880
Current assets		93,660,406	241,810,317
Non-current liabilities		(4,529,233)	(11,473,256)
Other payables, accruals and contract liabilities		(1,233,590)	(5,479,766)
Net assets (100%)		210,157,272	243,462,860	(400,894,913)	$ 31,007,007
Interest income		3,923,279	471,878	201
Income tax expense		(269,359)	(244,816)	2,568,522
Total comprehensive income for the year		$ (62,981,709)	$ (195,296,319)	$ (173,756,730)
Insighta
Disclosure of associates [line items]
Percentage of shareholding of an equity accounted investee (%)	50.00%	50.00%
Insighta
Disclosure of associates [line items]
Non-current assets		$ 132,725,811
Cash and cash equivalents		79,108,498
Current assets		79,310,442
Non-current liabilities		(15,192,930)
Other payables, accruals and contract liabilities		(200,052)
Amount due to a related company		(925,631)
Net assets (100%)		195,717,640
Other income		580,440
Interest income		927,019
Depreciation and amortization		(2,141,759)
Other expenses		(1,054,858)
Income tax expense		349,018
Loss and total comprehensive income (100%)		(1,340,140)
Insighta
Disclosure of associates [line items]
Net assets (100%)		97,858,820
Total comprehensive income for the year		(670,070)
Dividends received by the Group		$ 0

Possible impact of amendments, new standards and interpretations issued but not yet effective for the year ended December 31, 2023

12 Months Ended

Dec. 31, 2023

Disclosure of expected impact of initial application of new standards or interpretations [abstract]

Possible impact of amendments, new standards and interpretations issued but not yet effective for the year ended December 31, 2023


			Effective for accounting periods beginning on or after
IFRS 17, Insurance Contracts, and amendments to IFRS 17, Insurance Contracts			January 1, 2023
Amendments to IAS 1 and IFRS Practice Statement 2, Disclosure of Accounting Policies			January 1, 2023
Amendments to IAS 8, Definition of Accounting Estimates			January 1, 2023
Amendments to IAS 12, Deferred Tax related to Assets and Liabilities arising from a Single Transaction			January 1, 2023
Amendments to IFRS 16, Lease Liabilities in a Sale and Leaseback			January 1, 2024
Amendments to IAS 1, Non-current Liabilities with Covenants			January 1, 2024
Amendments to IAS 1, Classification of Liabilities as Current or Non-current			January 1, 2024
Amendments to IAS21, The effects of changes in foreign exchange rates, Lack of exchangeability			January 1, 2025
IFRS 18, Presentation and Disclosure in Financial Statements			January 1, 2027

The Group is in the process of making an assessment of what the impact of these developments is expected to be in the period of initial application. So far it has concluded that the adoption of them is unlikely to have a significant impact on the consolidated financial statements.

Capital and reserves

12 Months Ended

Dec. 31, 2023

Miscellaneous equity [abstract]

Capital and reserves

See accounting policies in note 38(K).

As described in Note 1, the Reverse Recapitalization has resulted in PHCL becoming a wholly owned subsidiary of the Company on May 18, 2022, effectuated by the holders of PHCL ordinary shares exchanging each of their shares for Class A or Class B ordinary shares of the Company (collectively “Prenetics Ordinary Shares”) as described below:

(a)Movement in ordinary shares of PHCL

Authorized and issued share capital


		2023			2022
	Note	No. of shares			No. of shares
Authorized ordinary shares of $1 each	(ii)	50,000	$	50,000	50,000	$	50,000
Ordinary shares, issued and fully paid:
Balance at January 1		1	$	1	14,932,033	$	1,493
Shares issued upon conversion of exchange loan notes	(iii)	—	—		1	1
Exchange for Prenetics Ordinary Shares as part of Reverse Recapitalization	(v)	—	—		(14,932,033)	(1,493)
Balance at December 31	(iv)	1	$	1	1	$	1
Total share capital			$	1		$	1

Notes:

(iii)On May 18, 2022, 1 ordinary share valued at $1 was issued upon the closing of the Acquisition Merger.

(iv)At December 31, 2022, the entire amount standing to the reclassification to share premium at $17,126,369 due to the Group’s restructuring.

(b)Movement in ordinary shares of the Company

Authorized and issued share capital


		2023			2022
	Note	No. of shares			No. of shares
Authorized Class A ordinary shares of $0.0015 each	(i)	30,000,001	$	45,000	30,000,001	$	45,000
Authorized Class B ordinary shares of $0.0015 each	(i)	3,333,333	5,000		3,333,333	5,000
		33,333,334	$	50,000	33,333,334	$	50,000
Class A ordinary shares, issued and fully paid:
As of the beginning of the year		8,484,616	$	12,727	—	$	—
Issuance of Prenetics Ordinary Shares as part of Reverse Recapitalization		—	—		6,751,061	10,127
Cancellation and retirement of repurchased shares		(112,317)	(168)		—	—
Share issued for vesting of restricted share units		513,345	770		523,519	785
Share issued upon conversion of exchange loan notes		52,620	79		52,619	79
Share issued for the investment in Insighta		1,481,481	2,222		—	—
Share issued for the ACT Acquisition		168,709	253		1,157,417	1,736
Adjustment for reverse stock split	(iv)	35,754	54		—	—
At the end of the year	(ii)	10,624,208	$	15,937	8,484,616	$	12,727
Class B ordinary shares, issued and fully paid:
As of the beginning of the year		647,591	$	971	—	$	—
Share issued for vesting of restricted share units		933,380	1,400		—	—
Issuance of Prenetics Ordinary Shares as part of Reverse Recapitalization		—	—		647,591	971
Adjustment for reverse stock split	(iv)	1	—		—	—
Balance at December 31	(iii)	1,580,972	$	2,371	647,591	$	971
Total share capital			$	18,308		$	13,698

Notes:

(iv)In November 2023, the Company approved a reverse stock split of issued and unissued ordinary shares at a ratio of 1-for-15. (see note 2)

(c)Nature and purpose of reserves

(i)Capital reserve

The capital reserve represents restricted shares granted to shareholders but are subjected to certain restrictions and portion of the grant date fair value of unexercised share options granted to employees of the Company that has been recognized in accordance with the accounting policy adopted for share-based payments in note 38(D)(ii).

(ii)Translation reserve

The translation reserve comprises all foreign exchange differences arising from the translation of the financial statements of foreign operations. The reserve is dealt with in accordance with the accounting policies set out in note 38(B).

(iii)Other reserves

The other reserves comprise (i) the fair value of shares to be issued of $5,061,304 in connection with the ACT Acquisition in 2022, which were issued in January 2023; (ii) the amortized cost of puttable financial instrument in connection with the ACT Acquisition; (iii) the then shareholders of Oxsed Limited exchanged GBP5,865,450 (equivalent to $7,549,258) into 110,150 ordinary shares in connection with the acquisition of Oxsed Limited; (iv) the remaining balance of the unconverted portion of the exchange loan notes recognized as equity instrument in accordance with the accounting policy adopted for convertible securities; and (v) the change in fair value of liabilities for puttable financial instrument, which had been granted under the shareholders’ agreements to the NCI of ACT.

(iv)Share premium

Under the Companies Law of the Cayman Islands, the funds in the share premium account of the Company are distributable to the shareholders of the Company provided that immediately following the date on which the dividend is proposed to be distributed, the Company will be in a position to pay off its debts as they fall due in the ordinary course of business.

(v)Treasury stock

As at December 31, 2023, the Company holds 14,134 shares (2022: 20,722 shares) in treasury and the aggregate price of the purchased shares is deducted from equity as “Treasury stock” for an amount of $63,294 (2022: $661,519).

(d)Capital management

The Group’s primary objectives when managing capital are to safeguard the Group’s ability to continue as a going concern, so that it can continue to provide returns for shareholders and benefits for other stakeholders, and to support the Group’s stability and growth, by pricing products and services commensurately with the level of risk.

The Group actively and regularly reviews and manages its capital structure to ensure optimal capital structure and shareholders return, taking into consideration the future of the Company and capital efficiency, prevailing and projected profitability, projected operating cash flows, projected capital expenditures and projected strategic investment opportunities.

The Group manages its capital structure and makes adjustments to it, in light of changes in economic conditions. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Group made no changes to its capital management objectives, policies or processes during the years ended December 31, 2021, 2022 and 2023.

Neither the Company nor any of its subsidiaries are subject to externally imposed capital requirements.

Income tax (credit)/expense (Tables)

12 Months Ended

Dec. 31, 2023

Major components of tax expense (income) [abstract]

Summary of income tax credit

Taxation in the consolidated statements of profit or loss represents:


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Current tax - Hong Kong Profits Tax
Changes in estimates related to prior years	$	(23,323)	$	—	$	—
Current tax - Overseas
Current year	69,760		34,817		38,475
Deferred tax
Origination and reversal of temporary differences	(315,796)		(279,633)		2,530,047
Tax (credit)/expense	$	(269,359)	$	(244,816)	$	2,568,522

Schedule of reconciliation between tax credit credited to profit or loss and accounting loss

Reconciliation of effective tax rate:


	2023		2022		2021
			(Restated)		(Restated)
Continuing operations
Loss before taxation	$	(56,669,031)	$	(225,820,154)	$	(216,553,522)
Notional tax on loss before taxation, calculated at the applicable rate	$	(8,935,753)	$	(24,306,622)	$	(13,864,746)
Tax effect of non-deductible expenses	3,917,601		24,387,021		17,502,323
Tax effect of non-taxable income	(1,136,909)		(163,797)		(846,573)
Tax effect on utilization of previously unrecognized tax losses	(70,806)		—		(579,657)
Tax effect of tax losses not recognized	6,186,067		101,854		—
Tax effect of previously unrecognized temporary differences recognized in current year	(272,720)		(263,272)		360,922
Others	43,161		—		(3,747)
	$	(269,359)	$	(244,816)	$	2,568,522

Schedule of deferred tax assets and liabilities recognized


	Depreciation allowances in excess of the related depreciation		Tax losses recognized		Intangible assets arising from business combination		Total
Deferred tax arising from:
At January 1, 2021	$	364,745	$	(3,347,753)	$	1,031,854	$	(1,951,154)
Charged to profit or loss	906,775		1,528,881		94,391		2,530,047
Exchange differences	(3,839)		9,710		(4,968)		903
At December 31, 2021 and January 1, 2022	1,267,681		(1,809,162)		1,121,277		579,796
(Credited)/charged to profit or loss	(957,459)		1,799,103		(1,121,277)		(279,633)
Additions from acquisition (note 34(C))	63,666		(235,879)		2,850,000		2,677,787
Exchange differences	(38,448)		2,489		—		(35,959)
At December 31, 2022 and January 1, 2023	335,440		(243,449)		2,850,000		2,941,991
Credited to profit or loss	(41,796)		—		(274,000)		(315,796)
Exchange differences	10,012		(49,064)		—		(39,052)
At December 31, 2023	$	303,656	$	(292,513)	$	2,576,000	$	2,587,143

Summary of deferred tax liability asset explanatory


	2023		2022
Represented by:
Deferred tax assets	$	(27,680)	$	(243,449)
Deferred tax liabilities	2,614,823		3,185,440
	$	2,587,143	$	2,941,991

Summary of expiry date of cumulative tax losses explanatory

The expiry dates of the cumulative tax losses are as follows:


	2023		2022
Within 1 year	$	32,048,645	$	893,511
Over 1 year but within 5 years	14,113,958		14,362,136
Over 5 years but within 10 years	28,452,567		25,085,050
Do not expire under the relevant tax legislation	23,178,432		22,245,856
	$	97,793,602	$	62,586,553

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2023
Auditor Information [Abstract]
Auditor Name	KPMG
Auditor Location	Hong Kong
Auditor Firm ID	1181

Goodwill (Details) - USD ($)	12 Months Ended
Goodwill (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Disclosure of reconciliation of changes in goodwill [abstract]
Goodwill at period start	$ 33,800,276	$ 3,978,065
Additions from acquisition (note 34(D))		33,800,276
Impairment loss	(3,900,268)	(3,272,253)
Exchange differences		(705,812)
Adjustments of non-controlling interests	(729,885)
Goodwill at period end	$ 29,170,123	$ 33,800,276